Thienopyrrole compounds

Abstract

To provide a method for treating disease.SOLUTION: The present disclosure relates generally to specific compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions provided herein may be used for the treatment or prevention of an autoimmune disease and / or inflammatory condition, including systemic lupus erythematosus and cutaneous lupus erythematosus. As described in detail and specifically demonstrated herein, it is surprisingly found that, the present invention achieves remarkable effects, which could not have been easily predicted by those skilled in the art based on the prior art.SELECTED DRAWING: None

Description

[Technical Field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority to U.S. Provisional Application No. 63 / 147,641, filed February 9, 2021, and U.S. Provisional Application No. 63 / 210,832, filed June 15, 2021, each of which is incorporated herein in its entirety for all purposes.

[0002] The present disclosure generally relates to thienopyrrole compounds, pharmaceutical compositions comprising the compounds, and methods of making and using the compounds and pharmaceutical compositions. In some embodiments, the novel thienopyrrole compounds provided herein can be used to treat certain diseases and disorders, including, but not limited to, inflammatory conditions, systemic lupus erythematosus, cutaneous lupus erythematosus, or lupus nephritis. [Background technology]

[0003] Toll-like receptors (TLRs) sense pathogens and regulate innate immunity TLR7 / 8 / 9 are a family of transmembrane immune receptors that trigger responses and stimulate adaptive immunity. TLR7 / 8 / 9 are endosome-localized TLRs that respond to single-stranded RNA (TLR7 / 8) or unmethylated DNA containing cytosine-phosphate-guanine (CpG) motifs (TLR9). Activation of TLR7 / 8 / 9 leads to inflammatory responses, including the production of type I interferons and proinflammatory cytokines, B cell activation and antibody production, and neutrophil NETosis. Aberrant activation of TLR7 / 8 / 9 contributes to elevated type I interferon responses, increased proinflammatory cytokines, and sustained autoantibody production, which can stimulate the chronic progression of various autoimmune diseases and inflammatory conditions, resulting in widespread inflammation and tissue damage. (Kawai et al., 2010, Nat Immunol 11,373; Joosten et al., 2016, Nat Rev Rheomatol 12,344; Crow et al., 2019, Lupus Sci Med 6,e000336; Garcia-Romo et al., 2011, Sci Transl Med 3,73ra20; Kono et al., 2009, PNAS 106,12061; Koh et al., 2013, J Immunol 190,4982). Thus, there is a need for compounds that are potent TLR7 and / or TLR8 and / or TLR9 antagonists that are stable and exhibit effective pharmacokinetic and / or pharmacodynamic profiles. [Prior art documents] [Non-patent literature]

[0004] [Non-Patent Document 1] Kawai et al.,2010,Nat Immunol 11,373 [Non-patent document 2] Joosten et al.,2016,Nat Rev Rheomatol 12,344 [Non-patent document 3] Crow et al.,2019,Lupus Sci Med 6,e000336 [Non-patent document 4] Garcia-Romo et al.,2011,Sci Transl Med 3,73ra20 [Non-Patent Document 5] Kono et al.,2009,PNAS 106,12061 [Non-patent document 6] Koh et al.,2013,J Immunol 190,4982 Summary of the Invention [Means for solving the problem]

[0005] In one embodiment, a compound of formula I: [ka] or a pharmaceutically acceptable salt thereof, During the ceremony, R 1 is a 4- to 7-membered monocyclic heterocyclyl, phenyl, naphthalenyl, a 5- to 6-membered monocyclic heteroaryl, an 8- to 10-membered fused bicyclic heterocyclyl, or an 8- to 10-membered fused bicyclic heteroaryl; The 4- to 7-membered monocyclic heterocyclyl, phenyl, naphthalenyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, and 8- to 10-membered fused bicyclic heteroaryl each independently represent 1 to 4 R a and optionally substituted with a group, R 2 are H, -CN, and C 1~6 Alkyl or C 3~7 is a monocyclic cycloalkyl, C 1~6 Alkyl and C 3~7 monocyclic cycloalkyls each independently represent a halogen and C 1~6 optionally substituted with 1 to 4 groups independently selected from alkoxy; X is N or CR 3 and R 3 is H, halogen, -CN, C 1~6 Alkyl, C 3~6 Monocyclic cycloalkyl, or -O(C 1~4 alkyl), and C 1~4 Alkyl is -OH, halogen, -CN, -NR 4 R 4 , and C 1~4 optionally substituted with 1 to 3 groups independently selected from alkoxy; Z is C 1~10 Alkyl, C 2~6 Alkynyl, -NR 6 R 7 , -C(O)R 13 , -C(O)NR 6 R 7 , -S(O)2R 6 , C 3~7 Monocyclic cycloalkyl, C 7~10Fused Bicyclic Cycloalkyl, C 5~10 bridged bicyclic cycloalkyl, 4- to 7-membered monocyclic heterocyclyl, phenyl, naphthalenyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, 7- to 10-membered spirocyclic heterocyclyl, or L 1 and C 1~10 Alkyl and C 2~6 Alkynyl is independently selected from 1 to 4 R b and optionally substituted with a group, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 Bridged bicyclic cycloalkyl, 4- to 7-membered monocyclic heterocyclyl, phenyl, naphthalenyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl each independently represent one to two R 8 groups, each independently being 1 to 3 R a and optionally substituted with a group, L 1 -OR 5 , -C(O)R 5 , -C(O)N(R 5 )(R 5 ), -NR 5 R 5 , -N(R 5 )2(R 5 ) + , -N(R 5 )C(O)R 5 , -N(R 5 )C(O)OR 5 , -N(R 5 )C(O)N(R 5 )(R 5 ), -N(R 5 )S(O)2(R 5a ), -NR 5 S(O)2N(R 5 )(R 5 ), -NR 5 S(O)2O(R5a ), -OC(O)N(R 5 )(R 5 ), -SR 5 , -S(O)R 5a , -S(O)(NH)R 5 , -S(O)2R 5a , S(O)2N(R 5 )(R 5 ), or -N=S(R 5a )(R 5a )=O, R 6 is C 1~6 Alkyl, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused bicyclic rings Chloroalkyl, C 5~10 a bridged bicyclic cycloalkyl, a 4- to 7-membered monocyclic heterocyclyl, a phenyl, a naphthalenyl, a 5- to 6-membered monocyclic heteroaryl, an 8- to 10-membered fused bicyclic heterocyclyl, a 6- to 10-membered bridged bicyclic heterocyclyl, an 8- to 10-membered fused bicyclic heteroaryl, or a 7- to 10-membered spirocyclic heterocyclyl; C 1~6 Alkyl is one to four R b and optionally substituted with a group, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 Bridged bicyclic cycloalkyl, 4- to 7-membered monocyclic heterocyclyl, phenyl, naphthalenyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl each independently represent 1 to 4 R a and optionally substituted with a group, R 13 is C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10a bridged bicyclic cycloalkyl, a 4- to 7-membered monocyclic heterocyclyl, a phenyl, a naphthalenyl, a 5- to 6-membered monocyclic heteroaryl, an 8- to 10-membered fused bicyclic heterocyclyl, a 6- to 10-membered bridged bicyclic heterocyclyl, an 8- to 10-membered fused bicyclic heteroaryl, or a 7- to 10-membered spirocyclic heterocyclyl; C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 Bridged bicyclic cycloalkyl, 4- to 7-membered monocyclic heterocyclyl, phenyl, naphthalenyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl each independently represent 1 to 4 R a and optionally substituted with a group, Each R 4 are independently H or C 1~3 is alkyl, R 7 is H, C1-6 alkyl, C 3~7 monocyclic cycloalkyl or 4- to 6-membered monocyclic heterocyclyl, 1~6 Alkyl, C 3~7 Monocyclic cycloalkyl and 4- to 6-membered monocyclic heterocyclyl are each independently selected from -OH, halogen, -CN, and C 1~6 optionally substituted with 1 to 4 groups independently selected from alkoxy; Each R 8 are independently halogen, -C(O)R 9 , -NR 10 R 10 , C 1~6 Alkyl, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 Bridged bicyclic cycloalkyl, 4-7 membered monocyclic heterocyclyl, phenyl, naphthalenyl, 5-6 membered monocyclic heteroaryl, 8-10 membered fused bicyclic heterocyclyl, 6-10 membered bridged bicyclic heterocyclyl, 8-10 membered fused bicyclic heteroaryl, 7-10 membered spirocyclic heterocyclyl, -OR 5 , -C(O)OR5 , -C(O)N(R 5 )(R 5 ), -N(R 5 )2(R 5 ) + , -N(R 5 )C(O)R 5 , -N(R 5 )C(O)OR 5 , -N(R 5 )C(O)N(R 5 )(R 5 ), -N(R 5 )S(O)2(R 5a ), -NR 5 S(O)2N(R 5 )(R 5 ), -NR 5 S(O)2O(R 5a ), -OC(O)R 5 , -OC(O)OR 5 , -OC(O)N(R 5 )(R 5 ), -SR 5 , -S(O)R 5a , -S(O)(NH)R 5 , -S(O)2R 5a , -S(O)2N(R 5 )(R 5 ), or -N=S(R 5a )(R 5a )=O, C 1~6 Alkyl is one to four R b and optionally substituted with a group, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 Bridged bicyclic cycloalkyl, 4- to 7-membered monocyclic heterocyclyl, phenyl, naphthalenyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl each independently represent 1 to 4 R a and optionally substituted with a group, R 9 is C 2~6 Alkenyl, C 2~6Alkynyl, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, or 7- to 10-membered spirocyclic heterocyclyl; C 2~6 Alkenyl and C 2~6 Alkynyl is independently selected from 1 to 4 R b and optionally substituted with a group, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 Bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl each independently represent 1 to 4 R a and optionally substituted with a group, Each R 5 and R 10 are independently H, C 1~6 Alkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, or 7- to 10-membered spirocyclic heterocyclyl; C 1~6 Alkyl, C 2~6 Alkenyl, and C 2~6 Alkynyl is independently selected from 1 to 4 R b and optionally substituted with a group, C3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 Bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl each independently represent 1 to 4 R a and optionally substituted with a group, Each R 5a independently, C 1~6 Alkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, or 7- to 10-membered spirocyclic heterocyclyl; C 1~6 Alkyl, C 2~6 Alkenyl, and C 2~6 Alkynyl is independently selected from 1 to 4 R b and optionally substituted with a group, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 Bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl each independently represent 1 to 4 R a and optionally substituted with a group, Each R a are independently oxo, imino, halogen, -NO2, -N3, -CN, C 1~6 Alkyl, C 2~6 Alkenyl, C2~6 Alkynyl, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 Bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, 7- to 10-membered spirocyclic heterocyclyl, -OR 11 , -C(O)R 11 , -C(O)OR 11 , -C(O)N(R 11 )(R 11 ), -NR 11 R 11 , -N(R 11 )2(R 11 ) + , -N(R 11 )C(O)R 11 , -N(R 11 )C(O)OR 11 , -N(R 11 )C(O)N(R 11 )(R 11 ), -N(R 11 )S(O)2(R 11a ), -NR 11 S(O)2N(R 11 )(R 11 ), -NR 11 S(O)2O(R 11a ), -OC(O)R 11 , -OC(O)OR 11 , -OC(O)N(R 11 )(R 11 ), -SR 11 , -S(O)R 11a , -S(O)(NH)R 11 , -S(O)2R 11a , -S(O)2N(R 11 )(R 11 ), or -N=S(R 11a )(R 11a )=O, C 1~6 Alkyl, C 2~6 Alkenyl, and C 2~6 Alkynyl is independently selected from 1 to 3 R cand optionally substituted with a group, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 Bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic The fused bicyclic heterocyclyl, 8- to 10-membered heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl each independently have 1 to 3 R d and optionally substituted with a group, Each R b are independently oxo, imino, halogen, -NO2, -N3, -CN, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 Bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 8- to 10-membered bridged bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, 7- to 10-membered spirocyclic heterocyclyl, -OR 11 , -C(O)R 11 , -C(O)OR 11 , -C(O)N(R 11 )(R 11 ), -NR 11 R 11 , -N(R 11 )2(R 11 ) + , -N(R 11 )C(O)R 11 , -N(R 11 )C(O)OR 11 , -N(R 11 )C(O)N(R 11 )(R 11 ), -N(R 11 )S(O)2(R 11a ), -NR 11 S(O)2N(R 11 )(R 11 ), -NR 11 S(O)2O(R 11a ), -OC(O)R11 , -OC(O)OR 11 , -OC(O)N(R 11 )(R 11 ), -SR 11 , -S(O)R 11a , -S(O)(NH)R 11 , -S(O)2R 11a , -S(O)2N(R 11 )(R 11 ), or -N=S(R 11a )(R 11a )=O, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 Bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl each independently represent 1 to 3 R d and optionally substituted with a group, Each R c are independently halogen, -CN, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 Bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, 7- to 10-membered spirocyclic heterocyclyl, -OR 12 , -C(O)R 12 , -C(O)OR 12 , -C(O)N(R 12 )(R 12 ), -NR 12 R 12 , -N(R 12 )2(R 12 ) + , -N(R 12 )C(O)R 12 , -N(R 12 )C(O)OR 12 , -N(R 12 )C(O)N(R 12 )(R12 ), -N(R 12 )S(O)2(R 12a ), -NR 12 S(O)2N(R 12 )(R 12 ), -NR 12 S(O)2O(R 12a ), -OC(O)R 12 , -OC(O)OR 12 , -OC(O)N(R 12 )(R 12 ), -SR 12 , -S(O)R 12a -S(O)(NH)R 12 , -S(O)2R 12a , -S(O)2N(R 12 )(R 12 ), or -N=S(R 12a )(R 12a )=O, Each R d are independently oxo, halogen, -CN, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 Bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, 7- to 10-membered spirocyclic heterocyclyl, -OR 12 , -C(O)R 12 , -C(O)OR 12 , -C(O)N(R 12 )(R 12 ), -NR 12 R 12 , -N(R 12 )2(R 12 ) + , -N(R 12 )C(O)R 12 , -N(R 12 )C(O)OR 12 , -N(R 12 )C(O)N(R 12 )(R 12 ), -N(R 12 )S(O)2(R 12a ), -NR 12 S(O)2N(R 12 )(R12 ), -NR 12 S(O)2O(R 12a ), -OC(O)R 12 , -OC(O)OR 12 , -OC(O)N(R 12 )(R 12 ), -SR 12 , -S(O)R 12a , -S(O)(NH)R 12 , -S(O)2R 12a , -S(O)2N(R 12 )(R 12 ), or -N=S(R 12a )(R 12a )=O, Each R 11 are independently H, C 1~6 Alkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, or 7- to 10-membered spirocyclic heterocyclyl; C 1~6 Alkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 Bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl each independently represent 1 to 3 R c and optionally substituted with a group, Each R 11a independently, C 1~6 Alkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, C3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, or 7- to 10-membered spirocyclic heterocyclyl; C 1~6 Alkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 Bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl each independently represent 1 to 3 R c and optionally substituted with a group, Each R 12 are independently H, C 1~6 Alkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, or 7- to 10-membered spirocyclic heterocyclyl; Each R 12a independently, C 1~6 Alkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, or 7- to 10-membered spirocyclic heterocyclyl; each 4-membered monocyclic heterocyclyl has one ring heteroatom independently selected from N, O, and S; each 5- to 7-membered monocyclic heterocyclyl independently has 1 to 2 ring heteroatoms independently selected from N, O, and S; each 6-membered bridged bicyclic heterocyclyl has one ring heteroatom independently selected from N, O, and S; each 7-membered bridged bicyclic heterocyclyl independently has 1 to 2 ring heteroatoms independently selected from N, O, and S; Provided herein are compounds or pharmaceutically acceptable salts thereof, wherein each 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 8- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl independently has 1 to 4 ring heteroatoms independently selected from N, O, and S.

[0006] In one embodiment, provided herein is a pharmaceutical composition comprising a compound provided herein, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient or carrier.

[0007] In one embodiment, a method for inhibiting the activity of toll-like receptors 7 and / or 8 in a subject in need thereof comprises administering to the subject a therapeutically effective amount of a compound provided herein or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of a pharmaceutical composition provided herein. Provided herein are methods that include administering.

[0008] In one embodiment, provided herein is a method of inhibiting the activity of toll-like receptor 7 in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound provided herein or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of a pharmaceutical composition provided herein.

[0009] In one embodiment, provided herein is a method of inhibiting the activity of toll-like receptor 8 in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound provided herein or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of a pharmaceutical composition provided herein.

[0010] In one embodiment, provided herein is a method of treating a disease or disorder associated with elevated toll-like receptor 7 and / or 8 activity in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound provided herein or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of a pharmaceutical composition provided herein.

[0011] In one embodiment, provided herein is a method of treating a disease or disorder associated with elevated toll-like receptor 7 activity in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound provided herein or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of a pharmaceutical composition provided herein.

[0012] In one embodiment, provided herein is a method of treating a disease or disorder associated with elevated toll-like receptor 8 activity in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound provided herein or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of a pharmaceutical composition provided herein.

[0013] In one embodiment, provided herein is a method of treating an inflammatory condition in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound provided herein or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of a pharmaceutical composition provided herein.

[0014] In one embodiment, provided herein is a method of treating systemic lupus erythematosus in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound provided herein or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of a pharmaceutical composition provided herein.

[0015] In one embodiment, provided herein is a method of treating cutaneous lupus erythematosus in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound provided herein or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of a pharmaceutical composition provided herein.

[0016] In one embodiment, provided herein is a method of treating lupus nephritis in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound provided herein or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of a pharmaceutical composition provided herein.

[0017] In one embodiment, provided herein is a compound provided herein or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition provided herein, for use in therapy.

[0018] In one embodiment, provided herein is a compound provided herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition provided herein, for use in a method of inhibiting the activity of toll-like receptors 7 and / or 8 in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the compound, or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of the pharmaceutical composition.

[0019] In one embodiment, provided herein is a compound provided herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition provided herein, for use in a method of inhibiting the activity of toll-like receptor 7 in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the compound, or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of the pharmaceutical composition.

[0020] In one embodiment, provided herein is a compound provided herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition provided herein, for use in a method of inhibiting the activity of toll-like receptor 8 in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the compound, or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of the pharmaceutical composition.

[0021] In one embodiment, provided herein is a compound provided herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition provided herein, for use in a method of treating a disease or disorder associated with elevated toll-like receptor 7 and / or 8 activity in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the compound, or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of the pharmaceutical composition.

[0022] In one embodiment, provided herein is a compound provided herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition provided herein, for use in a method of treating a disease or disorder associated with elevated toll-like receptor 7 activity in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the compound, or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of the pharmaceutical composition.

[0023] In one embodiment, provided herein is a compound provided herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition provided herein, for use in a method of treating a disease or disorder associated with elevated toll-like receptor 8 activity in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the compound, or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of the pharmaceutical composition.

[0024] In one embodiment, provided herein is a compound provided herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition provided herein, for use in a method of treating an inflammatory condition in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the compound, or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of the pharmaceutical composition.

[0025] In one embodiment, provided herein is a compound provided herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition provided herein, for use in a method of treating systemic lupus erythematosus in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the compound, or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of the pharmaceutical composition.

[0026] In one embodiment, a compound provided herein, or a pharmaceutically acceptable salt thereof, for use in a method for treating cutaneous lupus erythematosus in a subject in need thereof. Alternatively, provided herein is a pharmaceutical composition, the method comprising administering to a subject a therapeutically effective amount of a compound or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of the pharmaceutical composition. DETAILED DESCRIPTION OF THE INVENTION

[0027] I. Definition The following description is made with the understanding that the present disclosure should be considered as an example of claimed subject matter and is not intended to limit the scope of the appended claims to the particular embodiments illustrated. Headings used throughout this disclosure are for convenience only and should not be construed as limiting the scope of the claims in any way. Embodiments illustrated under any heading may be combined with embodiments illustrated under any other heading.

[0028] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art. It should be noted that, as used in this specification and the appended claims, the singular forms "a," "and," and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, a reference to a "compound" includes a plurality of such compounds, and a reference to an "assay" includes a reference to one or more assays and equivalents thereof known to those skilled in the art, etc.

[0029] As used in this disclosure, the following words, phrases, and symbols are generally intended to have the meanings set forth below, unless the context in which they are used indicates otherwise.

[0030] A dash ("-") that is not between two letters or symbols is used to indicate the point of attachment for a substituent. For example, -CONH2 is attached through a carbon atom. Dashes at the front or end of a chemical group are for convenience, and chemical groups may be designated with or without one or more dashes without losing their ordinary meaning. A wavy line drawn across a line in a structure indicates the point of attachment of the group. No directionality is indicated or implied by the order in which chemical groups are written or named, unless chemically or structurally required. A solid line extending from the center of a ring (including fused, bridged, or spirocyclic ring systems) indicates that the point of attachment of a substituent to that ring may be at any ring atom. For example, R in the following structure: aamay be attached to any of the five carbon ring atoms, or the hydrogen attached to the nitrogen ring atom may be attached to R aa may be replaced by:

[0031] [ka]

[0032] As another example, R in the following structure: aa So,

[0033] [ka] R aa can be attached at any of the numbered positions shown below:

[0034] [ka]

[0035] A solid line projecting from the center of a ring (including fused, bridged, or spirocyclic ring systems) indicates that the point of attachment of the ring system to the remainder of the compound can be at any ring atom of the fused, bridged, or spirocyclic ring system. For example, in the structure:

[0036] [ka] The monocyclic heterocyclyl can be attached to the remainder of the compound at any of the numbered positions shown below:

[0037] [ka]

[0038] As another example, in the following fused bicyclic heterocyclic structure:

[0039] [ka] The fused bicyclic heterocyclyl can be attached to the rest of the compound at any of the eight numbered positions shown below:

[0040] [ka]

[0041] "C u~v " prefix indicates that the following group has u to v carbon atoms. For example, "C 1~6 Similarly, the term "x- to y-membered" ring, where x and y are numerical ranges (e.g., 3- to 12-membered rings), refers to an alkyl group having 1 to 6 carbon atoms. "Heterocyclyl" and the like) means a ring having x to y (i.e., 3 to 12) atoms, up to 80% of which may be heteroatoms such as N, O, S, P, and the remaining atoms are carbon.

[0042] Also, certain commonly used alternative chemical names may or may not be used. For example, divalent groups such as divalent "alkyl" groups, divalent "aryl" groups, etc. may also be referred to as "alkylene" or "alkylenyl" groups, or alkylyl groups, "arylene" or "arylenyl" groups, or aryl groups, respectively.

[0043] "Compounds disclosed herein" or "compounds of the disclosure" or "compounds provided herein" or "compounds described herein" refer to compounds of Formula I. Also included are the specific compounds of Examples 1-68.

[0044] Reference herein to "about" a value or parameter includes (and describes) embodiments related to the value or parameter itself. In certain embodiments, the term "about" includes the stated amount ±10%. In other embodiments, the term "about" includes the stated amount ±5%. In certain other embodiments, the term "about" includes the stated amount ±1%. Additionally, the term "about X" includes the description of "X."

[0045] "Alkyl" refers to an unbranched or branched saturated hydrocarbon chain. As used herein, alkyl has 1 to 20 carbon atoms (i.e., C 1~20 alkyl), having 1 to 12 carbon atoms (i.e., C 1~12 alkyl), having 1 to 8 carbon atoms (i.e., C 1~8 alkyl), having 1 to 6 carbon atoms (i.e., C 1~6 alkyl), having 1 to 4 carbon atoms (i.e., C 1~4 alkyl), having 1 to 3 carbon atoms (i.e., C 1~3 alkyl), or having 1 to 2 carbon atoms (i.e., C 1~2 alkyl). Examples of alkyl groups are methyl, ethyl, propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, pentyl, 2-pentyl, isopentyl, neopentyl, hexyl, 2-hexyl, 3-hexyl, and 3-methylpentyl. When an alkyl group having a specific number of carbon atoms is designated by a chemical name or identified by a molecular formula, all positional isomers having that number of carbon atoms can be included; thus, for example, "butyl" includes n-butyl (i.e., -(CH2)3CH3), sec-butyl (i.e., -CH(CH3)CH2CH3), isobutyl (i.e., -CH2CH(CH3)2), and tert-butyl (i.e., -C(CH3)3), and "propyl" includes n-propyl (i.e., -(CH2)2CH3) and isopropyl (i.e., -CH(CH3)2).

[0046] "Alkenyl" refers to an alkyl group containing at least one carbon-carbon double bond and having 2 to 20 carbon atoms (i.e., C 2~20 alkenyl), having 2 to 8 carbon atoms (i.e., C 2~8 alkenyl), having 2 to 6 carbon atoms (i.e., C 2~6 alkenyl), or having 2 to 4 carbon atoms (i.e., C 2~4 Alkenyl refers to an aliphatic group. Examples of alkenyl groups are ethenyl, propenyl, and butadienyl (including 1,2-butadienyl and 1,3-butadienyl).

[0047] "Alkynyl" refers to an alkyl group containing at least one carbon-carbon triple bond and having 2 to 20 carbon atoms (i.e., C 2~20 alkynyl), having 2 to 8 carbon atoms (i.e., C 2~8 alkynyl), having 2 to 6 carbon atoms (i.e., C 2~6 alkynyl), or having 2 to 4 carbon atoms (i.e., C 2~4 alkynyl), an aliphatic group. The term "alkynyl" also includes alkynyl groups having one triple bond and one double bond.

[0048] "Alkylene" refers to a divalent unbranched saturated hydrocarbon chain. As used herein, alkylene has 1 to 20 carbon atoms (i.e., C 1~20 alkylene), having 1 to 12 carbon atoms (i.e., C 1~12 alkylene), having 1 to 8 carbon atoms (i.e., C 1~8 alkylene), having 1 to 6 carbon atoms (i.e., C 1~6 alkylene), having 1 to 4 carbon atoms (i.e., C 1~4 alkylene), having 1 to 3 carbon atoms (i.e., C 1~3 alkylene), or having 1 to 2 carbon atoms (i.e., C 1~2alkylene). Examples of alkylene groups include methylene, ethylene, propylene, butylene, pentylene, and hexylene. In some embodiments, alkylene is optionally substituted with an alkyl group. Substituted alkylene groups include -CH(CH3)CH2-, -CH2CH(CH3)-, -CH2CH(CH2CH3)-, -CH2C(CH3)2-, -C(CH3)2CH2-, -CH(CH3)CH(CH3)-, -CH2C(CH2CH3)(CH3)-, and -CH2C(CH2CH3)2.

[0049] "Alkoxy" refers to an "alkyl-O-" group. Examples of alkoxy groups include methoxy, ethoxy, n-propoxy, iso-propoxy, n-butoxy, tert-butoxy, sec-butoxy, n-pentoxy, n-hexoxy, and 1,2-dimethylbutoxy. "Haloalkoxy" refers to an alkoxy group, as defined above, in which one or more hydrogen atoms are replaced by halogen.

[0050] "Acyl" refers to the group -C(=O)R, where R is hydrogen, alkyl, cycloalkyl, heterocyclyl, aryl, heteroalkyl, or heteroaryl, each of which may be optionally substituted as defined herein. Examples of acyl include formyl, acetyl, cyclohexylcarbonyl, cyclohexylmethyl-carbonyl, and benzoyl.

[0051] "Amide" is -C(=O)NR y R z "C-amido" refers to the group, and -NR y C(=O)R z "N-amide group" refers to both the N-amide group and the N-amide group. y and R z is independently selected from the group consisting of hydrogen, alkyl, aryl, haloalkyl, heteroaryl, cycloalkyl, or heterocyclyl, each of which is optionally substituted.

[0052] "Amino" is -NRy R z refers to a group, wherein R y and R z is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, aryl, heteroaryl, cycloalkyl, or heterocyclyl, each of which is optionally substituted.

[0053] "Aryl" refers to an aromatic carbocyclic group having a single ring (e.g., monocyclic) or multiple rings (e.g., bicyclic or tricyclic), including fused systems. As used herein, aryl refers to a group having 6 to 20 ring carbon atoms (i.e., C 6~20 aryl), having 6 to 12 carbon ring atoms (i.e., C 6~12 aryl), or having 6 to 10 carbon ring atoms (i.e., C 6~10 Aryl). Examples of aryl groups include phenyl, naphthyl, fluorenyl, and anthryl. However, aryl does not encompass or overlap in any way with heteroaryl, as defined below. When one or more aryl groups are fused to a heteroaryl ring, the resulting ring system is heteroaryl.

[0054] "Cyano" or "carbonitrile" refers to the group --CN.

[0055] "Cycloalkyl" refers to saturated or partially saturated cyclic alkyl groups having single or multiple rings, including fused, bridged, and spiro ring systems. The term "cycloalkyl" , including cycloalkenyl groups (i.e., cyclic groups having at least one double bond). As used herein, cycloalkyl refers to groups having 3 to 20 ring carbon atoms (i.e., C 3~20 cycloalkyl), having 3 to 12 ring carbon atoms (i.e., C 3~12 cycloalkyl), having 3 to 10 ring carbon atoms (i.e., C 3~10 cycloalkyl), having 3 to 8 ring carbon atoms (i.e., C 3~8cycloalkyl), or having 3 to 6 ring carbon atoms (i.e., C 3~6 Examples of cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.

[0056] "Bridged" refers to a ring fusion in which different atoms on the ring are joined by a divalent substituent such as an alkylenyl group, an alkylenyl group containing one or two heteroatoms, or a single heteroatom. Quinuclidinyl and admantanyl are examples of bridged ring systems.

[0057] The term "fused" refers to rings that are joined to adjacent rings.

[0058] "Spiro" refers to a ring substituent joined by two bonds at the same carbon atom. Examples of spiro groups include 1,1-diethylcyclopentane, dimethyl-dioxolane, and 4-benzyl-4-methylpiperidine, where cyclopentane and piperidine, respectively, are spiro substituents.

[0059] "Halogen" or "halo" includes fluoro, chloro, bromo, and iodo.

[0060] "Haloalkyl" refers to an unbranched or branched alkyl group, as defined above, in which one or more hydrogen atoms are replaced by halogen. For example, if a residue is substituted with two or more halogens, it can be referred to by using a prefix corresponding to the number of halogen moieties attached. Dihaloalkyl and trihaloalkyl refer to alkyl substituted with two ("di") or three ("tri") halo groups, which may, but are not necessarily, the same halogen. Examples of haloalkyl include difluoromethyl (-CHF2) and trifluoromethyl (-CF3).

[0061] "Heteroalkylene" refers to a divalent unbranched saturated hydrocarbon chain having 1, 2, or 3 heteroatoms selected from NH, O, or S. As used herein, heteroalkylene refers to a heterocyclic group having 1 to 20 carbon atoms and 1, 2, or 3 heteroatoms selected from NH, O, and S (i.e., C 1~20 heteroalkylene; 1 to 8 carbon atoms and 1, 2, or 3 heteroatoms selected from NH, O, and S (i.e., C 1~8 heteroalkylene; 1 to 6 carbon atoms and 1, 2, or 3 heteroatoms selected from NH, O, and S (i.e., C 1~6 heteroalkylene; 1 to 4 carbon atoms and 1, 2, or 3 heteroatoms selected from NH, O, and S (i.e., C 1~4 heteroalkylene; 1 to 3 carbon atoms and 1, 2, or 3 heteroatoms selected from NH, O, and S (i.e., C 1~3 heteroalkylene); or 1 to 2 carbon atoms and 1, 2, or 3 heteroatoms selected from NH, O, and S (i.e., C 1~3 Heteroalkylene groups include -CH2CHOCH2-, -CH2SCH2OCH2-, -CH2O-, and -CH2NHCH2-. In some embodiments, heteroalkylene groups are optionally substituted with an alkyl group. Examples of substituted heteroalkylene groups include -CH(CH3)N(CH3)CH2-, -CH2OCH(CH3)-, -CH2CH(CH2CH3)S-, -CH2NHC(CH3)2-, -C(CH3)2SCH2-, -CH(CH3)N(CH3)C Examples include -H(CH3)O-, -CH2SC(CH2CH3)(CH3)-, and -CH2C(CH2CH3)2NH-.

[0062] "Heteroaryl" refers to an aromatic group having a single ring, multiple rings, or multiple fused rings, with one or more ring heteroatoms independently selected from nitrogen, oxygen, and sulfur. As used herein, heteroaryl refers to a group having 1 to 20 carbon ring atoms (i.e., C 1~20 heteroaryl), 3 to 12 carbon ring atoms (i.e., C 3~12 heteroaryl), or 3 to 8 carbon ring atoms (i.e., C 3~8 Heteroaryl) and contains 1 to 5 ring heteroatoms, 1 to 4 ring heteroatoms, 1 to 3 ring heteroatoms, 1 to 2 ring heteroatoms, or 1 ring heteroatom independently selected from nitrogen, oxygen, and sulfur. Examples of heteroaryl groups include pyrimidinyl, purinyl, pyridyl, pyridazinyl, benzothiazolyl, and pyrazolyl. Heteroaryl does not encompass and does not overlap with aryl, as defined above.

[0063] "Heterocyclyl" or "heterocyclic ring" or "heterocycle" refers to a non-aromatic cyclic alkyl group having one or more ring heteroatoms independently selected from nitrogen, oxygen, and sulfur. As used herein, "heterocyclyl" or "heterocyclic ring" or "heterocycle" refers to a saturated or partially saturated ring unless otherwise specified. For example, in some embodiments, "heterocyclyl" or "heterocyclic ring" or "heterocycle" refers to a partially saturated ring when specified. The term "heterocyclyl" or "heterocyclic ring" or "heterocycle" includes heterocycloalkenyl groups (i.e., heterocyclyl groups having at least one double bond). Heterocyclyls may be monocyclic or polycyclic, and polycyclic rings may be fused, bridged, or spiro. As used herein, heterocyclyls have 2 to 20 carbon ring atoms (i.e., C 2~20 heterocyclyl), having 2 to 12 carbon ring atoms (i.e., C 2~12 heterocyclyl), having 2 to 10 carbon ring atoms (i.e., C 2~10 heterocyclyl), having 2 to 8 carbon ring atoms (i.e., C 2~8heterocyclyl), having 3 to 12 carbon ring atoms (i.e., C 3~12 heterocyclyl), having 3 to 8 carbon ring atoms (i.e., C 3~8 heterocyclyl), or having 3 to 6 carbon ring atoms (i.e., C 3~6 Heterocyclyl; having 1 to 5 ring heteroatoms, 1 to 4 ring heteroatoms, 1 to 3 ring heteroatoms, 1 to 2 ring heteroatoms, or 1 ring heteroatom independently selected from nitrogen, sulfur, or oxygen. Examples of heterocyclyl groups include pyrrolidinyl, piperidinyl, piperazinyl, oxetanyl, dioxolanyl, azetidinyl, and morpholinyl. As used herein, the term "bridged heterocyclyl" refers to a 4- to 10-membered ring moiety in which each heteroatom is independently connected to at least one heteroatom selected from nitrogen, oxygen, and sulfur at two non-adjacent atoms of a heterocyclyl having one or more (e.g., one or two) 4- to 10-membered ring moieties. As used herein, "bridged heterocyclyl" includes bicyclic and tricyclic ring systems. As used herein, the term "spiroheterocyclyl" refers to a ring system in which a 3- to 10-membered heterocyclyl has one or more additional rings, wherein the one or more additional rings are 3- to 10-membered cycloalkyl or 3- to 10-membered heterocyclyl, and a single atom of the one or more additional rings is also an atom of the 3- to 10-membered heterocyclyl. Examples of spiroheterocyclyls include bicyclic and tricyclic ring systems such as 2-oxa-7-azaspiro[3.5]nonanyl, 2-oxa-6-azaspiro[3.4]octanyl, and 6-oxa-1-azaspiro[3.3]heptanyl. As used herein, the terms "heterocycle," "heterocyclyl," and "heterocyclic ring" are used interchangeably. In some embodiments, the heterocyclyl is substituted with an oxo group.

[0064] "Hydroxy" or "hydroxyl" refers to the group --OH.

[0065] "Oxo" refers to the (=O) or (O) radical.

[0066] "Sulfonyl" is -S(O)R bb refers to a group, wherein R bb is alkyl, haloalkyl, heterocyclyl, cycloalkyl, heteroaryl, or aryl. Examples of sulfonyl are methylsulfonyl, ethylsulfonyl, phenylsulfonyl, and toluenesulfonyl.

[0067] Whenever a group illustration terminates in a single bonded nitrogen atom, that group represents an -NH group unless otherwise indicated. Similarly, unless otherwise stated, hydrogen atoms are implied and considered to be present when needed to complete valence or provide stability, given the knowledge of those skilled in the art.

[0068] The term "optional" or "optionally" means that the subsequently described event or circumstance may or may not occur, and that the description includes instances when the event or circumstance occurs and instances when the event or circumstance does not occur. Also, the term "optionally substituted" means that any one or more hydrogen atoms on a specified atom or group may or may not be replaced by a non-hydrogen moiety.

[0069] The term "substituted" means that any one or more hydrogen atoms on the specified atom or group are replaced with one or more substituents other than hydrogen, provided that the normal valence of the specified atom is not exceeded. The one or more substituents include, but are not limited to, alkyl, alkenyl, alkynyl, alkoxy, acyl, amino, amido, amidino, aryl, azido, carbamoyl, carboxyl, carboxyl ester, cyano, guanidino, halo, haloalkyl, heteroalkyl, heteroaryl, heterocyclyl, hydroxy, hydrazino, imino, oxo, nitro, alkylsulfinyl, sulfonic acid, alkylsulfonyl, thiocyanato, thiol, thione, or combinations thereof. Polymers or similar amorphous structures resulting from defining the substituents with an infinite number of additional substituents (e.g., substituted aryls with substituted alkyls, which themselves are substituted with substituted aryl groups, which are further substituted with substituted heteroalkyl groups, etc.) are not intended to be included herein. Unless otherwise specified, the maximum number of consecutive substitutions in the compounds described herein is three. For example, consecutive substitution of a substituted aryl group with two other substituted aryl groups is limited to ((substituted aryl)substituted aryl)substituted aryl. Similarly, the above definition is not intended to include impermissible substitution patterns (e.g., methyl substituted with five fluorines or a heteroaryl group having two adjacent oxygen ring atoms). Such impermissible substitution patterns are well known to those of ordinary skill in the art. When used to modify a chemical group, the term "substituted" can describe other chemical groups defined herein. For example, the term "substituted aryl" includes, but is not limited to, "alkylaryl." Unless otherwise specified, if a group is described as optionally substituted, any substituents of the group are themselves unsubstituted.

[0070] In some embodiments, the substituted cycloalkyl, substituted heterocyclyl, substituted aryl, and / or substituted heteroaryl includes a cycloalkyl, heterocyclyl, aryl, and / or heteroaryl having a substituent on a ring atom, where the cycloalkyl, heterocyclyl, aryl, and / or heteroaryl is attached to the remainder of the compound. For example, in the moiety below, the cyclopropyl is substituted with a methyl group:

[0071] [ka]

[0072] The compounds of the embodiments disclosed herein, or pharmaceutically acceptable salts thereof, may contain one or more asymmetric centers and thus give rise to enantiomers, diastereomers, and other stereoisomeric forms that can be defined, with respect to absolute stereochemistry, as (R)- or (S)-, or for amino acids, as (D)- or (L)-. The present disclosure is meant to include all such possible isomers, as well as their racemic and optically pure forms. Optically active (+)- and (−), (R)- and (S)-, or (D)- and (L)-isomers may be prepared using chiral synthons or chiral reagents or resolved using conventional techniques, such as chromatography and fractional crystallization. Conventional techniques for the preparation / isolation of individual enantiomers include chiral synthesis from suitable optically pure precursors, or resolution of the racemate (or racemate of a salt or derivative) using, for example, chiral high-pressure liquid chromatography (HPLC). When compounds described herein contain olefinic double bonds or other centers of geometric asymmetry, and unless otherwise specified, these compounds are intended to include both E and Z geometric isomers. Likewise, all tautomeric forms are also intended to be included. When compounds are represented in their chiral form, it is understood that embodiments include, but are not limited to, the specific diastereomerically or enantiomerically enriched forms. Where chirality is not specified, it is understood that embodiments are directed to either the specific diastereomerically or enantiomerically enriched forms, or racemic or scalemic mixtures of such compounds. As used herein, a "scalemic mixture" is a mixture of stereoisomers in a ratio other than 1:1.

[0073] "Stereoisomers" refer to compounds made up of the same atoms connected by the same bonds but with different, not interchangeable, three-dimensional structures. The present disclosure contemplates various stereoisomers and mixtures thereof, and includes "enantiomers," which refer to two stereoisomers whose molecules are non-superimposable mirror images of one another.

[0074] "Enantiomers" are a pair of stereoisomers that are non-superimposable mirror images of each other. A 1:1 mixture of a pair of enantiomers is a "racemic" mixture. A mixture of enantiomers in a ratio other than 1:1 is a "scalemic" mixture.

[0075] "Diastereoisomers" are stereoisomers that have at least two asymmetric atoms, but which are not mirror-images of each other.

[0076] "Tautomer" refers to a proton migration from one atom of a molecule to another atom of the same molecule. The present disclosure includes tautomers of any compounds provided herein.

[0077] Some of the compounds provided herein exist as tautomeric isomers. Tautomeric isomers are in equilibrium with each other. For example, an amide-containing compound may exist in equilibrium with an imidic acid tautomer. Regardless of which tautomer is shown and regardless of the nature of the equilibrium between the tautomers, it is understood by those skilled in the art that the compound includes both the amide and imidic acid tautomers. Thus, amide-containing compounds are understood to include their imidic acid tautomers. Similarly, imidic acid-containing compounds are understood to include their amide tautomers.

[0078] A "solvate" is formed by the interaction of a solvent and a compound. Solvates of salts of the compounds provided herein are also provided. Hydrates of the compounds provided herein are also provided.

[0079] Any formula or structure provided herein is also intended to represent unlabeled and isotopically labeled forms of the compound.Isotopically labeled compounds have the structure shown by the formula provided herein, except that one or more atoms are replaced by atoms having a selected atomic mass or mass number.Examples of isotopes that can be incorporated into compounds of the present disclosure include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, fluorine, and chlorine, such as:2 H (deuterium, D), 3 H (tritium), 11 C. 13 C. 14 C. 15 N, 18 F, 31 P, 32 P, 35 S, 36 Cl and 125 I. Various isotopically labeled compounds of the present disclosure include, but are not limited to, 2 H, 3 H, 13 C and 14 1C, which incorporate a radioactive isotope, also provided herein. Such isotopically labeled compounds are useful for metabolic studies, reaction kinetic studies, positron emission tomography (PET) or single-photon emission computed tomography (SPECT) including drug or substrate tissue distribution assays. Such techniques may be useful in detection or imaging techniques such as radiotherapy, or in the radiation treatment of patients.

[0080] The present disclosure also includes compounds of Formula I or II in which 1 to n hydrogens bonded to a carbon atom have been replaced by deuterium, where n is the number of hydrogens in the molecule. Such compounds exhibit increased resistance to metabolism and are therefore useful for extending the half-life of any compound of Formula I or II when administered to a mammal, particularly a human. See, e.g., Foster, "Deuterium Isotope Effects in Studies of Drug Metabolism," Trends Pharmacol. Sci. 5(12):524-527 (1984). Such compounds are synthesized by means well known in the art, for example, by employing starting materials in which one or more hydrogens have been replaced by deuterium.

[0081] Deuterium-labeled or deuterium-substituted therapeutic compounds of the present disclosure may have improved DMPK (drug metabolism and pharmacokinetics) properties with respect to absorption, distribution, metabolism, and excretion (ADME). Substitution with heavier isotopes, such as deuterium, may confer certain therapeutic advantages due to greater metabolic stability, such as increased in vivo half-life, reduced dosage requirements, and / or improved therapeutic index. 18 F-labeled compounds can be useful in PET or SPECT studies.The isotopically labeled compounds of the present disclosure and their prodrugs can generally be prepared by replacing readily available isotopically labeled reagents with non-isotopically labeled reagents, and carrying out the procedures disclosed in the schemes or the examples and preparations described below.In this context, it is understood that deuterium is considered to be a substituent in the compound of formula I or II.

[0082] The concentration of such heavier isotopes, specifically deuterium, can be defined by the isotopic enrichment factor. In the compounds of the present disclosure, any atom not specifically designated as a particular isotope is meant to represent any stable isotope of that atom. Unless otherwise specified, when a position is specifically designated as "H" or "hydrogen," the position is understood to have that hydrogen at the natural abundance isotopic composition of hydrogen. Thus, in the compounds of the present disclosure, any atom specifically designated as deuterium (D) is meant to represent deuterium.

[0083] In many cases, the compounds of the present disclosure are capable of forming acid and / or base salts by virtue of the presence of amino and / or carboxyl groups or groups similar thereto.

[0084] The term "pharmaceutically acceptable salt" of a given compound refers to a salt that retains the biological effectiveness and properties of the given compound and is not biologically or otherwise undesirable. Pharmaceutically acceptable base addition salts can be prepared from inorganic and organic bases. Salts derived from inorganic bases include, by way of example only, sodium, potassium, lithium, ammonium, calcium, and magnesium salts. Salts derived from organic bases include, but are not limited to, salts of primary, secondary, and tertiary amines, such as alkylamines, dialkylamines, trialkylamines, substituted alkylamines, di(substituted alkyl)amines, tri(substituted alkyl)amines, alkenylamines, dialkenylamines, trialkenylamines, substituted alkenylamines, di(substituted alkenyl)amines, tri(substituted alkenyl)amines, mono-, di-, or tricycloalkylamines, mono-, di-, or triarylamines, or mixed amines. Specific examples of suitable amines include, by way of example only, isopropylamine, trimethylamine, diethylamine, tri(iso-propyl)amine, tri(n-propyl)amine, ethanolamine, 2-dimethylaminoethanol, piperazine, piperidine, morpholine, N-ethylpiperidine, and the like.

[0085] Pharmaceutically acceptable acid addition salts can be prepared from inorganic and organic acids. Salts derived from inorganic acids include hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, etc. Salts derived from organic acids include acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, malic acid, malonic acid, succinic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, etc.

[0086] As used herein, "pharmaceutically acceptable carriers" or "pharmaceutically acceptable excipients" include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic agents, and absorption delaying agents. The use of such media and agents for pharmaceutically active substances is well known in the art. Except as far as any conventional media or agent is incompatible with the active ingredient, its use in therapeutic compositions is contemplated. Supplementary active ingredients can also be incorporated into the compositions.

[0087] "Treatment" or "treating" is an approach for obtaining beneficial or desired results, including clinical results. Beneficial or desired clinical results can include one or more of the following: a) inhibiting the disease or condition (i.e., reducing one or more symptoms resulting from the disease or condition and / or attenuating the severity of the disease or condition), b) slowing or arresting the onset of one or more clinical symptoms associated with the disease or condition (i.e., stabilizing the disease or condition, preventing or slowing the worsening or progression of the disease or condition, and / or preventing or slowing the spread (i.e., metastasis) of the disease or condition), and / or c) palliating the disease, i.e., causing regression of clinical symptoms (i.e., improving the disease state, providing partial or complete remission of the disease or condition, enhancing the effect of another drug, slowing the progression of the disease, improving quality of life, and / or prolonging survival).

[0088] "Prevention" or "preventing" means any treatment of a disease or condition that results in the non-development of clinical symptoms of the disease or condition. In some embodiments, the compounds may be administered to subjects (including humans) who are at risk or have a family history of the disease or condition.

[0089] "Subject" refers to an animal, such as a mammal (including a human), that has been or will be the object of treatment, observation, or experiment. The methods described herein may be useful in human therapy and / or veterinary applications. In some embodiments, a subject is a mammal In one embodiment, the subject is a human.

[0090] The term "therapeutically effective amount" or "effective amount" of a compound described herein or a pharmaceutically acceptable salt, isomer, or mixture thereof means an amount sufficient to effect treatment and provide a therapeutic benefit, such as amelioration of symptoms or slowing of disease progression, when administered to a subject. For example, a therapeutically effective amount can be an amount sufficient to ameliorate the symptoms of a disease or condition in response to inhibition of toll-like receptors 7, 8, and / or 9. A therapeutically effective amount may vary depending on the subject, the disease or condition being treated, the weight and age of the subject, the severity of the disease or condition, and the mode of administration, and can be readily determined by one of ordinary skill in the art.

[0091] II. Compounds In one embodiment, a compound of formula I:

[0092] [ka] or a pharmaceutically acceptable salt thereof, During the ceremony, R 1 is a 4- to 7-membered monocyclic heterocyclyl, phenyl, naphthalenyl, a 5- to 6-membered monocyclic heteroaryl, an 8- to 10-membered fused bicyclic heterocyclyl, or an 8- to 10-membered fused bicyclic heteroaryl; The 4- to 7-membered monocyclic heterocyclyl, phenyl, naphthalenyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, and 8- to 10-membered fused bicyclic heteroaryl each independently represent 1 to 4 R a and optionally substituted with a group, R 2 are H, -CN, and C 1~6 Alkyl, or C 3~7 is a monocyclic cycloalkyl, C 1~6Alkyl and C 3~7 monocyclic cycloalkyls each independently represent a halogen and C 1~6 optionally substituted with 1 to 4 groups independently selected from alkoxy; X is N or CR 3 and R 3 is H, halogen, -CN, C 1~6 Alkyl, C 3~6 Monocyclic cycloalkyl, or -O(C 1~4 alkyl), and C 1~4 Alkyl is -OH, halogen, -CN, -NR 4 R 4 , and C 1~4 optionally substituted with 1 to 3 groups independently selected from alkoxy; Z is C 1~10 Alkyl, C 2~6 Alkynyl, -NR 6 R 7 , -C(O)R 13 , -C(O)NR 6 R 7 , -S(O)2R 6 , C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 bridged bicyclic cycloalkyl, 4- to 7-membered monocyclic heterocyclyl, phenyl, naphthalenyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, 7- to 10-membered spirocyclic heterocyclyl, or L 1 and C 1~10 Alkyl and C 2~6 Alkynyl is independently selected from 1 to 4 R b and optionally substituted with a group, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10Bridged bicyclic cycloalkyl, 4- to 7-membered monocyclic heterocyclyl, phenyl, naphthalenyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl each independently represent one to two R 8 and optionally substituted with a group, and each independently, 1 to 3 R a and optionally substituted with a group, L 1 -OR 5 , -C(O)R 5 , -C(O)N(R 5 )(R 5 ), -NR 5 R 5 , -N(R 5 )2(R 5 ) + , -N(R 5 )C(O)R 5 , -N(R 5 )C(O)OR 5 , -N(R 5 )C(O)N(R 5 )(R 5 ), -N(R 5 )S(O)2(R 5a ), -NR 5 S(O)2N(R 5 )(R 5 ), -NR 5 S(O)2O(R 5a ), -OC(O)N(R 5 )(R 5 ), -SR 5 , -S(O)R 5a , -S(O)(NH)R 5 , -S(O)2R 5a , S(O)2N(R 5 )(R 5 ), or -N=S(R 5a )(R 5a )=O, R 6 is C 1~6 Alkyl, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C5~10 a bridged bicyclic cycloalkyl, a 4- to 7-membered monocyclic heterocyclyl, a phenyl, a naphthalenyl, a 5- to 6-membered monocyclic heteroaryl, an 8- to 10-membered fused bicyclic heterocyclyl, a 6- to 10-membered bridged bicyclic heterocyclyl, an 8- to 10-membered fused bicyclic heteroaryl, or a 7- to 10-membered spirocyclic heterocyclyl; C 1~6 Alkyl is one to four R b and optionally substituted with a group, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 Bridged bicyclic cycloalkyl, 4- to 7-membered monocyclic heterocyclyl, phenyl, naphthalenyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl each independently represent 1 to 4 R a and optionally substituted with a group, R 13 is C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 a bridged bicyclic cycloalkyl, a 4- to 7-membered monocyclic heterocyclyl, a phenyl, a naphthalenyl, a 5- to 6-membered monocyclic heteroaryl, an 8- to 10-membered fused bicyclic heterocyclyl, a 6- to 10-membered bridged bicyclic heterocyclyl, an 8- to 10-membered fused bicyclic heteroaryl, or a 7- to 10-membered spirocyclic heterocyclyl; C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 Bridged bicyclic cycloalkyl, 4- to 7-membered monocyclic heterocyclyl, phenyl, naphthalenyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl each independently represent 1 to 4 R a and optionally substituted with a group, Each R 4 are independently H or C 1~3 is alkyl, R 7 is H, C1-6 alkyl, C 3~7 monocyclic cycloalkyl or 4- to 6-membered monocyclic heterocyclyl, 1~6 Alkyl, C 3~7 Monocyclic cycloalkyl and 4- to 6-membered monocyclic heterocyclyl are each independently selected from -OH, halogen, -CN, and C 1~6 optionally substituted with 1 to 4 groups independently selected from alkoxy; Each R 8 are independently halogen, -C(O)R 9 , -NR 10 R 10 , C 1~6 Alkyl, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 Bridged bicyclic cycloalkyl, 4-7 membered monocyclic heterocyclyl, phenyl, naphthalenyl, 5-6 membered monocyclic heteroaryl, 8-10 membered fused bicyclic heterocyclyl, 6-10 membered bridged bicyclic heterocyclyl, 8-10 membered fused bicyclic heteroaryl, 7-10 membered spirocyclic heterocyclyl, -OR 5 , -C(O)OR 5 , -C(O)N(R 5 )(R 5 ), -N(R 5 )2(R 5 ) + , -N(R 5 )C(O)R 5 , -N(R 5 )C(O)OR 5 , -N(R 5 )C(O)N(R 5 )(R 5 ), -N(R 5 )S(O)2(R 5a ), -NR 5 S(O)2N(R 5 )(R 5 ), -NR 5 S(O)2O(R 5a ), -OC(O)R 5 , -OC(O)OR 5 , -OC(O)N(R 5 )(R 5 ), -SR5 , -S(O)R 5a , -S(O)(NH)R 5 , -S(O)2R 5a , -S(O)2N(R 5 )(R 5 ), or -N=S(R 5a )(R 5a )=O, C 1~6 Alkyl is one to four R b and optionally substituted with a group, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 Bridged bicyclic cycloalkyl, 4-7 membered monocyclic heterocyclyl, phenyl, naphthalenyl, 5-6 membered monocyclic heteroaryl, 8-10 membered fused bicyclic heterocyclyl, 6-10 membered bridged bicyclic The fused bicyclic heterocyclyl, 8- to 10-membered heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl each independently represent 1 to 4 R a and optionally substituted with a group, R 9 is C 2~6 Alkenyl, C 2~6 Alkynyl, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, or 7- to 10-membered spirocyclic heterocyclyl; C 2~6 Alkenyl and C 2~6 Alkynyl is independently selected from 1 to 4 R b and optionally substituted with a group, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10Bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl each independently represent 1 to 4 R a and optionally substituted with a group, Each R 5 and R 10 are independently H, C 1~6 Alkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, or 7- to 10-membered spirocyclic heterocyclyl; C 1~6 Alkyl, C 2~6 Alkenyl, and C 2~6 Alkynyl is independently selected from 1 to 4 R b and optionally substituted with a group, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 Bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl each independently represent 1 to 4 R a and optionally substituted with a group, Each R 5a independently, C 1~6 Alkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C5~10 bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, or 7- to 10-membered spirocyclic heterocyclyl; C 1~6 Alkyl, C 2~6 Alkenyl, and C 2~6 Alkynyl is independently selected from 1 to 4 R b and optionally substituted with a group, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 Bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl each independently represent 1 to 4 R a and optionally substituted with a group, Each R a are independently oxo, imino, halogen, -NO2, -N3, -CN, C 1~6 Alkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 Bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, 7- to 10-membered spirocyclic heterocyclyl, -OR 11 , -C(O)R 11 , -C(O)OR 11 , -C(O)N(R 11 )(R 11 ), -NR 11 R 11 , -N(R 11 )2(R 11 ) +, -N(R 11 )C(O)R 11 , -N(R 11 )C(O)OR 11 , -N(R 11 )C(O)N(R 11 )(R 11 ), -N(R 11 )S(O)2(R 11a ), -NR 11 S(O)2N(R 11 )(R 11 ), -NR 11 S(O )2O(R 11a ), -OC(O)R 11 , -OC(O)OR 11 , -OC(O)N(R 11 )(R 11 ), -SR 11 , -S(O)R 11a , -S(O)(NH)R 11 , -S(O)2R 11a , -S(O)2N(R 11 )(R 11 ), or -N=S(R 11a )(R 11a )=O, C 1~6 Alkyl, C 2~6 Alkenyl, and C 2~6 Alkynyl is independently selected from 1 to 3 R c and optionally substituted with a group, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 Bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl each independently represent 1 to 3 R d and optionally substituted with a group, Each R b are independently oxo, imino, halogen, -NO2, -N3, -CN, C 3~7 Monocyclic cycloalkyl, C 7~10Fused Bicyclic Cycloalkyl, C 5~10 Bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 8- to 10-membered bridged bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, 7- to 10-membered spirocyclic heterocyclyl, -OR 11 , -C(O)R 11 , -C(O)OR 11 , -C(O)N(R 11 )(R 11 ), -NR 11 R 11 , -N(R 11 )2(R 11 ) + , -N(R 11 )C(O)R 11 , -N(R 11 )C(O)OR 11 , -N(R 11 )C(O)N(R 11 )(R 11 ), -N(R 11 )S(O)2(R 11a ), -NR 11 S(O)2N(R 11 )(R 11 ), -NR 11 S(O)2O(R 11a ), -OC(O)R 11 , -OC(O)OR 11 , -OC(O)N(R 11 )(R 11 ), -SR 11 , -S(O)R 11a , -S(O)(NH)R 11 , -S(O)2R 11a , -S(O)2N(R 11 )(R 11 ), or -N=S(R 11a )(R 11a )=O, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10Bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl each independently represent 1 to 3 R d and optionally substituted with a group, Each R c are independently halogen, -CN, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 Bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, 7- to 10-membered spirocyclic heterocyclyl, -OR 12 , -C(O)R 12 , -C(O)OR 12 , -C(O)N(R 12 )(R 12 ), -NR 12 R 12 , -N(R 12 )2(R 12 ) + , -N(R 12 )C(O)R 12 , -N(R 12 )C(O)OR 12 , -N(R 12 )C(O)N(R 12 )(R 12 ), -N(R 12 )S(O)2(R 12a ), -NR 12 S(O)2N(R 12 )(R 12 ), -NR 12 S(O)2O(R 12a ), -OC(O)R 12 , -OC(O)OR 12 , -OC(O)N(R 12 )(R 12 ), -SR 12 , -S(O)R 12a -S(O)(NH)R 12 , -S(O)2R 12a , -S(O)2N(R12 )(R 12 ), or -N=S(R 12a )(R 12a )=O, Each R d are independently oxo, halogen, -CN, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 Bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, 7- to 10-membered spirocyclic heterocyclyl, -OR 12 , -C(O)R 12 , -C(O)OR 12 , -C(O)N(R 12 )(R 12 ), -NR 12 R 12 , -N(R 12 )2(R 12 ) + , -N(R 12 )C(O)R 12 , -N(R 12 )C(O)OR 12 , -N(R 12 )C(O)N(R 12 )(R 12 ), -N(R 12 )S(O)2(R 12a ), -NR 12 S(O)2N(R 12 )(R 12 ), -NR 12 S(O)2O(R 12a ), -OC(O)R 12 , -OC(O)OR 12 , -OC(O)N(R 12 )(R 12 ), -SR 12 , -S(O)R 12a , -S(O)(NH)R 12 , -S(O)2R 12a , -S(O)2N(R 12 )(R 12 ), or -N=S(R 12a )(R 12a )=O, Each R 11 are independently H, C 1~6 Alkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, or 7- to 10-membered spirocyclic heterocyclyl; C 1~6 Alkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 Bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl each independently represent 1 to 3 R c and optionally substituted with a group, Each R 11a independently, C 1~6 Alkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, or 7- to 10-membered spirocyclic heterocyclyl; C 1~6 Alkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, C 3~7 Monocyclic cycloalkyl, C7~10 Fused Bicyclic Cycloalkyl, C 5~10 Bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl each independently represent 1 to 3 R c and optionally substituted with a group, Each R 12 are independently H, C 1~6 Alkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, or 7- to 10-membered spirocyclic heterocyclyl; Each R 12a independently, C 1~6 Alkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, or 7- to 10-membered spirocyclic heterocyclyl; each 4-membered monocyclic heterocyclyl has one ring heteroatom independently selected from N, O, and S; each 5- to 7-membered monocyclic heterocyclyl independently has 1 to 2 ring heteroatoms independently selected from N, O, and S; each 6-membered bridged bicyclic heterocyclyl has one ring heteroatom independently selected from N, O, and S; each 7-membered bridged bicyclic heterocyclyl independently has 1 to 2 ring heteroatoms independently selected from N, O, and S; Each 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 8- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl is independently selected from N, O, and S. Provided herein are compounds having a ring heteroatom of the formula: or a pharmaceutically acceptable salt thereof.

[0093] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 1 is a 4- to 7-membered monocyclic heterocyclyl, phenyl, naphthalenyl, a 5- to 6-membered monocyclic heteroaryl, an 8- to 10-membered fused bicyclic heterocyclyl, or an 8- to 10-membered fused bicyclic heteroaryl; The 4- to 7-membered monocyclic heterocyclyl, phenyl, naphthalenyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, and 8- to 10-membered fused bicyclic heteroaryl each independently represent 1 to 4 R a and optionally substituted with a group, R 2 are H, -CN, and C 1~6 Alkyl, or C 3~7 is a monocyclic cycloalkyl, C 1~6 Alkyl and C 3~7 The monocyclic cycloalkyls each independently represent a halogen and C 1~6 optionally substituted with 1 to 4 groups independently selected from alkoxy; X is N or CR 3 and R 3 is H, halogen, -CN, C 1~6 Alkyl, C 3~6 Monocyclic cycloalkyl, or -O(C 1~4 alkyl), and C 1~4 Alkyl is -OH, halogen, -CN, -NR 4 R 4 , and C 1~4optionally substituted with 1 to 3 groups independently selected from alkoxy; Z is C 1~10 Alkyl, C 2~6 Alkynyl, -NR 6 R 7 , -C(O)R 13 , -C(O)NR 6 R 7 , -S(O)2R 6 , C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 bridged bicyclic cycloalkyl, 4- to 7-membered monocyclic heterocyclyl, phenyl, naphthalenyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, 7- to 10-membered spirocyclic heterocyclyl, or L 1 and C 1~10 Alkyl and C 2~6 Alkynyl is independently selected from 1 to 4 R b and optionally substituted with a group, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 Bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl each independently represent 1 to 2 R 8 groups, each independently being 1 to 3 R a and optionally substituted with a group, A 4- to 7-membered monocyclic heterocyclyl is one or two R 8 substituted with 1 to 3 R a and optionally substituted with a group, L 1 -OR 5 , -C(O)R 5 , -C(O)N(R 5 )(R 5 ), -NR5 R 5 , -N(R 5 )2(R 5 ) + , -N(R 5 )C(O)R 5 , -N(R 5 )C(O)OR 5 , -N(R 5 )C(O)N(R 5 )(R 5 ), -N(R 5 )S(O)2(R 5a ), -NR 5 S(O)2N(R 5 )(R 5 ), -NR 5 S(O)2O(R 5a ), -OC(O)N(R 5 )(R 5 ), -SR 5 , -S(O)R 5a , -S(O)(NH)R 5 , -S(O)2R 5a , S(O)2N(R 5 )(R 5 ), or -N=S(R 5a )(R 5a )=O, R 6 is C 1~6 Alkyl, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 a bridged bicyclic cycloalkyl, a 4- to 7-membered monocyclic heterocyclyl, a phenyl, a naphthalenyl, a 5- to 6-membered monocyclic heteroaryl, an 8- to 10-membered fused bicyclic heterocyclyl, a 6- to 10-membered bridged bicyclic heterocyclyl, an 8- to 10-membered fused bicyclic heteroaryl, or a 7- to 10-membered spirocyclic heterocyclyl; C 1~6 Alkyl is one to four R b and optionally substituted with a group, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 Bridged bicyclic cycloalkyl, 4- to 7-membered monocyclic heterocyclyl, phenyl, naphthalenyl, 5 The 6- to 10-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl each independently represent 1 to 4 R a and optionally substituted with a group, R 13 is C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 a bridged bicyclic cycloalkyl, a 4- to 7-membered monocyclic heterocyclyl, a phenyl, a naphthalenyl, a 5- to 6-membered monocyclic heteroaryl, an 8- to 10-membered fused bicyclic heterocyclyl, a 6- to 10-membered bridged bicyclic heterocyclyl, an 8- to 10-membered fused bicyclic heteroaryl, or a 7- to 10-membered spirocyclic heterocyclyl; C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 Bridged bicyclic cycloalkyl, 4- to 7-membered monocyclic heterocyclyl, phenyl, naphthalenyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl each independently represent 1 to 4 R a and optionally substituted with a group, Each R 4 are independently H or C 1~3 is alkyl, R 7 is H, C1-6 alkyl, C 3~7 monocyclic cycloalkyl or 4- to 6-membered monocyclic heterocyclyl, 1~6 Alkyl, C 3~7 Monocyclic cycloalkyl and 4- to 6-membered monocyclic heterocyclyl are each independently selected from -OH, halogen, -CN, and C 1~6 optionally substituted with 1 to 4 groups independently selected from alkoxy; Each R 8 are independently halogen, -C(O)R 9 , -NR 10 R 10 , C1~6 Alkyl, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 Bridged bicyclic cycloalkyl, 4-7 membered monocyclic heterocyclyl, phenyl, naphthalenyl, 5-6 membered monocyclic heteroaryl, 8-10 membered fused bicyclic heterocyclyl, 6-10 membered bridged bicyclic heterocyclyl, 8-10 membered fused bicyclic heteroaryl, 7-10 membered spirocyclic heterocyclyl, -OR 5 , -C(O)OR 5 , -C(O)N(R 5 )(R 5 ), -N(R 5 )2(R 5 ) + , -N(R 5 )C(O)R 5 , -N(R 5 )C(O)OR 5 , -N(R 5 )C(O)N(R 5 )(R 5 ), -N(R 5 )S(O)2(R 5a ), -NR 5 S(O)2N(R 5 )(R 5 ), -NR 5 S(O)2O(R 5a ), -OC(O)R 5 , -OC(O)OR 5 , -OC(O)N(R 5 )(R 5 ), -SR 5 , -S(O)R 5a , -S(O)(NH)R 5 , -S(O)2R 5a , -S(O)2N(R 5 )(R 5 ), or -N=S(R 5a )(R 5a )=O, C 1~6 Alkyl is one to four R b and optionally substituted with a group, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10Bridged bicyclic cycloalkyl, 4- to 7-membered monocyclic heterocyclyl, phenyl, naphthalenyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl each independently represent 1 to 4 R a and optionally substituted with a group, R 9 is C 2~6 Alkenyl, C 2~6 Alkynyl, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, or 7- to 10-membered spirocyclic heterocyclyl; C 2~6 Alkenyl and C 2~6 Alkynyl is independently selected from 1 to 4 R b and optionally substituted with a group, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 Bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl each independently represent 1 to 4 R a and optionally substituted with a group, Each R 5 and R 10 are independently H, C 1~6 Alkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, C 3~7 Monocyclic cycloalkyl, C 7~10 fused bicyclic cycloalkyl, C 5~10bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, or 7- to 10-membered spirocyclic heterocyclyl; C 1~6 Alkyl, C 2~6 Alkenyl, and C 2~6 Alkynyl is independently selected from 1 to 4 R b and optionally substituted with a group, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 Bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl each independently represent 1 to 4 R a and optionally substituted with a group, Each R 5a independently, C 1~6 Alkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, or 7- to 10-membered spirocyclic heterocyclyl; C 1~6 Alkyl, C 2~6 Alkenyl, and C 2~6 Alkynyl is independently selected from 1 to 4 R b and optionally substituted with a group, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10Bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl each independently represent 1 to 4 R a and optionally substituted with a group, Each R a are independently oxo, imino, halogen, -NO2, -N3, -CN, C 1~6 Alkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 Bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, 7- to 10-membered spirocyclic heterocyclyl, -OR 11 , -C(O)R 11 , -C(O)OR 11 , -C(O)N(R 11 )(R 11 ), -NR 11 R 11 , -N(R 11 )2(R 11 ) + , -N(R 11 )C(O)R 11 , -N(R 11 )C(O)OR 11 , -N(R 11 )C(O)N(R 11 )(R 11 ), -N(R 11 )S(O)2(R 11a ), -NR 11 S(O)2N(R 11 )(R 11 ), -NR 11 S(O)2O(R 11a ), -OC(O)R 11 , -OC(O)OR 11 , -OC(O)N(R 11 )(R11 ), -SR 11 , -S(O)R 11a , -S(O)(NH)R 11 , -S(O)2R 11a , -S(O)2N(R 11 )(R 11 ), or -N=S(R 11a )(R 11a )=O, C 1~6 Alkyl, C 2~6 Alkenyl, and C 2~6 Alkynyl is independently selected from 1 to 3 R c and optionally substituted with a group, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 Bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl each independently represent 1 to 3 R d and optionally substituted with a group, Each R b are independently oxo, imino, halogen, -NO2, -N3, -CN, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 Bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 8- to 10-membered bridged bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl -CH, 7-10 membered spirocyclic heterocyclyl, -OR 11 , -C(O)R 11 , -C(O)OR 11 , -C(O)N(R 11 )(R 11 ), -NR 11 R 11 , -N(R 11 )2(R 11 )+ , -N(R 11 )C(O)R 11 , -N(R 11 )C(O)OR 11 , -N(R 11 )C(O)N(R 11 )(R 11 ), -N(R 11 )S(O)2(R 11a ), -NR 11 S(O)2N(R 11 )(R 11 ), -NR 11 S(O)2O(R 11a ), -OC(O)R 11 , -OC(O)OR 11 , -OC(O)N(R 11 )(R 11 ), -SR 11 , -S(O)R 11a , -S(O)(NH)R 11 , -S(O)2R 11a , -S(O)2N(R 11 )(R 11 ), or -N=S(R 11a )(R 11a )=O, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 Bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl each independently represent 1 to 3 R d and optionally substituted with a group, Each R c are independently halogen, -CN, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 Bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, 7- to 10-membered spirocyclic heterocyclyl, -OR12 , -C(O)R 12 , -C(O)OR 12 , -C(O)N(R 12 )(R 12 ), -NR 12 R 12 , -N(R 12 )2(R 12 ) + , -N(R 12 )C(O)R 12 , -N(R 12 )C(O)OR 12 , -N(R 12 )C(O)N(R 12 )(R 12 ), -N(R 12 )S(O)2(R 12a ), -NR 12 S(O)2N(R 12 )(R 12 ), -NR 12 S(O)2O(R 12a ), -OC(O)R 12 , -OC(O)OR 12 , -OC(O)N(R 12 )(R 12 ), -SR 12 , -S(O)R 12a -S(O)(NH)R 12 , -S(O)2R 12a , -S(O)2N(R 12 )(R 12 ), or -N=S(R 12a )(R 12a )=O, Each R d are independently oxo, halogen, -CN, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 Bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, 7- to 10-membered spirocyclic heterocyclyl, -OR 12 , -C(O)R 12 , -C(O)OR 12 , -C(O)N(R 12 )(R 12 ), -NR12 R 12 , -N(R 12 )2(R 12 ) + , -N(R 12 )C(O)R 12 , -N(R 12 )C(O)OR 12 , -N(R 12 )C(O)N(R 12 )(R 12 ), -N(R 12 )S(O)2(R 12a ), -NR 12 S(O)2N(R 12 )(R 12 ), -NR 12 S(O)2O(R 12a ), -OC(O)R 12 , -OC(O)OR 12 , -OC(O)N(R 12 )(R 12 ), -SR 12 , -S(O)R 12a , -S(O)(NH)R 12 , -S(O)2R 12a , -S(O)2N(R 12 )(R 12 ), or -N=S(R 12a )(R 12a )=O, Each R 11 are independently H, C 1~6 Alkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, or 7- to 10-membered spirocyclic heterocyclyl; C 1~6 Alkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, C 3~7 Monocyclic cycloalkyl, C 7~10Fused Bicyclic Cycloalkyl, C 5~10 Bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl each independently represent 1 to 3 R c and optionally substituted with a group, Each R 11a independently, C 1~6 Alkyl, C 2~6 Alkenyl, C 2~6 Alkini Lu, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, or 7- to 10-membered spirocyclic heterocyclyl; C 1~6 Alkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 Bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl each independently represent 1 to 3 R c and optionally substituted with a group, Each R 12 are independently H, C 1~6 Alkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, or 7- to 10-membered spirocyclic heterocyclyl; Each R 12a independently, C 1~6 Alkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, or 7- to 10-membered spirocyclic heterocyclyl; each 4-membered monocyclic heterocyclyl has one ring heteroatom independently selected from N, O, and S; each 5- to 7-membered monocyclic heterocyclyl independently has 1 to 2 ring heteroatoms independently selected from N, O, and S; each 6-membered bridged bicyclic heterocyclyl has one ring heteroatom independently selected from N, O, and S; each 7-membered bridged bicyclic heterocyclyl independently has 1 to 2 ring heteroatoms independently selected from N, O, and S; Each 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 8- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl independently has 1 to 4 ring heteroatoms independently selected from N, O, and S.

[0094] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 1 is a 4- to 7-membered monocyclic heterocyclyl, a 5- to 6-membered monocyclic heteroaryl, or an 8- to 10-membered fused bicyclic heteroaryl; The 4- to 7-membered monocyclic heterocyclyl, the 5- to 6-membered monocyclic heteroaryl, and the 8- to 10-membered fused bicyclic heteroaryl each independently have 1 to 3 R a and optionally substituted with a group, R 2 is C 1~6 alkyl, C 1~6 Alkyl is halogen and C 1~6 optionally substituted with 1 to 3 groups independently selected from alkoxy; X is CR 3 and R 3 is H, halogen, or C 1~4 is alkyl, Z is C 1~10 Alkyl, -C(O)R 13 , -C(O)NR 6 R 7 , C 3~7 monocyclic cycloalkyl, 4- to 7-membered monocyclic heterocyclyl, phenyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, or 7- to 10-membered spirocyclic heterocyclyl; , C 1~10 Alkyl is one to three R b and optionally substituted with a group, C 3~7 Monocyclic cycloalkyl, phenyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl each independently represent 1 to 2 R 8 groups, each independently being 1 to 3 R a and optionally substituted with a group, A 4- to 7-membered monocyclic heterocyclyl is one or two R 8 substituted with 1 to 3 R a and optionally substituted with a group, R 6 is C 1~6 Alkyl, C 3~7monocyclic cycloalkyl, 4- to 7-membered monocyclic heterocyclyl, or 6- to 10-membered bridged bicyclic heterocyclyl; C 1~6 Alkyl is one to three R b and optionally substituted with a group, C 3~7 The monocyclic cycloalkyl, 4- to 7-membered monocyclic heterocyclyl, and 6- to 10-membered bridged bicyclic heterocyclyl each independently have 1 to 3 R a and optionally substituted with a group, R 13 is a 4- to 7-membered monocyclic heterocyclyl, an 8- to 10-membered fused bicyclic heterocyclyl, a 6- to 10-membered bridged bicyclic heterocyclyl, or a 7- to 10-membered spirocyclic heterocyclyl; The 4- to 7-membered monocyclic heterocyclyl, the 8- to 10-membered fused bicyclic heterocyclyl, the 6- to 10-membered bridged bicyclic heterocyclyl, and the 7- to 10-membered spirocyclic heterocyclyl each independently represent 1 to 3 R a and optionally substituted with a group, R 7 is H, C 1~3 Alkyl or C 3~7 is a monocyclic cycloalkyl; C 1~3 Alkyl is a group consisting of -OH, halogen, -CN, and C 1~3 optionally substituted with 1 to 3 groups independently selected from alkoxy; Each R 8 are independently -C(O)R 9 , C 1~6 Alkyl, -NR 10 R 10 , C 3~7 Monocyclic cycloalkyl, 4- to 7-membered monocyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 7- to 10-membered spirocyclic heterocyclyl, or -S(O)R 5a and C 1~6 Alkyl is one to three R b and optionally substituted with a group, C 3~7Monocyclic cycloalkyl, 4- to 7-membered monocyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, and 7- to 10-membered spirocyclic heterocyclyl each independently represent 1 to 3 R a and optionally substituted with a group, R 9 is a 4- to 7-membered monocyclic heterocyclyl or a 6- to 10-membered bridged bicyclic heterocyclyl, The 4- to 7-membered monocyclic heterocyclyl and the 6- to 10-membered bridged bicyclic heterocyclyl each independently have 1 to 3 R a and optionally substituted with a group, Each R 10 are independently H, a 4- to 7-membered monocyclic heterocyclyl, or a 6- to 10-membered bridged bicyclic heterocyclyl; The 4- to 7-membered monocyclic heterocyclyl and the 6- to 10-membered bridged bicyclic heterocyclyl each independently have 1 to 3 R a and optionally substituted with a group, R 5a is a 4- to 7-membered monocyclic heterocyclyl, and the 4- to 7-membered monocyclic heterocyclyl is a 4- to 7-membered monocyclic heterocyclyl having 1 to 3 R a and optionally substituted with a group, each 4-membered monocyclic heterocyclyl has one ring heteroatom independently selected from N, O, and S; each 5- to 7-membered monocyclic heterocyclyl independently has 1 to 2 ring heteroatoms independently selected from N, O, and S; each 6-membered bridged bicyclic heterocyclyl has one ring heteroatom independently selected from N, O, and S; each 7-membered bridged bicyclic heterocyclyl independently has 1 to 2 ring heteroatoms independently selected from N, O, and S; Each of 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 8- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spin A bicyclic heterocyclyl has 1 to 4 ring heteroatoms independently selected from N, O, and S.

[0095] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 1 is a 4- to 7-membered monocyclic heterocyclyl, a 5- to 6-membered monocyclic heteroaryl, or an 8- to 10-membered fused bicyclic heteroaryl; The 4- to 7-membered monocyclic heterocyclyl, the 5- to 6-membered monocyclic heteroaryl, and the 8- to 10-membered fused bicyclic heteroaryl are each independently —OH, halogen, —CN, oxo, —NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 optionally substituted with 1 to 3 groups independently selected from alkyl; C 1~5 the alkyl is optionally substituted with 1 to 3 groups independently selected from —OH, halogen, and CN; R 2 is C 1~6 alkyl, C 1~6 Alkyl is halogen and C 1~3 optionally substituted with 1 to 3 groups independently selected from alkoxy; X is CR 3 and R 3 is H, halogen, or C 1~4 is alkyl, Z is C 1~10 Alkyl, -C(O)R 13 , -C(O)NR 6 R 7 , C 3~7 monocyclic cycloalkyl, 4- to 7-membered monocyclic heterocyclyl, phenyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, or 7- to 10-membered spirocyclic heterocyclyl; C 1~10 Alkyl is -OH, halogen, -CN, oxo, -NR 11 R 11 , and C 1~4 optionally substituted with 1 to 3 groups independently selected from alkoxy; C 3~7Monocyclic cycloalkyl, phenyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl each independently represent 1 to 2 R 8 groups, each independently selected from the group consisting of —OH, halogen, —CN, oxo, and —NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 optionally substituted with 1 to 3 groups independently selected from alkyl; A 4- to 7-membered monocyclic heterocyclyl is one or two R 8 and substituted with -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 optionally substituted with 1 to 3 groups independently selected from alkyl; R 6 is C 1~6 Alkyl, C 3~7 monocyclic cycloalkyl, 4- to 7-membered monocyclic heterocyclyl, or 6- to 10-membered bridged bicyclic heterocyclyl; C 1~6 Alkyl is -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and R e and optionally substituted with 1 to 3 groups independently selected from C 3~7 The monocyclic cycloalkyl, the 4- to 7-membered monocyclic heterocyclyl, and the 6- to 10-membered bridged bicyclic heterocyclyl are each independently —OH, halogen, —CN, oxo, —C(O)R 11 , -NR 11 R 11 , C 1~4 Alkoxy, C 1~5 Alkyl, and R f and optionally substituted with 1 to 3 groups independently selected from C 1~5Alkyl is -OH, halogen, -CN, oxo, -NR 12 R 12 , and -C(O)N(R 12 )(R 12 Optionally substituted with 1 to 3 groups independently selected from Each R e is independently a 4- to 7-membered monocyclic heterocyclyl or a 5- to 6-membered monocyclic heteroaryl; Each R f independently, C 3~7 monocyclic cycloalkyl, 4- to 7-membered monocyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, or 7- to 10-membered spirocyclic heterocyclyl, 3~7 Monocyclic cycloalkyl, 4-7 membered monocyclic heterocyclyl, 6-10 membered bridged bicyclic the cyclic heterocyclyl and the 7- to 10-membered spirocyclic heterocyclyl are each independently optionally substituted with 1 to 3 groups independently selected from oxo and halogen; R 13 is a 4- to 7-membered monocyclic heterocyclyl, an 8- to 10-membered fused bicyclic heterocyclyl, a 6- to 10-membered bridged bicyclic heterocyclyl, or a 7- to 10-membered spirocyclic heterocyclyl; The 4- to 7-membered monocyclic heterocyclyl, the 8- to 10-membered fused bicyclic heterocyclyl, the 6- to 10-membered bridged bicyclic heterocyclyl, and the 7- to 10-membered spirocyclic heterocyclyl are each independently —OH, halogen, —CN, oxo, —NR 11 R 11 , phenyl, C 1~4 Alkoxy, and C 1~5 optionally substituted with 1 to 3 groups independently selected from alkyl; C 1~5 Alkyl is -OH, halogen, -CN, oxo, -NR 12 R 12 , -C(O)N(R 12 )(R 12 ), and R g and optionally substituted with 1 to 3 groups independently selected from Each R g is independently a 4- to 7-membered monocyclic heterocyclyl; R 7 is H, C 1~3 Alkyl or C 3~7 is a monocyclic cycloalkyl; C 1~3 Alkyl is a group that can be substituted with -OH, halogen, and C 1~3 optionally substituted with 1 to 2 groups independently selected from alkoxy; Each R 8 are independently -C(O)R 9 , C 1~6 Alkyl, -NR 10 R 10 , C 3~7 Monocyclic cycloalkyl, 4- to 7-membered monocyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 7- to 10-membered spirocyclic heterocyclyl, or -S(O)R 5a and C 1~6 Alkyl is -OH, halogen, -CN, oxo, -NR 11 R 11 , -C(O)N(R 11 )(R 11 ), -S(O)R 11a , C 1~4 Alkoxy, and R h and optionally substituted with 1 to 3 groups independently selected from C 3~7 Monocyclic cycloalkyl, 4- to 7-membered monocyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, and 7- to 10-membered spirocyclic heterocyclyl are each independently -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 optionally substituted with 1 to 3 groups independently selected from alkyl; C 1~5 Alkyl includes -OH, halogen, oxo, and -C(O)N(R 12 )(R 12 Optionally substituted with 1 to 3 groups independently selected from C 1~4 The alkoxy is optionally substituted with 1 to 3 halogen groups; Each R h independently, C 3~7 monocyclic cycloalkyl or 4- to 7-membered monocyclic heterocyclyl; R 9 is a 4- to 7-membered monocyclic heterocyclyl or a 6- to 10-membered bridged bicyclic heterocyclyl, The 4- to 7-membered monocyclic heterocyclyl and the 6- to 10-membered bridged bicyclic heterocyclyl are each independently —OH, halogen, —CN, oxo, —NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 optionally substituted with 1 to 3 groups independently selected from alkyl; C 1~5 the alkyl is optionally substituted with 1 to 3 groups independently selected from -OH, halogen, and -CN; Each R 10 are independently H, a 4- to 7-membered monocyclic heterocyclyl, or a 6- to 10-membered bridged bicyclic heterocyclyl, and the 4- to 7-membered monocyclic heterocyclyl and the 6- to 10-membered bridged bicyclic heterocyclyl are each independently —OH, halogen, —CN, oxo, —NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 optionally substituted with alkyl; R 5a is a 4- to 7-membered monocyclic heterocyclyl; Each R 11 are independently H, C 1~4 Alkyl, or C 3~7 is a monocyclic cycloalkyl; Each R 11a are independently H or C 1~4 is alkyl, Each R 12 are independently H or C 1~4 is alkyl, each 4-membered monocyclic heterocyclyl has one ring heteroatom independently selected from N, O, and S; each 5- to 7-membered monocyclic heterocyclyl independently has 1 to 2 ring heteroatoms independently selected from N, O, and S; each 6-membered bridged bicyclic heterocyclyl has one ring heteroatom independently selected from N, O, and S; each 7-membered bridged bicyclic heterocyclyl independently has 1 to 2 ring heteroatoms independently selected from N, O, and S; Each 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 8- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl independently has 1 to 4 ring heteroatoms independently selected from N, O, and S.

[0096] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 1 is a 4- to 7-membered monocyclic heterocyclyl, a 5- to 6-membered monocyclic heteroaryl, or an 8- to 10-membered fused bicyclic heteroaryl; The 4- to 7-membered monocyclic heterocyclyl, the 5- to 6-membered monocyclic heteroaryl, and the 8- to 10-membered fused bicyclic heteroaryl each independently have 1 to 3 R a and optionally substituted with a group, R 2 is C 1~6 alkyl, C 1~6 Alkyl is halogen and C 1~6 optionally substituted with 1 to 3 groups independently selected from alkoxy; X is CR 3 and R 3 is H, halogen, or C 1~4 is alkyl, Z is C 1~10 Alkyl, -C(O)R 13 , -C(O)NR 6 R 7 , C 3~7 monocyclic cycloalkyl, 4- to 7-membered monocyclic heterocyclyl, phenyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, or 7- to 10-membered spirocyclic heterocyclyl; C 1~10 Alkyl is one to three Rb and optionally substituted with a group, C 3~7 Monocyclic cycloalkyl, phenyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl each independently represent 1 to 2 R 8 groups, each independently being 1 to 3 R a and optionally substituted with a group, A 4- to 7-membered monocyclic heterocyclyl is one or two R 8 substituted with 1 to 3 R a and optionally substituted with a group, R 6 is C 1~6 Alkyl, C 3~7 monocyclic cycloalkyl, 4- to 7-membered monocyclic heterocyclyl, or 6- to 10-membered bridged bicyclic heterocyclyl; C 1~6 Alkyl is one to three R b and optionally substituted with a group, C 3~7 The monocyclic cycloalkyl, 4- to 7-membered monocyclic heterocyclyl, and 6- to 10-membered bridged bicyclic heterocyclyl each independently have 1 to 3 R a and optionally substituted with a group, R 13 is a 4- to 7-membered monocyclic heterocyclyl, an 8- to 10-membered fused bicyclic heterocyclyl, a 6- to 10-membered bridged bicyclic heterocyclyl, or a 7- to 10-membered spirocyclic heterocyclyl; The 4- to 7-membered monocyclic heterocyclyl, the 8- to 10-membered fused bicyclic heterocyclyl, the 6- to 10-membered bridged bicyclic heterocyclyl, and the 7- to 10-membered spirocyclic heterocyclyl each independently represent 1 to 3 R a and optionally substituted with a group, R 7 is H, C 1~3 Alkyl or C 3~7 is a monocyclic cycloalkyl; C 1~3 Alkyl is a group consisting of -OH, halogen, -CN, and C 1~3optionally substituted with 1 to 3 groups independently selected from alkoxy; Each R 8 are independently -C(O)R 9 , C 1~6 Alkyl, -NR 10 R 10 , C 3~7 Monocyclic cycloalkyl, 4- to 7-membered monocyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 7- to 10-membered spirocyclic heterocyclyl, or -S(O)R 5a and C 1~6 Alkyl is one to three R b and optionally substituted with a group, C 3~7 Monocyclic cycloalkyl, 4- to 7-membered monocyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, and 7- to 10-membered spirocyclic heterocyclyl each independently represent 1 to 3 R a and optionally substituted with a group, R 9 is a 4- to 7-membered monocyclic heterocyclyl or a 6- to 10-membered bridged bicyclic heterocyclyl, The 4- to 7-membered monocyclic heterocyclyl and the 6- to 10-membered bridged bicyclic heterocyclyl each independently have 1 to 3 R a and optionally substituted with a group, Each R 10 are independently H, a 4- to 7-membered monocyclic heterocyclyl, or a 6- to 10-membered bridged bicyclic heterocyclyl; The 4- to 7-membered monocyclic heterocyclyl and the 6- to 10-membered bridged bicyclic heterocyclyl each independently have 1 to 3 R a and optionally substituted with a group, R 5a is a 4- to 7-membered monocyclic heterocyclyl, and the 4- to 7-membered monocyclic heterocyclyl is a 4- to 7-membered monocyclic heterocyclyl having 1 to 3 R a and optionally substituted with a group, each 4-membered monocyclic heterocyclyl has one ring heteroatom independently selected from N, O, and S; each 5- to 7-membered monocyclic heterocyclyl independently has 1 to 2 ring heteroatoms independently selected from N, O, and S; each 6-membered bridged bicyclic heterocyclyl has one ring heteroatom independently selected from N, O, and S; each 7-membered bridged bicyclic heterocyclyl independently has 1 to 2 ring heteroatoms independently selected from N, O, and S; Each 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 8- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl independently has 1 to 4 ring heteroatoms independently selected from N, O, and S.

[0097] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 1 is a 4- to 7-membered monocyclic heterocyclyl, a 5- to 6-membered monocyclic heteroaryl, or an 8- to 10-membered fused bicyclic heteroaryl; The 4- to 7-membered monocyclic heterocyclyl, the 5- to 6-membered monocyclic heteroaryl, and the 8- to 10-membered fused bicyclic heteroaryl are each independently —OH, halogen, —CN, oxo, —NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 optionally substituted with 1 to 3 groups independently selected from alkyl; R 2 is C 1~6 alkyl, C 1~6 Alkyl is halogen and C 1~3 optionally substituted with 1 to 3 groups independently selected from alkoxy; X is CR 3 and R 3 is H, halogen, or C 1~4 is alkyl, Z is C 1~10 Alkyl, -C(O)R 13 , -C(O)NR 6 R 7 , C 3~7monocyclic cycloalkyl, 4- to 7-membered monocyclic heterocyclyl, phenyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, or 7- to 10-membered spirocyclic heterocyclyl; C 1~10 Alkyl is -OH, halogen, -CN, oxo, -NR 11 R 11 , and C 1~4 optionally substituted with 1 to 3 groups independently selected from alkoxy; C 3~7 Monocyclic cycloalkyl, phenyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl each independently represent 1 to 2 R 8 groups, each independently selected from the group consisting of —OH, halogen, —CN, oxo, and —NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 optionally substituted with 1 to 3 groups independently selected from alkyl; A 4- to 7-membered monocyclic heterocyclyl is one or two R 8 and substituted with -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 optionally substituted with 1 to 3 groups independently selected from alkyl; R 6 is C 1~6 Alkyl, C 3~7 monocyclic cycloalkyl, 4- to 7-membered monocyclic heterocyclyl, or 6- to 10-membered bridged bicyclic heterocyclyl; C 1~6 Alkyl is -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and R e and optionally substituted with 1 to 3 groups independently selected from C 3~7The monocyclic cycloalkyl, the 4- to 7-membered monocyclic heterocyclyl, and the 6- to 10-membered bridged bicyclic heterocyclyl are each independently —OH, halogen, —CN, oxo, —C(O)R 11 , -NR 11 R 11 , C 1~4 Alkoxy, C 1~5 Alkyl, and R f and optionally substituted with 1 to 3 groups independently selected from C 1~5 Alkyl is -OH, halogen, -CN, oxo, -NR 12 R 12 , and -C(O)N(R 12 )(R 12 Optionally substituted with 1 to 3 groups independently selected from Each R e is independently a 4- to 7-membered monocyclic heterocyclyl or a 5- to 6-membered monocyclic heteroaryl; Each R f independently, C 3~7 monocyclic cycloalkyl, 4- to 7-membered monocyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, or 7- to 10-membered spirocyclic heterocyclyl, 3~7 monocyclic cycloalkyl, 4- to 7-membered monocyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, and 7- to 10-membered spirocyclic heterocyclyl are each independently optionally substituted with 1 to 3 groups independently selected from oxo and halogen; R 13 is a 4- to 7-membered monocyclic heterocyclyl, an 8- to 10-membered fused bicyclic heterocyclyl, a 6- to 10-membered bridged bicyclic heterocyclyl, or a 7- to 10-membered spirocyclic heterocyclyl; The 4- to 7-membered monocyclic heterocyclyl, the 8- to 10-membered fused bicyclic heterocyclyl, the 6- to 10-membered bridged bicyclic heterocyclyl, and the 7- to 10-membered spirocyclic heterocyclyl are each independently —OH, halogen, —CN, oxo, —NR 11 R 11 , phenyl, C 1~4 Alkoxy, and C 1~5 optionally substituted with 1 to 3 groups independently selected from alkyl; C 1~5 Alkyl is -OH, halogen, -CN, oxo, -NR 12 R 12 , -C(O)N(R 12 )(R 12 ), and R g and optionally substituted with 1 to 3 groups independently selected from Each R g is independently a 4- to 7-membered monocyclic heterocyclyl; R 7 is H, C 1~3 Alkyl, or C 3~7 is a monocyclic cycloalkyl; C 1~3 Alkyl is a group that can be substituted with -OH, halogen, and C 1~3 optionally substituted with 1 to 2 groups independently selected from alkoxy; Each R 8 are independently -C(O)R 9 , C 1~6 Alkyl, -NR 10 R 10 , C 3~7 Monocyclic cycloalkyl, 4- to 7-membered monocyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 7- to 10-membered spirocyclic heterocyclyl, or -S(O)R 5a and C 1~6 Alkyl is -OH, halogen, -CN, oxo, -NR 11 R 11 , -S(O)2R 11a , C 1~4 Alkoxy, and R h and optionally substituted with 1 to 3 groups independently selected from C 3~7 Monocyclic cycloalkyl, 4- to 7-membered monocyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, and 7- to 10-membered spirocyclic heterocyclyl are each independently -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 optionally substituted with 1 to 3 groups independently selected from alkyl; C 1~5 Alkyl includes -OH, halogen, oxo, and -C(O)N(R 12 )(R 12 Optionally substituted with 1 to 3 groups independently selected from C 1~4 The alkoxy is optionally substituted with 1 to 3 halogen groups; Each R h independently, C 3~7 Monocyclic cycloalkyl or 4- to 7-membered monocyclic heterocyclyl It is R 9 is a 4- to 7-membered monocyclic heterocyclyl or a 6- to 10-membered bridged bicyclic heterocyclyl, The 4- to 7-membered monocyclic heterocyclyl and the 6- to 10-membered bridged bicyclic heterocyclyl are each independently —OH, halogen, —CN, oxo, —NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 optionally substituted with 1 to 3 groups independently selected from alkyl; Each R 10 are independently H, a 4- to 7-membered monocyclic heterocyclyl, or a 6- to 10-membered bridged bicyclic heterocyclyl, and the 4- to 7-membered monocyclic heterocyclyl and the 6- to 10-membered bridged bicyclic heterocyclyl are each independently —OH, halogen, —CN, oxo, —NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 optionally substituted with alkyl; R 5a is a 4- to 7-membered monocyclic heterocyclyl; Each R 11 are independently H, C 1~4 Alkyl or C 3~7 is a monocyclic cycloalkyl; Each R 11a are independently H or C 1~4 is alkyl, Each R 12 are independently H or C 1~4 is alkyl, each 4-membered monocyclic heterocyclyl has one ring heteroatom independently selected from N, O, and S; each 5- to 7-membered monocyclic heterocyclyl independently has 1 to 2 ring heteroatoms independently selected from N, O, and S; each 6-membered bridged bicyclic heterocyclyl has one ring heteroatom independently selected from N, O, and S; each 7-membered bridged bicyclic heterocyclyl independently has 1 to 2 ring heteroatoms independently selected from N, O, and S; Each 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 8- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl independently has 1 to 4 ring heteroatoms independently selected from N, O, and S.

[0098] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 1 is a 4- to 7-membered monocyclic heterocyclyl, a 5- to 6-membered monocyclic heteroaryl, or an 8- to 10-membered fused bicyclic heteroaryl; The 4- to 7-membered monocyclic heterocyclyl, the 5- to 6-membered monocyclic heteroaryl, and the 8- to 10-membered fused bicyclic heteroaryl each independently have 1 to 3 R a and optionally substituted with a group, R 2 is C 1~6 is alkyl, C 1~6 Alkyl is halogen and C 1~6 optionally substituted with 1 to 3 groups independently selected from alkoxy; X is N or CR 3 and R 3 is H, halogen, or C 1~4 is alkyl, Z is -C(O)R 13 , -C(O)NR 6 R 7, a 5- to 6-membered monocyclic heteroaryl, or a 7- to 10-membered spirocyclic heterocyclyl; The 5- to 6-membered monocyclic heteroaryl and the 7- to 10-membered spirocyclic heterocyclyl each independently have 1 to 2 R 8 groups, each independently being 1 to 3 R a and optionally substituted with a group, R 6 is C 1~6 alkyl or 4- to 7-membered monocyclic heterocyclyl; C 1~6 Alkyl is one to three R b and optionally substituted with a group, A 4- to 7-membered monocyclic heterocyclyl is one to three R a and optionally substituted with a group, R 13 is a 4- to 7-membered monocyclic heterocyclyl, an 8- to 10-membered fused bicyclic heterocyclyl, a 6- to 10-membered bridged bicyclic heterocyclyl, or a 7- to 10-membered spirocyclic heterocyclyl; The 4- to 7-membered monocyclic heterocyclyl, the 8- to 10-membered fused bicyclic heterocyclyl, the 6- to 10-membered bridged bicyclic heterocyclyl, and the 7- to 10-membered spirocyclic heterocyclyl each independently represent 1 to 3 R a and optionally substituted with a group, R 7 is H or C 1~3 is alkyl, Each R 8 are independently 4- to 7-membered monocyclic heterocyclyl, and the 4- to 7-membered monocyclic heterocyclyl is a 4- to 7-membered monocyclic heterocyclyl having 1 to 3 R a and optionally substituted with a group, each 4-membered monocyclic heterocyclyl has one ring heteroatom independently selected from N, O, and S; each 5- to 7-membered monocyclic heterocyclyl independently has 1 to 2 ring heteroatoms independently selected from N, O, and S; each 6-membered bridged bicyclic heterocyclyl has one ring heteroatom independently selected from N, O, and S; each 7-membered bridged bicyclic heterocyclyl independently has 1 to 2 ring heteroatoms independently selected from N, O, and S; Each 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 8- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl independently has 1 to 4 ring heteroatoms independently selected from N, O, and S.

[0099] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 1 is a 4- to 7-membered monocyclic heterocyclyl, a 5- to 6-membered monocyclic heteroaryl, or an 8- to 10-membered fused bicyclic heteroaryl; The 4- to 7-membered monocyclic heterocyclyl, the 5- to 6-membered monocyclic heteroaryl, and the 8- to 10-membered fused bicyclic heteroaryl each independently have 1 to 3 R a and optionally substituted with a group, R 2 is C 1~6 is alkyl, C 1~6 Alkyl is halogen and C 1~6 optionally substituted with 1 to 3 groups independently selected from alkoxy; X is CR 3 and R 3 is H, halogen, or C 1~4 is alkyl, Z is -C(O)R 13 , -C(O)NR 6 R 7 , a 5- to 6-membered monocyclic heteroaryl, or a 7- to 10-membered spirocyclic heterocyclyl; The 5- to 6-membered monocyclic heteroaryl and the 7- to 10-membered spirocyclic heterocyclyl each independently have 1 to 2 R 8 groups, each independently being 1 to 3 R a and optionally substituted with a group, R 6 is C 1~6alkyl or 4- to 7-membered monocyclic heterocyclyl; C 1~6 Alkyl is one to three R b and optionally substituted with a group, A 4- to 7-membered monocyclic heterocyclyl is one to three R a and optionally substituted with a group, R 13 is a 4- to 7-membered monocyclic heterocyclyl, an 8- to 10-membered fused bicyclic heterocyclyl, a 6- to 10-membered bridged bicyclic heterocyclyl, or a 7- to 10-membered spirocyclic heterocyclyl; The 4- to 7-membered monocyclic heterocyclyl, the 8- to 10-membered fused bicyclic heterocyclyl, the 6- to 10-membered bridged bicyclic heterocyclyl, and the 7- to 10-membered spirocyclic heterocyclyl each independently represent 1 to 3 R a and optionally substituted with a group, R 7 is H or C 1~3 is alkyl, Each R 8 are independently 4- to 7-membered monocyclic heterocyclyl, and the 4- to 7-membered monocyclic heterocyclyl is a 4- to 7-membered monocyclic heterocyclyl having 1 to 3 R a and optionally substituted with a group, each 4-membered monocyclic heterocyclyl has one ring heteroatom independently selected from N, O, and S; Each 5- to 7-membered monocyclic heterocyclyl is independently selected from N, O, and S. having 1 to 2 ring heteroatoms, each 6-membered bridged bicyclic heterocyclyl has one ring heteroatom independently selected from N, O, and S; each 7-membered bridged bicyclic heterocyclyl independently has 1 to 2 ring heteroatoms independently selected from N, O, and S; Each 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 8- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl independently has 1 to 4 ring heteroatoms independently selected from N, O, and S.

[0100] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 1 is a 4- to 7-membered monocyclic heterocyclyl, a 5- to 6-membered monocyclic heteroaryl, or an 8- to 10-membered fused bicyclic heteroaryl; The 4- to 7-membered monocyclic heterocyclyl, the 5- to 6-membered monocyclic heteroaryl, and the 8- to 10-membered fused bicyclic heteroaryl are each independently —OH, halogen, —CN, oxo, —NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 optionally substituted with 1 to 3 groups independently selected from alkyl; R 2 is C 1~6 alkyl, C 1~6 Alkyl is halogen and C 1~3 optionally substituted with 1 to 3 groups independently selected from alkoxy; X is N or CR 3 and R 3 is H, halogen, or C 1~4 is alkyl, Z is -C(O)R 13 , -C(O)NR 6 R 7 , a 5- to 6-membered monocyclic heteroaryl, or a 7- to 10-membered spirocyclic heterocyclyl; The 5- to 6-membered monocyclic heteroaryl and the 7- to 10-membered spirocyclic heterocyclyl each independently have 1 to 2 R 8 groups, each independently selected from the group consisting of —OH, halogen, —CN, oxo, and —NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 optionally substituted with 1 to 3 groups independently selected from alkyl; R 6 is C 1~6 alkyl or 4- to 7-membered monocyclic heterocyclyl; C 1~6 Alkyl is -OH, halogen, -CN, oxo, -NR 11R 11 , and C 1~4 optionally substituted with 1 to 3 groups independently selected from alkoxy; 4- to 7-membered monocyclic heterocyclyl is -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 optionally substituted with 1 to 3 groups independently selected from alkyl; R 13 is a 4- to 7-membered monocyclic heterocyclyl, an 8- to 10-membered fused bicyclic heterocyclyl, a 6- to 10-membered bridged bicyclic heterocyclyl, or a 7- to 10-membered spirocyclic heterocyclyl; The 4- to 7-membered monocyclic heterocyclyl, the 8- to 10-membered fused bicyclic heterocyclyl, the 6- to 10-membered bridged bicyclic heterocyclyl, and the 7- to 10-membered spirocyclic heterocyclyl are each independently —OH, halogen, —CN, oxo, —NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 optionally substituted with 1 to 3 groups independently selected from alkyl; C 1~5 Alkyl is -OH, halogen, -CN, oxo, and -NR 12 R 12 and optionally substituted with 1 to 3 groups independently selected from R 7 is H or C 1~3 is alkyl, Each R 8 are independently 4- to 7-membered monocyclic heterocyclyl, and the 4- to 7-membered monocyclic heterocyclyl is selected from -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 optionally substituted with 1 to 3 groups independently selected from alkyl; Each R 11 are independently H or C 1~4 is alkyl, Each R 12 are independently H or C1~4 is alkyl, each 4-membered monocyclic heterocyclyl has one ring heteroatom independently selected from N, O, and S; each 5- to 7-membered monocyclic heterocyclyl independently has 1 to 2 ring heteroatoms independently selected from N, O, and S; each 6-membered bridged bicyclic heterocyclyl has one ring heteroatom independently selected from N, O, and S; each 7-membered bridged bicyclic heterocyclyl independently has 1 to 2 ring heteroatoms independently selected from N, O, and S; Each 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 8- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl independently has 1 to 4 ring heteroatoms independently selected from N, O, and S.

[0101] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 1 is a 4- to 7-membered monocyclic heterocyclyl, a 5- to 6-membered monocyclic heteroaryl, or an 8- to 10-membered fused bicyclic heteroaryl; The 4- to 7-membered monocyclic heterocyclyl, the 5- to 6-membered monocyclic heteroaryl, and the 8- to 10-membered fused bicyclic heteroaryl are each independently —OH, halogen, —CN, oxo, —NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 optionally substituted with 1 to 3 groups independently selected from alkyl; R 2 is C 1~6 alkyl, C 1~6 Alkyl is halogen and C 1~3 optionally substituted with 1 to 3 groups independently selected from alkoxy; X is CR 3 and R 3 is H, halogen, or C 1~4is alkyl, Z is -C(O)R 13 , -C(O)NR 6 R 7 , a 5- to 6-membered monocyclic heteroaryl, or a 7- to 10-membered spirocyclic heterocyclyl; The 5- to 6-membered monocyclic heteroaryl and the 7- to 10-membered spirocyclic heterocyclyl each independently have 1 to 2 R 8 groups, each independently selected from the group consisting of —OH, halogen, —CN, oxo, and —NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 optionally substituted with 1 to 3 groups independently selected from alkyl; R 6 is C 1~6 alkyl or 4- to 7-membered monocyclic heterocyclyl; C 1~6 Alkyl is -OH, halogen, -CN, oxo, -NR 11 R 11 , and C 1~4 optionally substituted with 1 to 3 groups independently selected from alkoxy; 4- to 7-membered monocyclic heterocyclyl is -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 optionally substituted with 1 to 3 groups independently selected from alkyl; R 13 is a 4- to 7-membered monocyclic heterocyclyl, an 8- to 10-membered fused bicyclic heterocyclyl, a 6- to 10-membered bridged bicyclic heterocyclyl, or a 7- to 10-membered spirocyclic heterocyclyl; The 4- to 7-membered monocyclic heterocyclyl, the 8- to 10-membered fused bicyclic heterocyclyl, the 6- to 10-membered bridged bicyclic heterocyclyl, and the 7- to 10-membered spirocyclic heterocyclyl are each independently —OH, halogen, —CN, oxo, —NR 11 R 11 , C 1~4 Alkoxy, and C 1~5optionally substituted with 1 to 3 groups independently selected from alkyl; C 1~5 Alkyl is -OH, halogen, -CN, oxo, and -NR 12 R 12 and optionally substituted with 1 to 3 groups independently selected from R 7 is H or C 1~3 is alkyl, Each R 8 are independently 4- to 7-membered monocyclic heterocyclyl, and the 4- to 7-membered monocyclic heterocyclyl is selected from -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 Optionally substituted with 1 to 3 groups independently selected from alkyl And, Each R 11 are independently H or C 1~4 is alkyl, Each R 12 are independently H or C 1~4 is alkyl, each 4-membered monocyclic heterocyclyl has one ring heteroatom independently selected from N, O, and S; each 5- to 7-membered monocyclic heterocyclyl independently has 1 to 2 ring heteroatoms independently selected from N, O, and S; each 6-membered bridged bicyclic heterocyclyl has one ring heteroatom independently selected from N, O, and S; each 7-membered bridged bicyclic heterocyclyl independently has 1 to 2 ring heteroatoms independently selected from N, O, and S; Each 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 8- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl independently has 1 to 4 ring heteroatoms independently selected from N, O, and S.

[0102] Unless otherwise specified, each 4-membered monocyclic heterocyclyl as used herein has one ring heteroatom selected from N, O, and S. Unless otherwise specified, each 5- to 7-membered monocyclic heterocyclyl as used herein has one to two ring heteroatoms independently selected from N, O, and S. Unless otherwise specified, each 6-membered bridged bicyclic heterocyclyl as used herein has one ring heteroatom selected from N, O, and S. Unless otherwise specified, each 7-membered bridged bicyclic heterocyclyl as used herein has one to two ring heteroatoms independently selected from N, O, and S. Unless otherwise specified, each 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 8- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl as used herein independently has 1 to 4 ring heteroatoms independently selected from N, O, and S.

[0103] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 1 is a 4- to 7-membered monocyclic heterocyclyl, phenyl, naphthalenyl, a 5- to 6-membered monocyclic heteroaryl, an 8- to 10-membered fused bicyclic heterocyclyl, or an 8- to 10-membered fused bicyclic heteroaryl; The 4- to 7-membered monocyclic heterocyclyl, phenyl, naphthalenyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, and 8- to 10-membered fused bicyclic heteroaryl each independently represent 1 to 4 R a is optionally substituted with a group.

[0104] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 1 is a 4- to 7-membered monocyclic heterocyclyl, a 5- to 6-membered monocyclic heteroaryl, or an 8- to 10-membered fused bicyclic heteroaryl; The 4- to 7-membered monocyclic heterocyclyl, the 5- to 6-membered monocyclic heteroaryl, and the 8- to 10-membered fused bicyclic heteroaryl each independently have 1 to 3 R a is optionally substituted with a group.

[0105] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 1 is a 4- to 7-membered monocyclic heterocyclyl, a 5- to 6-membered monocyclic heteroaryl, or an 8- to 10-membered fused bicyclic heteroaryl; The 4- to 7-membered monocyclic heterocyclyl, the 5- to 6-membered monocyclic heteroaryl, and the 8- to 10-membered fused bicyclic heteroaryl are each independently —OH, halogen, —CN, oxo, —NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 Optionally substituted with 1 to 3 groups independently selected from alkyl.

[0106] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 1 is a 4- to 7-membered monocyclic heterocyclyl, a 5- to 6-membered monocyclic heteroaryl, or an 8- to 10-membered fused bicyclic heteroaryl; The 4- to 7-membered monocyclic heterocyclyl, the 5- to 6-membered monocyclic heteroaryl, and the 8- to 10-membered fused bicyclic heteroaryl are each independently —OH, halogen, —CN, oxo, —NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 optionally substituted with 1 to 3 groups independently selected from alkyl; C 1~5 The alkyl is optionally substituted with 1 to 3 groups independently selected from -OH, halogen, and CN.

[0107] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 1 is a 6-membered monocyclic heterocyclyl, a 6-membered monocyclic heteroaryl, or an 8- to 10-membered fused bicyclic heteroaryl, and each of the 6-membered monocyclic heterocyclyl, the 6-membered monocyclic heteroaryl, and the 8- to 10-membered fused bicyclic heteroaryl is independently —OH, halogen, —CN, oxo, —NR 11 R 11 , C1~4 Alkoxy, and C 1~5 Optionally substituted with 1 to 3 groups independently selected from alkyl.

[0108] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 1 is a 4- to 7-membered monocyclic heterocyclyl, which is a 4- to 7-membered monocyclic heterocyclyl having 1 to 4 R a In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 1 is a 4- to 7-membered monocyclic heterocyclyl, and the 4- to 7-membered monocyclic heterocyclyl is a 4- to 7-membered monocyclic heterocyclyl having 1 to 3 R a In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 1 is a 4- to 7-membered monocyclic heterocyclyl, and the 4- to 7-membered monocyclic heterocyclyl is selected from -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 Optionally substituted with 1 to 3 groups independently selected from alkyl.

[0109] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 1 is a 4- to 7-membered monocyclic heterocyclyl, which is a 4- to 7-membered monocyclic heterocyclyl having 1 to 4 R a In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 1 is a 4- to 7-membered monocyclic heterocyclyl, and the 4- to 7-membered monocyclic heterocyclyl is a 4- to 7-membered monocyclic heterocyclyl having 1 to 3 R a In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 1 is a 4- to 7-membered monocyclic heterocyclyl, and the 4- to 7-membered monocyclic heterocyclyl is selected from -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4Alkoxy, and C 1~5 and substituted with 1 to 3 groups independently selected from alkyl.

[0110] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 1 is a 4- to 7-membered monocyclic heterocyclyl.

[0111] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 1 is a 5- to 7-membered monocyclic heterocyclyl, which is a 5- to 7-membered monocyclic heterocyclyl having 1 to 4 R a In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 1 is a 5- to 7-membered monocyclic heterocyclyl, and the 5- to 7-membered monocyclic heterocyclyl is a 5- to 7-membered monocyclic heterocyclyl having 1 to 3 R a In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 1 is a 5- to 7-membered monocyclic heterocyclyl, and the 5- to 7-membered monocyclic heterocyclyl is selected from -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 The compound of Formula I is optionally substituted with 1 to 3 groups independently selected from alkyl. In some embodiments of the compound of formula II or II or a pharmaceutically acceptable salt thereof, R 1 is a 6-membered monocyclic heterocyclyl, and the 6-membered monocyclic heterocyclyl is selected from -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 Optionally substituted with 1 to 3 groups independently selected from alkyl.

[0112] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 1is a 5- to 7-membered monocyclic heterocyclyl, which is a 5- to 7-membered monocyclic heterocyclyl having 1 to 4 R a In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 1 is a 5- to 7-membered monocyclic heterocyclyl, and the 5- to 7-membered monocyclic heterocyclyl is a 5- to 7-membered monocyclic heterocyclyl having 1 to 3 R a In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 1 is a 5- to 7-membered monocyclic heterocyclyl, and the 5- to 7-membered monocyclic heterocyclyl is selected from -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 1 is a 6-membered monocyclic heterocyclyl, and the 6-membered monocyclic heterocyclyl is selected from -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 and substituted with 1 to 3 groups independently selected from alkyl.

[0113] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 1 is a 5- to 7-membered monocyclic heterocyclyl. In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 1 is a 6-membered monocyclic heterocyclyl.

[0114] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 1 is phenyl, and the phenyl is a group having one to four R a In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 1 is phenyl, and the phenyl is a group having one to three R aIn some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 1 is phenyl, and phenyl is -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 Optionally substituted with 1 to 3 groups independently selected from alkyl.

[0115] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 1 is phenyl, and the phenyl is a group having one to four R a In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 1 is phenyl, and the phenyl is a group having one to three R a In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 1 is phenyl, and phenyl is -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 and substituted with 1 to 3 groups independently selected from alkyl.

[0116] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 1 is phenyl.

[0117] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 1 is naphthalenyl, and naphthalenyl is a group having 1 to 4 R a In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 1 is naphthalenyl, and naphthalenyl is a group having one to three R aIn some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 1 is naphthalenyl, and naphthalenyl is -OH, halogen, - CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 Optionally substituted with 1 to 3 groups independently selected from alkyl.

[0118] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 1 is naphthalenyl, and naphthalenyl is a group having 1 to 4 R a In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 1 is naphthalenyl, and naphthalenyl is a group having one to three R a In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 1 is naphthalenyl, and naphthalenyl is -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 and substituted with 1 to 3 groups independently selected from alkyl.

[0119] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 1 is naphthalenyl.

[0120] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 1 is a 5- to 6-membered monocyclic heteroaryl, and the 5- to 6-membered monocyclic heteroaryl is a 5- to 6-membered monocyclic heteroaryl having 1 to 4 R a In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 1is a 5- to 6-membered monocyclic heteroaryl, and the 5- to 6-membered monocyclic heteroaryl is a 5- to 6-membered monocyclic heteroaryl having 1 to 3 R a In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 1 is a 5- to 6-membered monocyclic heteroaryl, and the 5- to 6-membered monocyclic heteroaryl is selected from -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 1 is a 6-membered monocyclic heteroaryl, and the 6-membered monocyclic heteroaryl is selected from -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 Optionally substituted with 1 to 3 groups independently selected from alkyl.

[0121] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 1 is a 5- to 6-membered monocyclic heteroaryl, and the 5- to 6-membered monocyclic heteroaryl is a 5- to 6-membered monocyclic heteroaryl having 1 to 4 R a In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 1 is a 5- to 6-membered monocyclic heteroaryl, and the 5- to 6-membered monocyclic heteroaryl is a 5- to 6-membered monocyclic heteroaryl having 1 to 3 R a In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 1 is a 5- to 6-membered monocyclic heteroaryl, and the 5- to 6-membered monocyclic heteroaryl is selected from -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 1 is a 6-membered monocyclic heteroaryl, and the 6-membered monocyclic heteroaryl is selected from -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 and substituted with 1 to 3 groups independently selected from alkyl.

[0122] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 1 is a 5-6 membered monocyclic heteroaryl. In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 1 is a 6-membered monocyclic heteroaryl.

[0123] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 1 is an 8- to 10-membered fused bicyclic heterocyclyl, Rill is 1 to 4 R a In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 1 is an 8- to 10-membered fused bicyclic heterocyclyl, and the 8- to 10-membered fused bicyclic heterocyclyl is a fused bicyclic heterocyclyl having 1 to 3 R a In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 1 is an 8- to 10-membered fused bicyclic heterocyclyl, and the 8- to 10-membered fused bicyclic heterocyclyl is selected from -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 Optionally substituted with 1 to 3 groups independently selected from alkyl.

[0124] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 1 is an 8- to 10-membered fused bicyclic heterocyclyl, and the 8- to 10-membered fused bicyclic heterocyclyl is a fused bicyclic heterocyclyl having 1 to 4 R a In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 1 is an 8- to 10-membered fused bicyclic heterocyclyl, and the 8- to 10-membered fused bicyclic heterocyclyl is a fused bicyclic heterocyclyl having 1 to 3 R a In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 1 is an 8- to 10-membered fused bicyclic heterocyclyl, and the 8- to 10-membered fused bicyclic heterocyclyl is selected from -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 and substituted with 1 to 3 groups independently selected from alkyl.

[0125] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 1 is an 8- to 10-membered fused bicyclic heterocyclyl.

[0126] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 1 is an 8- to 10-membered fused bicyclic heteroaryl, and the 8- to 10-membered fused bicyclic heteroaryl is a fused bicyclic heteroaryl having 1 to 4 R a In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 1 is an 8- to 10-membered fused bicyclic heteroaryl, and the 8- to 10-membered fused bicyclic heteroaryl is a fused bicyclic heteroaryl having 1 to 3 R a In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 1 is an 8- to 10-membered fused bicyclic heteroaryl, and the 8- to 10-membered fused bicyclic heteroaryl is selected from -OH, halogen, -CN, oxo, -NR 11 R11 , C 1~4 Alkoxy, and C 1~5 In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 1 is an 8- to 10-membered fused bicyclic heteroaryl, and the 8- to 10-membered fused bicyclic heteroaryl is selected from -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 optionally substituted with 1 to 3 groups independently selected from alkyl, C 1~5 The alkyl is optionally substituted with 1 to 3 groups independently selected from -OH, halogen, and CN.

[0127] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 1 is an 8- to 10-membered fused bicyclic heteroaryl, and the 8- to 10-membered fused bicyclic heteroaryl is a fused bicyclic heteroaryl having 1 to 4 R a In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 1 is an 8- to 10-membered fused bicyclic heteroaryl, and the 8- to 10-membered fused bicyclic heteroaryl is a fused bicyclic heteroaryl having 1 to 3 R a In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 1 is an 8- to 10-membered fused bicyclic heteroaryl, and the 8- to 10-membered fused bicyclic heteroaryl is selected from -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 1 is an 8- to 10-membered fused bicyclic heteroaryl, and the 8- to 10-membered fused bicyclic heteroaryl is selected from -OH, halogen, -CN, oxo, -NR 11 R11 , C 1~4 Alkoxy and C1 ~5 substituted with 1 to 3 groups independently selected from alkyl, C 1~5 The alkyl is optionally substituted with 1 to 3 groups independently selected from -OH, halogen, and CN.

[0128] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 1 is an 8-10 membered fused bicyclic heteroaryl.

[0129] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 1 teeth,

[0130] [ka] and Each of these has 1 to 4 R a is optionally substituted with a group.

[0131] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 1 is pyridinyl,

[0132] [ka] and Each of these independently represents -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 optionally substituted with 1 to 3 groups independently selected from alkyl, C 1~5 The alkyl is optionally substituted with 1 to 3 halogen groups.

[0133] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R1 is pyridinyl,

[0134] [ka] and Each of these independently represents -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 Optionally substituted with 1 to 3 groups independently selected from alkyl.

[0135] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 1 is oxo, C 1~3 Alkoxy, and C 1~3 In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 1 is substituted with 1 to 3 groups independently selected from oxo, methoxy, and methyl.

[0136] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 1 is pyridinyl or

[0137] [ka] and Each of these is optionally substituted with 1 to 3 groups independently selected from methoxy and methyl.

[0138] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 1 teeth,

[0139] [ka] is.

[0140] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 1 teeth,

[0141] [ka] is.

[0142] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 1 teeth,

[0143] [ka] is.

[0144] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 2 are H, -CN, and C 1~6 Alkyl or C 3~7 is a monocyclic cycloalkyl, C 1~6 Alkyl and C 3~7 The monocyclic cycloalkyls each independently represent a halogen and C 1~6 In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R is optionally substituted with 1 to 4 groups independently selected from alkoxy. 2 are H, -CN, and C 1~6 Alkyl or C 3~7 is a monocyclic cycloalkyl, C 1~6 Alkyl and C 3~7 The monocyclic cycloalkyls each independently represent a halogen and C 1~6 In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R is optionally substituted with 1 to 3 groups independently selected from alkoxy. 2 are H, -CN, and C 1~6 Alkyl or C 3~7 is a monocyclic cycloalkyl, C 1~6 Alkyl and C 3~7The monocyclic cycloalkyls each independently represent a halogen and C 1~3 Optionally substituted with 1 to 3 groups independently selected from alkoxy.

[0145] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 2 is H. In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 2 is -CN.

[0146] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 2 is C 1~6 alkyl, C 1~6 Alkyl is halogen and C 1~6 In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R is optionally substituted with 1 to 4 groups independently selected from alkoxy. 2 is C 1~6 alkyl, C 1~6 Alkyl is halogen and C 1~6 In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R is optionally substituted with 1 to 3 groups independently selected from alkoxy. 2 is C 1~6 alkyl, C 1~6 Alkyl is halogen and C 1~3 In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R is optionally substituted with 1 to 3 groups independently selected from alkoxy. 2 is C 1~6 alkyl, C 1~6 Alkyl is halogen and C 1~6 In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R is substituted with 1 to 4 groups independently selected from alkoxy. 2 is C 1~6 alkyl, C 1~6 Alkyl is halogen and C1~6 In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R is substituted with 1 to 3 groups independently selected from alkoxy. 2 is C 1~6 alkyl, C 1~6 Alkyl is halogen and C 1~3 In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R is substituted with 1 to 3 groups independently selected from alkoxy. 2 is C 1~6 It is alkyl.

[0147] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 2 is C 1~4 alkyl, C 1~4 Alkyl is halogen and C 1~6 In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R is optionally substituted with 1 to 4 groups independently selected from alkoxy. 2 is C 1~4 alkyl, C 1~4 Alkyl is halogen and C 1~6 In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R is optionally substituted with 1 to 3 groups independently selected from alkoxy. 2 is C 1~4 alkyl, C 1~4 Alkyl is halogen and C 1~3 Optionally substituted with 1 to 3 groups independently selected from alkoxy.

[0148] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 2 is C 1~4 alkyl, C 1~4 Alkyl is halogen and C 1~6 In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R is substituted with 1 to 4 groups independently selected from alkoxy.2 is C 1~4 alkyl, C 1~4 Alkyl is halogen and C 1~6 In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R is substituted with 1 to 3 groups independently selected from alkoxy. 2 is C 1~4 alkyl, C 1~4 Alkyl is halogen and C 1~3 and substituted with 1 to 3 groups independently selected from alkoxy.

[0149] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 2 is C 1~4 In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 2 is C 1~3 In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 2 is ethyl or isopropyl. In some embodiments of the compound of Formula I or II or a pharmaceutically acceptable salt thereof, R 2 is methyl. A compound of formula I or II or a pharmaceutically acceptable salt thereof In some embodiments of acceptable salts, R 2 In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 2 In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 2 is isopropyl.

[0150] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 2 is C 3~7 is a monocyclic cycloalkyl, C 3~7 Monocyclic cycloalkyl is substituted with halogen and C 1~6In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R is optionally substituted with 1 to 4 groups independently selected from alkoxy. 2 is C 3~7 is a monocyclic cycloalkyl, C 3~7 Monocyclic cycloalkyl is substituted with halogen and C 1~6 In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R is optionally substituted with 1 to 3 groups independently selected from alkoxy. 2 is C 3~7 is a monocyclic cycloalkyl, C 3~7 Monocyclic cycloalkyl is substituted with halogen and C 1~3 In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R is optionally substituted with 1 to 3 groups independently selected from alkoxy. 2 is C 3~7 is a monocyclic cycloalkyl, C 3~7 Monocyclic cycloalkyl is substituted with halogen and C 1~6 In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R is substituted with 1 to 4 groups independently selected from alkoxy. 2 is C 3~7 is a monocyclic cycloalkyl, C 3~7 Monocyclic cycloalkyl is substituted with halogen and C 1~6 In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R is substituted with 1 to 3 groups independently selected from alkoxy. 2 is C 3~7 is a monocyclic cycloalkyl, C 3~7 Monocyclic cycloalkyl is substituted with halogen and C 1~3 In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R is substituted with 1 to 3 groups independently selected from alkoxy. 2 is C 3~7 It is a monocyclic cycloalkyl.

[0151] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 2 is cyclopropyl, and cyclopropyl is a halogen and C 1~3 In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R is optionally substituted with 1 to 3 groups independently selected from alkoxy. 2 is cyclopropyl, and cyclopropyl is a halogen and C 1~3 In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R is substituted with 1 to 3 groups independently selected from alkoxy. 2 is cyclopropyl.

[0152] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 2 is C 1~3 alkyl, and R 1 teeth,

[0153] [ka] is.

[0154] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 2 is isopropyl, and R 1 teeth,

[0155] [ka] is.

[0156] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, X is N or CR 3 is.

[0157] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, X is N or CH. In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, X is N. In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, X is CR 3 In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, X is CR 3 and R 3 is H, halogen, or C 1~4 In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, X is CR 3 and R 3 is H, halogen, or C 1~3 In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, X is CH.

[0158] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 3 is H, halogen, -CN, C 1~6 Alkyl, C 3~6 Monocyclic cycloalkyl, or -O(C 1~4 alkyl), and C 1~4 Alkyl is -OH, halogen, -CN, -NR 4 R 4 , and C 1~4 In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R is optionally substituted with 1 to 3 groups independently selected from alkoxy. 3 is H, halogen, or C 1~4 In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 3 is H, halogen, or C 1~3 It is alkyl.

[0159] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 3is H. In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 3 is halogen. In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 3 is C 1~6 In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 3 is C 1~4 In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 3 is C 1~3 In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 3 is C 3~6 In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 3 is -O(C 1~4 alkyl), and C 1~4 Alkyl is -OH, halogen, -CN, -NR 4 R 4 , and C 1~4 In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R is optionally substituted with 1 to 3 groups independently selected from alkoxy. 3 is -OCF3. In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 3 is -OCHF2.

[0160] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, each R 4 are independently H or C 1~3 In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one R is alkyl. 4 is H. In some embodiments of the compound of Formula I or II or a pharmaceutically acceptable salt thereof, one R 4 is C 1~3 It is alkyl.

[0161] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is C 1~10 Alkyl, C 2~6 Alkynyl, -NR 6 R 7 , -C(O)R 13 , -C(O)NR 6 R 7 , -S(O)2R 6 , C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 bridged bicyclic cycloalkyl, 4- to 7-membered monocyclic heterocyclyl, phenyl, naphthalenyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, 7- to 10-membered spirocyclic heterocyclyl, or L 1 and C 1~10 Alkyl and C 2~6 Alkynyl is independently selected from 1 to 4 R b and optionally substituted with a group, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 Bridged bicyclic cycloalkyl, 4- to 7-membered monocyclic heterocyclyl, phenyl, naphthalenyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl each independently represent one to two R 8 groups, each independently being 1 to 3 R a is optionally substituted with a group.

[0162] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is C 1~10 Alkyl, C 2~6 Alkynyl, -NR 6 R 7 , -C(O)R 13 , -C(O)NR 6 R7 , -S(O)2R 6 , C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 bridged bicyclic cycloalkyl, 4- to 7-membered monocyclic heterocyclyl, phenyl, naphthalenyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, 7- to 10-membered spirocyclic heterocyclyl, or L 1 and C 1~10 Alkyl and C 2~6 Alkynyl is independently selected from 1 to 4 R b and optionally substituted with a group, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 Bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl each independently represent 1 to 2 R 8 groups, each independently being 1 to 3 R a and optionally substituted with a group, A 4- to 7-membered monocyclic heterocyclyl is one or two R 8 substituted with 1 to 3 R a is optionally substituted with a group.

[0163] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is C 7~10 a fused bicyclic cycloalkyl, an 8- to 10-membered fused bicyclic heterocyclyl, a 6- to 10-membered bridged bicyclic heterocyclyl, or an 8- to 10-membered fused bicyclic heteroaryl; C 7~10 The fused bicyclic cycloalkyl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, and 8- to 10-membered fused bicyclic heteroaryl each independently represent one to two R 8groups, each independently being 1 to 3 R a is optionally substituted with a group.

[0164] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is C 1~10 Alkyl, -C(O)R 13 , -C(O)NR 6 R 7 , C 3~7 monocyclic cycloalkyl, 4- to 7-membered monocyclic heterocyclyl, phenyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, or 7- to 10-membered spirocyclic heterocyclyl; C 1~10 Alkyl is one to three R b and optionally substituted with a group, C 3~7 Monocyclic cycloalkyl, phenyl, 5-6 membered monocyclic heteroaryl, 8-10 The 6- to 10-membered fused bicyclic heterocyclyl, the 6- to 10-membered bridged bicyclic heterocyclyl, the 8- to 10-membered fused bicyclic heteroaryl, and the 7- to 10-membered spirocyclic heterocyclyl each independently represent one to two R 8 groups, each independently being 1 to 3 R a and optionally substituted with a group, A 4- to 7-membered monocyclic heterocyclyl is one or two R 8 substituted with 1 to 3 R a is optionally substituted with a group.

[0165] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is C 1~10 Alkyl, -C(O)R 13 , -C(O)NR 6 R 7 , C 3~7monocyclic cycloalkyl, 4- to 7-membered monocyclic heterocyclyl, phenyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, or 7- to 10-membered spirocyclic heterocyclyl; C 1~10 Alkyl is -OH, halogen, -CN, oxo, -NR 11 R 11 , and C 1~4 optionally substituted with 1 to 3 groups independently selected from alkoxy; C 3~7 Monocyclic cycloalkyl, phenyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl each independently represent 1 to 2 R 8 groups, each independently selected from the group consisting of —OH, halogen, —CN, oxo, and —NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 optionally substituted with 1 to 3 groups independently selected from alkyl; A 4- to 7-membered monocyclic heterocyclyl is one or two R 8 and substituted with -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 Optionally substituted with 1 to 3 groups independently selected from alkyl.

[0166] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is C 1~10 Alkyl, -C(O)R 13 , -C(O)NR 6 R 7 , C 3~7monocyclic cycloalkyl, 4- to 7-membered monocyclic heterocyclyl, phenyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, or 7- to 10-membered spirocyclic heterocyclyl; C 1~10 Alkyl is one to three R b and optionally substituted with a group, C 3~7 Monocyclic cycloalkyl, phenyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl each independently represent 1 to 2 R 8 groups, each independently being 1 to 3 R a and optionally substituted with a group, A 4- to 7-membered monocyclic heterocyclyl is one or two R 8 substituted with 1 to 3 R a is optionally substituted with a group.

[0167] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is C 1~10 Alkyl, -C(O)R 13 , -C(O)NR 6 R 7 , C 3~7 monocyclic cycloalkyl, 4- to 7-membered monocyclic heterocyclyl, phenyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, or 7- to 10-membered spirocyclic heterocyclyl; C 1~10 Alkyl is -OH, halogen, -CN, oxo, -NR 11 R 11 , and C 1~4 optionally substituted with 1 to 3 groups independently selected from alkoxy; C 3~7 Monocyclic cycloalkyl, phenyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl each independently represent 1 to 2 R8 groups, each independently selected from the group consisting of —OH, halogen, —CN, oxo, and —NR 11 R 11 , C1 ~4 Alkoxy, and C 1~5 optionally substituted with 1 to 3 groups independently selected from alkyl; A 4- to 7-membered monocyclic heterocyclyl is one or two R 8 and substituted with -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 Optionally substituted with 1 to 3 groups independently selected from alkyl.

[0168] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is —C(O)R 13 , -C(O)NR 6 R 7 , a 5- to 6-membered monocyclic heteroaryl, or a 7- to 10-membered spirocyclic heterocyclyl; The 5- to 6-membered monocyclic heteroaryl and the 7- to 10-membered spirocyclic heterocyclyl each independently have 1 to 2 R 8 groups, each independently being 1 to 3 R a is optionally substituted with a group.

[0169] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is —C(O)R 13 , -C(O)NR 6 R 7 , a 5- to 6-membered monocyclic heteroaryl, or a 7- to 10-membered spirocyclic heterocyclyl; The 5- to 6-membered monocyclic heteroaryl and the 7- to 10-membered spirocyclic heterocyclyl each independently have 1 to 2 R 8 groups, each independently selected from the group consisting of —OH, halogen, —CN, oxo, and —NR 11 R 11 , C 1~4 Alkoxy, and C1~5 Optionally substituted with 1 to 3 groups independently selected from alkyl.

[0170] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is C 1~10 alkyl, C 1~10 Alkyl is one to four R b In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is optionally substituted with a C group. 1~10 alkyl, C 1~10 Alkyl is one to three R b In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is optionally substituted with a C group. 1~10 alkyl, C 1~10 Alkyl is one to four R b In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is substituted with a C group. 1~10 alkyl, C 1~10 Alkyl is one to three R b In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is substituted with a C group. 1~10 It is alkyl.

[0171] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is C 1~6 It is alkyl.

[0172] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is selected from one R 8 C substituted with a group 1~6 alkyl, and R 8 is a 7- to 10-membered spirocyclic heterocyclyl; 7-10 membered spirocyclic heterocyclyl is -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 optionally substituted with 1 to 3 groups independently selected from alkyl; A 7-10 membered spirocyclic heterocyclyl has only one ring heteroatom, and that one ring heteroatom is N.

[0173] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is selected from one R 8 C substituted with a group 1~3 alkyl, and R 8 teeth,

[0174] [ka] is.

[0175] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is C 2~6 Alkynyl, C 2~6 Alkynyl is a group consisting of 1 to 4 R b In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is optionally substituted with a C group. 2~6 Alkynyl, C 2~6 Alkynyl is a group consisting of one to three R b In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is optionally substituted with a C group. 2~6 Alkynyl, C 2~6 Alkynyl is a group consisting of 1 to 4 R b In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is substituted with a C group. 2~6 Alkynyl, C 2~6 Alkynyl is a group consisting of one to three R b In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is substituted with a C group. 2~6 It is alkynyl.

[0176] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is L 1 is.

[0177] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, L 1 is OR 5 , -C(O)R 5 , -C(O)N(R 5 )(R 5 ), -NR 5 R 5 , -N(R 5 )2(R 5 ) + , -N(R 5 )C(O)R 5 , -N(R 5 )C(O)OR 5 , -N(R 5 )C(O)N(R 5 )(R 5 ), -N(R 5 )S(O)2(R 5a ), -NR 5 S(O)2N(R 5 )(R 5 ), -NR 5 S(O)2O(R 5a ), -OC(O)N(R 5 )(R 5 ), -SR 5 , -S(O)R 5a , -S(O)(NH)R 5 , -S(O)2R 5a , -S(O)2N(R 5 )(R 5 ), or -N=S(R 5a )(R 5a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, L 1 -OR 5 In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, L 1 is -C(O)R 5 In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, L 1 is -C(O)N(R 5 )(R 5 In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, L 1 is -NR 5 R 5In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, L 1 is -N(R 5 )2(R 5 ) + In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, L 1 is -N(R 5 )C(O)R 5 In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, L 1 is -N(R 5 )C(O)OR 5 In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, L 1 is -N(R 5 )C(O)N(R 5 )(R 5 In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, L 1 is -N(R 5 )S(O)2(R 5a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, L 1 is -NR 5 S(O)2N(R 5 )(R 5 In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, L 1 is -NR 5 S(O)2O(R 5a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, L 1 is -OC(O)N(R 5 )(R 5 In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, L 1 -SR 5 In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, L 1 is -S(O)R 5a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, L 1 is -S(O)(NH)R 5In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, L 1 is -S(O)2R 5a Formula I In some embodiments of the compound of formula (I) or a pharmaceutically acceptable salt thereof, L 1 is -S(O)2N(R 5 )(R 5 In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, L 1 is -N=S(R 5a )(R 5a )=O.

[0178] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is C 3~7 is a monocyclic cycloalkyl, C 3~7 Monocyclic cycloalkyl is one to two R 8 optionally substituted with a group and 1 to 3 R a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is optionally substituted with a C group. 3~7 is a monocyclic cycloalkyl, C 3~7 Monocyclic cycloalkyl is one to two R 8 substituted with 1 to 3 R a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is optionally substituted with a C group. 3~7 is a monocyclic cycloalkyl, C 3~7 Monocyclic cycloalkyl is one to two R 8 substituted with 1 to 3 R a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is substituted with a C group. 3~7 is a monocyclic cycloalkyl, C 3~7 Monocyclic cycloalkyl is one to two R 8 In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is substituted with a C group. 3~7 is a monocyclic cycloalkyl, C 3~7 Monocyclic cycloalkyl is one to three Ra In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is optionally substituted with a C group. 3~7 It is a monocyclic cycloalkyl.

[0179] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is selected from one R 8 cyclohexyl substituted with a group, R 8 is -NR 10 R 10 or a 5- to 7-membered monocyclic heterocyclyl, and the 5- to 7-membered monocyclic heterocyclyl is selected from the group consisting of -OH, halogen, -CN, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 substituted with 1 to 3 groups independently selected from alkyl; C 1~5 Alkyl includes -OH, halogen, oxo, and -C(O)N(R 12 )(R 12 Optionally substituted with 1 to 3 groups independently selected from C 1~4 The alkoxy is optionally substituted with 1 to 3 halogen groups; One R 10 is a 4- to 7-membered monocyclic heterocyclyl or a 6- to 10-membered bridged bicyclic heterocyclyl.

[0180] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is C 7~10 is a fused bicyclic cycloalkyl, C 7~10 A fused bicyclic cycloalkyl is one to two R 8 optionally substituted with a group and 1 to 3 R a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is optionally substituted with a C group. 7~10 is a fused bicyclic cycloalkyl, C 7~10 A fused bicyclic cycloalkyl is one to two R 8 substituted with 1 to 3 R aIn some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is optionally substituted with a C group. 7~10 is a fused bicyclic cycloalkyl, C 7~10 A fused bicyclic cycloalkyl is one to two R 8 substituted with 1 to 3 R a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is substituted with a C group. 7~10 is a fused bicyclic cycloalkyl, C 7~10 A fused bicyclic cycloalkyl is one to two R 8 In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is substituted with a C group. 7~10 is a fused bicyclic cycloalkyl, C 7~10 A fused bicyclic cycloalkyl is one to three R a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is optionally substituted with a C group. 7~10 It is a fused bicyclic cycloalkyl.

[0181] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is C 5~10 Bridged bicyclic cycloalkyl, C 5~10 Bridged bicyclic cycloalkyl is 1-2 R 8 optionally substituted with a group and 1 to 3 R a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is optionally substituted with a C group. 5~10 Bridged bicyclic cycloalkyl, C 5~10 A bridged bicyclic cycloalkyl is one to two R 8 substituted with 1 to 3 R a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is optionally substituted with a C group. 5~10 Bridged bicyclic cycloalkyl, C 5~10 A bridged bicyclic cycloalkyl is one to two R 8 substituted with 1 to 3 Ra In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is substituted with a C group. 5~10 Bridged bicyclic cycloalkyl, C 5~10 A bridged bicyclic cycloalkyl is one to two R 8 In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is substituted with a C group. 5~10 Bridged bicyclic cycloalkyl, C 5~10 A bridged bicyclic cycloalkyl is one to three R a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is optionally substituted with a C group. 5~10 It is a bridged bicyclic cycloalkyl.

[0182] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is a 4- to 7-membered monocyclic heterocyclyl, wherein the 4- to 7-membered monocyclic heterocyclyl is selected from one to two R 8 optionally substituted with a group and 1 to 3 R a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is a 4- to 7-membered monocyclic heterocyclyl, wherein the 4- to 7-membered monocyclic heterocyclyl is optionally substituted with one to two R 8 substituted with 1 to 3 R a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is a 4- to 7-membered monocyclic heterocyclyl, wherein the 4- to 7-membered monocyclic heterocyclyl is optionally substituted with one to two R 8 substituted with 1 to 3 R a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is a 4- to 7-membered monocyclic heterocyclyl, wherein the 4- to 7-membered monocyclic heterocyclyl is substituted with one to two R 8 In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is a 4- to 7-membered monocyclic heterocyclyl, wherein the 4- to 7-membered monocyclic heterocyclyl is substituted with one to three R aIn some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is a 4- to 7-membered monocyclic heterocyclyl.

[0183] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is a 4- to 7-membered monocyclic heterocyclyl, wherein the 4- to 7-membered monocyclic heterocyclyl is selected from one to two R 8 substituted with 1 to 3 R a is optionally substituted with a group.

[0184] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is a 5- to 7-membered monocyclic heterocyclyl, wherein the 5- to 7-membered monocyclic heterocyclyl is selected from one to two R 8 optionally substituted with a group and 1 to 3 R a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is a 5- to 7-membered monocyclic heterocyclyl, wherein the 5- to 7-membered monocyclic heterocyclyl is optionally substituted with one to two R 8 and optionally substituted with -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 Optionally substituted with 1 to 3 groups independently selected from alkyl.

[0185] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is a 5- to 7-membered monocyclic heterocyclyl, wherein the 5- to 7-membered monocyclic heterocyclyl is selected from one to two R 8 substituted with 1 to 3 R a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is a 5- to 7-membered monocyclic heterocyclyl, wherein the 5- to 7-membered monocyclic heterocyclyl is optionally substituted with one to two R 8 and substituted with -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 Optionally substituted with 1 to 3 groups independently selected from alkyl.

[0186] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is a 5- to 7-membered monocyclic heterocyclyl, wherein the 5- to 7-membered monocyclic heterocyclyl is selected from one to two R 8 substituted with 1 to 3 R a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is a 5- to 7-membered monocyclic heterocyclyl, wherein the 5- to 7-membered monocyclic heterocyclyl is substituted with one to two R 8 and substituted with -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 and substituted with 1 to 3 groups independently selected from alkyl.

[0187] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is a 5- to 7-membered monocyclic heterocyclyl, wherein the 5- to 7-membered monocyclic heterocyclyl is selected from one to two R 8 In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is a 5- to 7-membered monocyclic heterocyclyl, wherein the 5- to 7-membered monocyclic heterocyclyl is selected from the group consisting of -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is optionally substituted with 1 to 3 groups independently selected from alkyl.

[0188] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is pyrrolidinyl.

[0189] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is selected from one R8 piperidinyl substituted with a group, R 8 is -C(O)R 9 and R 9 is azetidinyl, pyrrolidinyl, or piperidinyl, wherein the azetidinyl, pyrrolidinyl, and piperidinyl are each optionally substituted with one methyl group.

[0190] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is selected from one R 8 piperidinyl substituted with a group, R 8 is -C(O)R 9 and R 9 is a 6- to 10-membered bridged bicyclic heterocyclyl, and the 6- to 10-membered bridged bicyclic heterocyclyl is selected from -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 Optionally substituted with 1 to 3 groups independently selected from alkyl.

[0191] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 9 teeth,

[0192] [ka] and This includes -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 Optionally substituted with 1 to 2 groups independently selected from alkyl.

[0193] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is piperidinyl, wherein the piperidinyl is selected from one to two R 8 and substituted with -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4Alkoxy, and C 1~5 substituted with 1 to 3 groups independently selected from alkyl, R 8 is C 1~6 Archi It is.

[0194] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is piperidinyl substituted with one cyclobutyl group.

[0195] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is selected from one R 8 piperidinyl substituted with a group, R 8 is C 1~6 alkyl, C 1~6 Alkyl is -OH, halogen, -CN, oxo, -NR 11 R 11 , -S(O)2R 11a , and C 1~4 and substituted with 1 to 3 groups independently selected from alkoxy.

[0196] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is selected from one R 8 piperidinyl substituted with a group, R 8 is C 1~6 alkyl, C 1~6 Alkyl is i) substituted with one oxo group; ii) One R h is substituted with an R h is C 3~7 monocyclic cycloalkyl or 4- to 7-membered monocyclic heterocyclyl, and iii) -OH, halogen, -CN, -NR 11 R 11 , and C 1~4 Optionally substituted with one group independently selected from alkoxy.

[0197] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is selected from one R 8piperidinyl substituted with a group, R 8 is C 1~6 alkyl, C 1~6 The alkyl is substituted with oxetanyl.

[0198] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is selected from one R 8 piperidinyl substituted with a group, R 8 is -S(O)2R 5a is.

[0199] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is piperidinyl, wherein the piperidinyl is substituted with 1 to 4 methyl groups.

[0200] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is azepanyl, which is selected from the group consisting of one to two R 8 and optionally substituted with -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 Optionally substituted with 1 to 3 groups independently selected from alkyl.

[0201] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is azepanyl.

[0202] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is phenyl, and the phenyl is selected from one to two R 8 optionally substituted with 1 to 3 R a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is phenyl, and the phenyl is optionally substituted with one to two R 8 substituted with 1 to 3 R aIn some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is phenyl, and the phenyl is optionally substituted with one to two R 8 substituted with 1 to 3 R a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is phenyl, and the phenyl is substituted with one to two R groups. 8 In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is phenyl, and the phenyl is substituted with one to three R groups. a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is optionally substituted with a group.

[0203] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is phenyl, and the phenyl is selected from one to two R 8 and optionally substituted with -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 Optionally substituted with 1 to 3 groups independently selected from alkyl.

[0204] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is naphthalenyl, and the naphthalenyl is selected from one to two R 8 optionally substituted with 1 to 3 R a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is naphthalenyl, and the naphthalenyl is optionally substituted with one to two R 8 substituted with 1 to 3 R a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is naphthalenyl, and the naphthalenyl is optionally substituted with one to two R 8 substituted with 1 to 3 R aIn some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is naphthalenyl, and the naphthalenyl is substituted with one to two R groups. 8 In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is naphthalenyl, and the naphthalenyl is substituted with one to three R groups. a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is optionally substituted with a group.

[0205] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is a 5-6 membered monocyclic heteroaryl, and the 5-6 membered monocyclic heteroaryl is selected from one to two R 8 optionally substituted with a group and 1 to 3 R a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is a 5- to 6-membered monocyclic heteroaryl, and the 5- to 6-membered monocyclic heteroaryl is optionally substituted with one to two R 8 substituted with 1 to 3 R a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is a 5- to 6-membered monocyclic heteroaryl, and the 5- to 6-membered monocyclic heteroaryl is optionally substituted with one to two R 8 substituted with 1 to 3 R a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is a 5- to 6-membered monocyclic heteroaryl, and the 5- to 6-membered monocyclic heteroaryl is substituted with one to two R 8 In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is a 5-6 membered monocyclic heteroaryl, and the 5-6 membered monocyclic heteroaryl is substituted with one to three R groups. a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is a 5-6 membered monocyclic heteroaryl.

[0206] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is a 5-6 membered monocyclic heteroaryl, and the 5-6 membered monocyclic heteroaryl is selected from one to two R 8 and optionally substituted with -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 Optionally substituted with 1 to 3 groups independently selected from alkyl.

[0207] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is a 5-6 membered monocyclic heteroaryl; 5-6 membered monocyclic heteroaryl is one or two R 8 and optionally substituted with -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 optionally substituted with 1 to 3 groups independently selected from alkyl; The 5-6 membered monocyclic heteroaryl has 1 or 2 ring heteroatoms which are N.

[0208] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is 8 to 1 0-membered fused bicyclic heterocyclyl, and 8- to 10-membered fused bicyclic heterocyclyl is a fused bicyclic heterocyclyl having 1 to 2 R 8 optionally substituted with a group and 1 to 3 R a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is an 8- to 10-membered fused bicyclic heterocyclyl, wherein the 8- to 10-membered fused bicyclic heterocyclyl is optionally substituted with one to two R 8 and optionally substituted with -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 Optionally substituted with 1 to 3 groups independently selected from alkyl.

[0209] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is an 8- to 10-membered fused bicyclic heterocyclyl, wherein the 8- to 10-membered fused bicyclic heterocyclyl is selected from one to two R 8 substituted with 1 to 3 R a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is an 8- to 10-membered fused bicyclic heterocyclyl, wherein the 8- to 10-membered fused bicyclic heterocyclyl is optionally substituted with one to two R 8 and substituted with -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 Optionally substituted with 1 to 3 groups independently selected from alkyl.

[0210] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is an 8- to 10-membered fused bicyclic heterocyclyl, wherein the 8- to 10-membered fused bicyclic heterocyclyl is selected from one to two R 8 substituted with 1 to 3 R a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is an 8- to 10-membered fused bicyclic heterocyclyl, wherein the 8- to 10-membered fused bicyclic heterocyclyl is substituted with one to two R 8 and substituted with -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 and substituted with 1 to 3 groups independently selected from alkyl.

[0211] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is an 8- to 10-membered fused bicyclic heterocyclyl, wherein the 8- to 10-membered fused bicyclic heterocyclyl is selected from one to two R 8In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is an 8- to 10-membered fused bicyclic heterocyclyl, wherein the 8- to 10-membered fused bicyclic heterocyclyl is selected from the group consisting of -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is optionally substituted with 1 to 3 groups independently selected from alkyl. In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is an 8- to 10-membered fused bicyclic heterocyclyl.

[0212] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is a 6- to 10-membered bridged bicyclic heterocyclyl, wherein the 6- to 10-membered bridged bicyclic heterocyclyl is selected from one to two R 8 optionally substituted with a group and 1 to 3 R a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is a 6- to 10-membered bridged bicyclic heterocyclyl, wherein the 6- to 10-membered bridged bicyclic heterocyclyl is optionally substituted with one to two R 8 and optionally substituted with -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 Optionally substituted with 1 to 3 groups independently selected from alkyl.

[0213] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is a 6- to 10-membered bridged bicyclic heterocyclyl, wherein the 6- to 10-membered bridged bicyclic heterocyclyl is selected from one to two R 8 substituted with 1 to 3 R a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is a 6- to 10-membered bridged bicyclic heterocyclyl, wherein the 6- to 10-membered bridged bicyclic heterocyclyl is optionally substituted with one to two R 8 and substituted with -OH, halogen, -CN, oxo, -NR11 R 11 , C 1~4 Alkoxy, and C 1~5 Optionally substituted with 1 to 3 groups independently selected from alkyl.

[0214] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is a 6- to 10-membered bridged bicyclic heterocyclyl, wherein the 6- to 10-membered bridged bicyclic heterocyclyl is selected from one to two R 8 substituted with 1 to 3 R a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is a 6- to 10-membered bridged bicyclic heterocyclyl, wherein the 6- to 10-membered bridged bicyclic heterocyclyl is substituted with one to two R groups. 8 and substituted with -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 and substituted with 1 to 3 groups independently selected from alkyl.

[0215] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is a 6- to 10-membered bridged bicyclic heterocyclyl, wherein the 6- to 10-membered bridged bicyclic heterocyclyl is selected from one to two R 8 In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is a 6- to 10-membered bridged bicyclic heterocyclyl, wherein the 6- to 10-membered bridged bicyclic heterocyclyl is substituted with -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is optionally substituted with 1 to 3 groups independently selected from alkyl. In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is a 6- to 10-membered bridged bicyclic heterocyclyl.

[0216] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is an 8- to 10-membered fused bicyclic heteroaryl, and the 8- to 10-membered fused bicyclic heteroaryl is selected from one to two R 8 optionally substituted with a group and 1 to 3 R a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is an 8- to 10-membered fused bicyclic heteroaryl, and the 8- to 10-membered fused bicyclic heteroaryl is optionally substituted with one to two R 8 substituted with 1 to 3 R a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is an 8- to 10-membered fused bicyclic heteroaryl, and the 8- to 10-membered fused bicyclic heteroaryl is optionally substituted with one to two R 8 substituted with 1 to 3 R a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is an 8- to 10-membered fused bicyclic heteroaryl, and the 8- to 10-membered fused bicyclic heteroaryl is substituted with one to two R 8 In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is an 8- to 10-membered fused bicyclic heteroaryl, and the 8- to 10-membered fused bicyclic heteroaryl is substituted with one to three R groups. a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is an 8-10 membered fused bicyclic heteroaryl.

[0217] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is a 7-10 membered spirocyclic heterocyclyl, wherein the 7-10 membered spirocyclic heterocyclyl is selected from the group consisting of one to two R 8 optionally substituted with a group and 1 to 3 R a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is a 7- to 10-membered spirocyclic heterocyclyl, wherein the 7- to 10-membered spirocyclic heterocyclyl is optionally substituted with one to two R 8and optionally substituted with -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 Optionally substituted with 1 to 3 groups independently selected from alkyl.

[0218] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is a 7- to 10-membered spirocyclic heterocyclyl; 7-10 membered spirocyclic heterocyclyl is one or two R 8 optionally substituted with a group -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 optionally substituted with 1 to 3 groups independently selected from alkyl; A 7-10 membered spirocyclic heterocyclyl has only one ring heteroatom, and that one ring heteroatom is N.

[0219] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is a 7-10 membered spirocyclic heterocyclyl, wherein the 7-10 membered spirocyclic heterocyclyl is selected from the group consisting of one to two R 8 substituted with 1 to 3 R a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is a 7- to 10-membered spirocyclic heterocyclyl, wherein the 7- to 10-membered spirocyclic heterocyclyl is optionally substituted with one to two R 8 and substituted with -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 Optionally substituted with 1 to 3 groups independently selected from alkyl.

[0220] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is a 7-10 membered spirocyclic heterocyclyl, wherein the 7-10 membered spirocyclic heterocyclyl is selected from the group consisting of one to two R 8 substituted with 1 to 3 R a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is a 7- to 10-membered spirocyclic heterocyclyl, wherein the 7- to 10-membered spirocyclic heterocyclyl is substituted with one to two R groups. 8 and substituted with -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 and substituted with 1 to 3 groups independently selected from alkyl.

[0221] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is a 7-10 membered spirocyclic heterocyclyl, wherein the 7-10 membered spirocyclic heterocyclyl is selected from the group consisting of one to two R 8 In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is a 7-10 membered spirocyclic heterocyclyl, wherein the 7-10 membered spirocyclic heterocyclyl is selected from the group consisting of -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is optionally substituted with 1 to 3 groups independently selected from alkyl. In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is a 7- to 10-membered spirocyclic heterocyclyl.

[0222] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is C 7~10 a fused bicyclic cycloalkyl, an 8- to 10-membered fused bicyclic heterocyclyl, a 6- to 10-membered bridged bicyclic heterocyclyl, or an 8- to 10-membered fused bicyclic heteroaryl; C 7~10The fused bicyclic cycloalkyl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, and 8- to 10-membered fused bicyclic heteroaryl each independently represent one to two R 8 groups, each independently selected from the group consisting of —OH, halogen, —CN, oxo, and —NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 Optionally substituted with 1 to 3 groups independently selected from alkyl.

[0223] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is an 8- to 10-membered fused bicyclic heterocyclyl, a 6- to 10-membered bridged bicyclic heterocyclyl, or an 8- to 10-membered fused bicyclic heteroaryl; The 8- to 10-membered fused bicyclic heterocyclyl, the 6- to 10-membered bridged bicyclic heterocyclyl, and the 8- to 10-membered fused bicyclic heteroaryl each independently represent one to two R 8 groups, each independently selected from the group consisting of —OH, halogen, —CN, oxo, and —NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 optionally substituted with 1 to 3 groups independently selected from alkyl; The 8- to 10-membered fused bicyclic heterocyclyl, the 6- to 10-membered bridged bicyclic heterocyclyl, and the 8- to 10-membered fused bicyclic heteroaryl each independently have 1 or 2 ring heteroatoms which are N.

[0224] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is a 5- to 6-membered monocyclic heteroaryl or a 7- to 10-membered spirocyclic heterocyclyl; The 5- to 6-membered monocyclic heteroaryl and the 7- to 10-membered spirocyclic heterocyclyl are each independently —OH, halogen, —CN, oxo, —NR 11 R 11 , C 1~4 Alkoxy, and C 1~5Optionally substituted with 1 to 3 groups independently selected from alkyl.

[0225] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is a 5- to 6-membered monocyclic heteroaryl or a 7- to 10-membered spirocyclic heterocyclyl; The 5- to 6-membered monocyclic heteroaryl and the 7- to 10-membered spirocyclic heterocyclyl are each independently —OH, halogen, —CN, oxo, —NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 optionally substituted with 1 to 3 groups independently selected from alkyl; The 5- to 6-membered monocyclic heteroaryl and the 7- to 10-membered spirocyclic heterocyclyl each independently have 1 or 2 ring heteroatoms which are N.

[0226] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is pyridinyl or

[0227] [ka] and Each of these independently contains one to two R 8 groups, and independently selected from the group consisting of -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~3 Alkoxy, and C 1~3 Optionally substituted with 1 to 2 groups independently selected from alkyl.

[0228] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is oxadiazolyl or thiadiazolyl, each of which independently represents one R 8 is optionally substituted with a group.

[0229] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is

[0230] [ka] and Each of these independently represents one R 8 is optionally substituted with a group.

[0231] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is

[0232] [ka] and Each of these independently represents one R 8 groups, and independently selected from the group consisting of -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~3 Alkoxy, and C 1~3 Optionally substituted with 1 to 2 groups independently selected from alkyl.

[0233] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is

[0234] [ka] and Each of these independently represents one R 8 groups, and independently selected from the group consisting of -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~3 Alkoxy, and C 1~3 Optionally substituted with 1 to 2 groups independently selected from alkyl.

[0235] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is

[0236] [ka] and Each of these independently represents one R 8 groups, and independently selected from the group consisting of -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~3 Alkoxy, and C 1~3 Optionally substituted with 1 to 2 groups independently selected from alkyl.

[0237] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is

[0238] [ka] and Each of these independently represents one R 8 groups, and independently selected from the group consisting of -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~3 Alkoxy, and C 1~3 Optionally substituted with 1 to 2 groups independently selected from alkyl.

[0239] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is

[0240] [ka] and Each of these independently represents one R 8 groups, and independently selected from the group consisting of -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~3 Alkoxy, and C 1~3 Optionally substituted with 1 to 2 groups independently selected from alkyl.

[0241] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, one to two R 8 Z substituted with a group is

[0242] [ka] is.

[0243] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, one to two R 8 Z substituted with a group is

[0244] [ka] is.

[0245] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, one to two R 8 Z substituted with a group is

[0246] [ka] is.

[0247] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, one to two R 8 Z substituted with a group is

[0248] [ka] is.

[0249] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is cyclopropyl, and cyclopropyl is selected from one to two R 8 and optionally substituted with -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5Optionally substituted with 1 to 3 groups independently selected from alkyl.

[0250] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is cyclopropyl, and cyclopropyl is selected from the group consisting of one R 8 is substituted with a group.

[0251] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, each R 8 are independently halogen, -C(O)R 9 , -NR 10 R 10 , C 1~6 Alkyl, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 Bridged bicyclic cycloalkyl, 4-7 membered monocyclic heterocyclyl, phenyl, naphthalenyl, 5-6 membered monocyclic heteroaryl, 8-10 membered fused bicyclic heterocyclyl, 6-10 membered bridged bicyclic heterocyclyl, 8-10 membered fused bicyclic heteroaryl, 7-10 membered spirocyclic heterocyclyl, -OR 5 , -C(O)OR 5 , -C(O)N(R 5 )(R 5 ), -N(R 5 )2(R 5 ) + , -N(R 5 )C(O)R 5 , -N(R 5 )C(O)OR 5 , -N(R 5 )C(O)N(R 5 )(R 5 ), -N(R 5 )S(O)2(R 5a ), -NR 5 S(O)2N(R 5 )(R 5 ), -NR 5 S(O)2O(R 5a ), -OC(O)R 5 , -OC(O)OR 5 , -OC(O)N(R 5 )(R 5 ), -SR5 , -S(O)R 5a , -S(O)(NH)R 5 , -S(O)2R 5a , -S(O)2N(R 5 )(R 5 ), or -N=S(R 5a )(R 5a )=O, C 1~6 Alkyl is one to four R b and optionally substituted with a group, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 rack Bridged bicyclic cycloalkyl, 4- to 7-membered monocyclic heterocyclyl, phenyl, naphthalenyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl each independently represent 1 to 4 R a is optionally substituted with a group.

[0252] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, each R 8 are independently -C(O)R 9 , C 1~6 Alkyl, -NR 10 R 10 , C 3~7 Monocyclic cycloalkyl, 4- to 7-membered monocyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 7- to 10-membered spirocyclic heterocyclyl, or -S(O)R 5a and C 1~6 Alkyl is one to three R b and optionally substituted with a group, C 3~7 Monocyclic cycloalkyl, 4- to 7-membered monocyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, and 7- to 10-membered spirocyclic heterocyclyl each independently represent 1 to 3 R a is optionally substituted with a group.

[0253] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, each R 8 are independently -C(O)R 9 , C 1~6 Alkyl, -NR 10 R 10 , C 3~7 Monocyclic cycloalkyl, 4- to 7-membered monocyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 7- to 10-membered spirocyclic heterocyclyl, or -S(O)R 5a and C 1~6 Alkyl is -OH, halogen, -CN, oxo, -NR 11 R 11 , -C(O)N(R 11 )(R 11 ), -S(O)R 11a , C 1~4 Alkoxy, and R h and optionally substituted with 1 to 3 groups independently selected from C 3~7 Monocyclic cycloalkyl, 4- to 7-membered monocyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, and 7- to 10-membered spirocyclic heterocyclyl are each independently -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 optionally substituted with 1 to 3 groups independently selected from alkyl; C 1~5 Alkyl includes -OH, halogen, oxo, and -C(O)N(R 12 )(R 12 Optionally substituted with 1 to 3 groups independently selected from C 1~4 The alkoxy is optionally substituted with 1 to 3 halogen groups; Each R h independently, C 3~7 It is a monocyclic cycloalkyl or a 4- to 7-membered monocyclic heterocyclyl.

[0254] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, each R 8are independently -C(O)R 9 , C 1~6 Alkyl, -NR 10 R 10 , C 3~7 Monocyclic cycloalkyl, 4- to 7-membered monocyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 7- to 10-membered spirocyclic heterocyclyl, or -S(O)R 5a and C 1~6 Alkyl is -OH, halogen, -CN, oxo, -NR 11 R 11 , -S(O)2R 11a , C 1~4 Alkoxy, and R h and optionally substituted with 1 to 3 groups independently selected from C 3~7 Monocyclic cycloalkyl, 4- to 7-membered monocyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, and 7- to 10-membered spirocyclic heterocyclyl are each independently -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 optionally substituted with 1 to 3 groups independently selected from alkyl; C 1~5 Alkyl includes -OH, halogen, oxo, and -C(O)N(R 12 )(R 12 Optionally substituted with 1 to 3 groups independently selected from C 1~4 The alkoxy is optionally substituted with 1 to 3 halogen groups; Each R h independently, C 3~7 It is a monocyclic cycloalkyl or a 4- to 7-membered monocyclic heterocyclyl.

[0255] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, one R 8 is halogen. In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, is one R 8 -OR5 In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, one R 8 is -C(O)OR 5 In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, one R 8 is -C(O)N(R 5 )(R 5 In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, one R 8 is -N(R 5 )2(R 5 ) + In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, one R 8 is -N(R 5 )C(O)R 5 In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, one R 8 is -N(R 5 )C(O)OR 5 In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, one R 8 is -N(R 5 )C(O)N(R 5 )(R 5 In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, one R 8 is -N(R 5 )S(O)2(R 5a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, one R 8 is -NR 5 S(O)2N(R 5 )(R 5 In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, one R 8 is -NR 5 S(O)2O(R 5a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, one R 8 is -OC(O)R 5 In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, one R8 is -OC(O)OR 5 In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, one R 8 is -OC(O)N(R 5 )(R 5 In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, one R 8 -SR 5 In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, one R 8 is -S(O)R 5a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, one R 8 is -S(O)(NH)R 5 In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, one R 8 is -S(O)2R 5a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, one R 8 is -S(O)2N(R 5 )(R 5 In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, one R 8 is -N=S(R 5a )(R 5a )=O.

[0256] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, one R 8 is C 1~6 alkyl, C 1~6 Alkyl is one to four R b In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, one R 8 is C 1~6 alkyl, C 1~6 Alkyl is one to three R b In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, one R 8 is C 1~6 alkyl, C1~6 Alkyl is -OH, halogen, -CN, oxo, -C(O)N(R 11 )(R 11 ), -NR 11 R 11 , and C 1~4 In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, one R is optionally substituted with 1 to 3 groups independently selected from alkoxy. 8 is C 1~3 alkyl, C 1~3 Alkyl is -OH, halogen, -CN, oxo, -C(O)N(R 11 )(R 11 ), -NR 11 R 11 , and C 1~4 In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, one R is optionally substituted with 1 to 3 groups independently selected from alkoxy. 8 is C 1~3 alkyl, C 1~3 Alkyl is -OH, halogen, -CN, -NR 11 R 11 , and C 1~4 In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, one R is optionally substituted with one to two groups independently selected from alkoxy. 8 is C 1~6 alkyl, C 1~6 Alkyl is one to four R b In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, one R 8 is C 1~6 alkyl, C 1~6 Alkyl is one to three R b In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, one R 8 is C 1~6 alkyl, C 1~6 Alkyl is -OH, halogen, -CN, oxo, -C(O)N(R 11 )(R 11 ), -NR 11 R11 , and C 1~4 Any of the compounds of formula I or pharmaceutically acceptable salts thereof is substituted with 1 to 3 groups independently selected from alkoxy. In some embodiments, one R 8 is C 1~3 alkyl, C 1~3 Alkyl is -OH, halogen, -CN, oxo, -C(O)N(R 11 )(R 11 ), -NR 11 R 11 , and C 1~4 In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, one R is substituted with 1 to 3 groups independently selected from alkoxy. 8 is C 1~3 alkyl, C 1~3 Alkyl is -OH, halogen, -CN, -NR 11 R 11 , and C 1~4 In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, one R is substituted with one to two groups independently selected from alkoxy. 8 is C 1~6 In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, one R is alkyl. 8 is C 1~3 It is alkyl.

[0257] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, one R 8 is C 3~7 is a monocyclic cycloalkyl, C 3~7 Monocyclic cycloalkyl is a group consisting of 1 to 4 R a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, one R 8 is C 3~7 is a monocyclic cycloalkyl, C 3~7 Monocyclic cycloalkyl is a group consisting of 1 to 4 R a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, one R 8is C 3~7 It is a monocyclic cycloalkyl.

[0258] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, one R 8 is C 7~10 is a fused bicyclic cycloalkyl, C 7~10 A fused bicyclic cycloalkyl is one to four R a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, one R 8 is C 7~10 is a fused bicyclic cycloalkyl, C 7~10 A fused bicyclic cycloalkyl is one to four R a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, one R 8 is C 7~10 It is a fused bicyclic cycloalkyl.

[0259] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, one R 8 is C 5~10 Bridged bicyclic cycloalkyl, C 5~10 A bridged bicyclic cycloalkyl is one to four R a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, one R 8 is C 5~10 Bridged bicyclic cycloalkyl, C 5~10 A bridged bicyclic cycloalkyl is one to four R a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, one R 8 is C 5~10 It is a bridged bicyclic cycloalkyl.

[0260] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, one R 8 is a 4- to 7-membered monocyclic heterocyclyl, which is a 4- to 7-membered monocyclic heterocyclyl having 1 to 4 R aIn some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, one R 8 is a 4- to 7-membered monocyclic heterocyclyl, and the 4- to 7-membered monocyclic heterocyclyl is a 4- to 7-membered monocyclic heterocyclyl having 1 to 3 R a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, one R 8 is a 4- to 7-membered monocyclic heterocyclyl, and the 4- to 7-membered monocyclic heterocyclyl is selected from -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 Optionally substituted with 1 to 3 groups independently selected from alkyl.

[0261] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, one R 8 is a 4- to 7-membered monocyclic heterocyclyl, which is a 4- to 7-membered monocyclic heterocyclyl having 1 to 4 R a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, one R 8 is a 4- to 7-membered monocyclic heterocyclyl, and the 4- to 7-membered monocyclic heterocyclyl is a 4- to 7-membered monocyclic heterocyclyl having 1 to 3 R a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, one R 8 is a 4- to 7-membered monocyclic heterocyclyl , 4- to 7-membered monocyclic heterocyclyl is -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 and substituted with 1 to 3 groups independently selected from alkyl.

[0262] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, one R 8 is a 4- to 7-membered monocyclic heterocyclyl.

[0263] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, one R 8 is phenyl, and the phenyl is a group having one to four R a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, one R 8 is phenyl, and the phenyl is a group having one to four R a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, one R 8 is phenyl.

[0264] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, one R 8 is naphthalenyl, and naphthalenyl is a group having 1 to 4 R a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, one R 8 is naphthalenyl, and naphthalenyl is a group having 1 to 4 R a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, one R 8 is naphthalenyl.

[0265] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, one R 8 is a 5- to 6-membered monocyclic heteroaryl, and the 5- to 6-membered monocyclic heteroaryl is a 5- to 6-membered monocyclic heteroaryl having 1 to 4 R a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, one R 8 is a 5- to 6-membered monocyclic heteroaryl, and the 5- to 6-membered monocyclic heteroaryl is a 5- to 6-membered monocyclic heteroaryl having 1 to 4 R a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, one R 8 is a 5-6 membered monocyclic heteroaryl.

[0266] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, one R 8is an 8- to 10-membered fused bicyclic heterocyclyl, and the 8- to 10-membered fused bicyclic heterocyclyl is a fused bicyclic heterocyclyl having 1 to 4 R a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, one R 8 is an 8- to 10-membered fused bicyclic heterocyclyl, and the 8- to 10-membered fused bicyclic heterocyclyl is a fused bicyclic heterocyclyl having 1 to 3 R a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, one R 8 is an 8- to 10-membered fused bicyclic heterocyclyl, and the 8- to 10-membered fused bicyclic heterocyclyl is selected from the group consisting of -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 Optionally substituted with 1 to 3 groups independently selected from alkyl.

[0267] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, one R 8 is an 8- to 10-membered fused bicyclic heterocyclyl, and the 8- to 10-membered fused bicyclic heterocyclyl is a fused bicyclic heterocyclyl having 1 to 4 R a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, one R 8 is an 8- to 10-membered fused bicyclic heterocyclyl, and the 8- to 10-membered fused bicyclic heterocyclyl is a fused bicyclic heterocyclyl having 1 to 3 R a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, one R 8 is an 8- to 10-membered fused bicyclic heterocyclyl, and the 8- to 10-membered fused bicyclic heterocyclyl is selected from the group consisting of -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 and substituted with 1 to 3 groups independently selected from alkyl.

[0268] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, one R 8 teeth , 8-10 membered fused bicyclic heterocyclyl.

[0269] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, one R 8 is a 6- to 10-membered bridged bicyclic heterocyclyl, which is a 6- to 10-membered bridged bicyclic heterocyclyl having 1 to 4 R a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, one R 8 is a 6- to 10-membered bridged bicyclic heterocyclyl, which is a 6- to 10-membered bridged bicyclic heterocyclyl having 1 to 3 R a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, one R 8 is a 6- to 10-membered bridged bicyclic heterocyclyl, and the 6- to 10-membered bridged bicyclic heterocyclyl is selected from -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 Optionally substituted with 1 to 3 groups independently selected from alkyl.

[0270] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, one R 8 is a 6- to 10-membered bridged bicyclic heterocyclyl, which is a 6- to 10-membered bridged bicyclic heterocyclyl having 1 to 4 R a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, one R 8 is a 6- to 10-membered bridged bicyclic heterocyclyl, which is a 6- to 10-membered bridged bicyclic heterocyclyl having 1 to 3 R a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, one R 8 is a 6- to 10-membered bridged bicyclic heterocyclyl, and the 6- to 10-membered bridged bicyclic heterocyclyl is selected from -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5and substituted with 1 to 3 groups independently selected from alkyl.

[0271] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, one R 8 is a 6- to 10-membered bridged bicyclic heterocyclyl.

[0272] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, one R 8 is a 7- to 10-membered spirocyclic heterocyclyl, which is a 7- to 10-membered spirocyclic heterocyclyl having 1 to 4 R a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, one R 8 is a 7- to 10-membered spirocyclic heterocyclyl, which is a 7- to 10-membered spirocyclic heterocyclyl having 1 to 4 R a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, one R 8 is a 7- to 10-membered spirocyclic heterocyclyl.

[0273] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 8 is a 4- to 7-membered monocyclic heterocyclyl, which is a 4- to 7-membered monocyclic heterocyclyl having 1 to 4 R a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 8 is a 4- to 7-membered monocyclic heterocyclyl, and the 4- to 7-membered monocyclic heterocyclyl is a 4- to 7-membered monocyclic heterocyclyl having 1 to 3 R a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 8 is a 4- to 7-membered monocyclic heterocyclyl, and the 4- to 7-membered monocyclic heterocyclyl is selected from -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 Optionally substituted with 1 to 3 groups independently selected from alkyl.

[0274] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 8 is a 4- to 7-membered monocyclic heterocyclyl, which is a 4- to 7-membered monocyclic heterocyclyl having 1 to 4 R a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 8 is a 4- to 7-membered monocyclic heterocyclyl, and the 4- to 7-membered monocyclic heterocyclyl is a 4- to 7-membered monocyclic heterocyclyl having 1 to 3 R a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 8 is a 4- to 7-membered monocyclic heterocyclyl; Tetracyclyl is -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 and substituted with 1 to 3 groups independently selected from alkyl.

[0275] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 8 is a 4- to 7-membered monocyclic heterocyclyl. In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 8 is a 6-membered monocyclic heterocyclyl.

[0276] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 8 is piperidinyl or piperazinyl.

[0277] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 8 teeth,

[0278] [ka] is.

[0279] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R8 -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 a 4- to 7-membered monocyclic heterocyclyl substituted by 1 to 3 groups independently selected from alkyl; C 1~5 Alkyl includes -OH, halogen, oxo, and -C(O)N(R 12 )(R 12 Optionally substituted with 1 to 3 groups independently selected from C 1~4 The alkoxy is optionally substituted with 1 to 3 halogen groups.

[0280] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 8 is piperidinyl or piperazinyl, each of which is independently selected from —OH, halogen, C 1~4 Alkoxy, and C 1~5 substituted with 1 to 3 groups independently selected from alkyl; C 1~5 Alkyl is —OH and —C(O)N(R 12 )(R 12 Optionally substituted with one group selected from C 1~4 The alkoxy is optionally substituted with 1 to 3 halogen groups.

[0281] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 8 is piperidinyl or piperazinyl, each of which is independently substituted with 1 to 3 groups independently selected from -OH, fluoro, -OCF3, -CH2CH2OH, and -CH2C(O)NH2.

[0282] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 8 is pyrrolidinyl.

[0283] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 8 -OH, halogen, C 1~4 Alkoxy, and C 1~5 pyrrolidinyl substituted with 1 to 3 groups independently selected from alkyl; C 1~5 Alkyl is —OH and —C(O)N(R 12 )(R 12 Optionally substituted with one group selected from C 1~4 The alkoxy is optionally substituted with 1 to 3 halogen groups.

[0284] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 8 -OH, halogens, and C l~3 pyrrolidinyl substituted with 1 to 3 groups independently selected from alkoxy; l~3 The alkoxy is optionally substituted with 1 to 3 fluoro groups.

[0285] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 8 is pyrrolidinyl substituted with 1 to 3 groups independently selected from -OH, fluoro, -OCF3, -CH2CH2OH, and -CH2C(O)NH2.

[0286] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 8 -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 C substituted with 1 to 3 groups independently selected from alkyl 3~7 is a monocyclic cycloalkyl; C 1~5 Alkyl includes -OH, halogen, oxo, and -C(O)N(R 12 )(R 12 Optionally substituted with 1 to 3 groups independently selected from C 1~4 The alkoxy is optionally substituted with 1 to 3 halogen groups.

[0287] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 8 is -NR 11 R 11 cyclohexyl substituted with R 11 is H or C 1~4 It is alkyl.

[0288] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 8 -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 a 6- to 10-membered bridged bicyclic heterocyclyl optionally substituted with 1 to 3 groups independently selected from alkyl; C 1~5 Alkyl includes -OH, halogen, oxo, and -C(O)N(R 12 )(R 12 Optionally substituted with 1 to 3 groups independently selected from C 1~4 The alkoxy is optionally substituted with 1 to 3 halogen groups.

[0289] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 8 is C 1~5 6-10 membered bridged bicyclic heterocyclyl optionally substituted with alkyl, C 1~5 Alkyl includes -OH, halogen, oxo, and -C(O)N(R 12 )(R 12 ), optionally substituted with 1 to 3 groups independently selected from R 12 is H or C 1~4 It is alkyl.

[0290] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R8 teeth,

[0291] [ka] and It is optionally substituted with -CH2C(O)NH2.

[0292] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 8 -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 a 7- to 10-membered spirocyclic heterocyclyl optionally substituted with 1 to 3 groups independently selected from alkyl; C 1~5 Alkyl includes -OH, halogen, oxo, and -C(O)N(R 12 )(R 1 2 Optionally substituted with 1 to 3 groups independently selected from C 1~4 The alkoxy is optionally substituted with 1 to 3 halogen groups.

[0293] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 8 is a 7-10 membered spirocyclic heterocyclyl optionally substituted with one or two oxo groups.

[0294] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 8 teeth,

[0295] [ka] and

[0296] Each of these is -OH, halogen, -CN, oxo, -NR 11 R 11 , C1~4 Alkoxy, and C 1~5 Optionally substituted with 1 to 3 groups independently selected from alkyl.

[0297] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 8 -OH, halogen, -CN, oxo, -NR 11 R 11 , -C(O)N(R 11 )(R 11 ), -S(O)R 11a , and C 1~4 C substituted with 1 to 3 groups independently selected from alkoxy 1~6 It is alkyl.

[0298] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 8 -OH, halogen, -CN, oxo, -NR 11 R 11 , -S(O)2R 11a , and C 1~4 C substituted with 1 to 3 groups independently selected from alkoxy 1~6 It is alkyl.

[0299] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 8 is C 1~6 alkyl, C 1~6 Alkyl is i) substituted with one oxo group; ii) One R h is substituted with an R h is C 3~7 monocyclic cycloalkyl or 4- to 7-membered monocyclic heterocyclyl, and iii) -OH, halogen, -CN, -NR 11 R 11 , and C 1~4 Optionally substituted with one group independently selected from alkoxy.

[0300] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 8 is C 1~6 alkyl, C 1~6 The alkyl is substituted with oxetanyl.

[0301] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 8 is C 1~6 alkyl, C 1~6 Alkyl is -C(O)N(R 11 )(R 11 ) has been replaced.

[0302] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 8 teeth,

[0303] [ka] is.

[0304] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 8 teeth,

[0305] [ka] is.

[0306] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 8 is -C(O)R 9 is.

[0307] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, one R 8 is -C(O)R 9 is.

[0308] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 9 is C 2~6 Alkenyl, C 2~6Alkynyl, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, or 7- to 10-membered spirocyclic heterocyclyl; C 2~6 Alkenyl and C 2~6 Alkynyl is independently selected from 1 to 4 R b and optionally substituted with a group, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 Bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl each independently represent 1 to 4 R a is optionally substituted with a group.

[0309] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 9 is a 4- to 7-membered monocyclic heterocyclyl or a 6- to 10-membered bridged bicyclic heterocyclyl, The 4- to 7-membered monocyclic heterocyclyl and the 6- to 10-membered bridged bicyclic heterocyclyl each independently have 1 to 3 R a is optionally substituted with a group.

[0310] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 9 is a 4- to 7-membered monocyclic heterocyclyl or a 6- to 10-membered bridged bicyclic heterocyclyl, The 4- to 7-membered monocyclic heterocyclyl and the 6- to 10-membered bridged bicyclic heterocyclyl are each independently —OH, halogen, —CN, oxo, —NR 11 R 11 , C1~4 Alkoxy, and C 1~5 optionally substituted with 1 to 3 groups independently selected from alkyl; C 1~5 The alkyl is optionally substituted with 1 to 3 groups independently selected from -OH, halogen, and -CN.

[0311] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 9 is a 4- to 7-membered monocyclic heterocyclyl or a 6- to 10-membered bridged bicyclic heterocyclyl, and each of the 4- to 7-membered monocyclic heterocyclyl and the 6- to 10-membered bridged bicyclic heterocyclyl is independently —OH, halogen, —CN, oxo, —NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 Optionally substituted with 1 to 3 groups independently selected from alkyl.

[0312] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 9 is C 2~6 alkenyl, C 2~6 Alkenyl is a group consisting of 1 to 4 R b In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 9 is C 2~6 Alkynyl, C 2~6 Alkynyl is a group consisting of 1 to 4 R b is optionally substituted with a group.

[0313] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 9 is C 3~7 is a monocyclic cycloalkyl, C 3~7 Monocyclic cycloalkyl is a group consisting of 1 to 4 R a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 9 is C 3~7 is a monocyclic cycloalkyl, C 3~7Monocyclic cycloalkyl is a group consisting of 1 to 4 R a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 9 is C 3~7 It is a monocyclic cycloalkyl.

[0314] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 9 is C 7~10 is a fused bicyclic cycloalkyl, C 7~10 A fused bicyclic cycloalkyl is one to four R a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 9 is C 7~10 is a fused bicyclic cycloalkyl, C 7~10 A fused bicyclic cycloalkyl is one to four R a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 9 is C 7~10 It is a fused bicyclic cycloalkyl.

[0315] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 9 is C 5~10 Bridged bicyclic cycloalkyl, C 5~10 A bridged bicyclic cycloalkyl is one to four R a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 9 is C 5~10 Bridged bicyclic cycloalkyl, C 5~10 A bridged bicyclic cycloalkyl is one to four R a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 9 is C 5~10 It is a bridged bicyclic cycloalkyl.

[0316] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 9is phenyl, and the phenyl is a group having one to four R a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 9 is phenyl, and the phenyl is a group having one to four R a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 9 is phenyl.

[0317] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 9 is naphthalenyl, and naphthalenyl is a group having 1 to 4 R a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 9 is naphthalenyl, and naphthalenyl is a group having 1 to 4 R a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 9 is naphthalenyl.

[0318] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 9 is a 5- to 6-membered monocyclic heteroaryl, and the 5- to 6-membered monocyclic heteroaryl is a 5- to 6-membered monocyclic heteroaryl having 1 to 4 R a Some of the compounds of formula I or pharmaceutically acceptable salts thereof are optionally substituted with a group. In an embodiment of the present invention, R 9 is a 5- to 6-membered monocyclic heteroaryl, and the 5- to 6-membered monocyclic heteroaryl is a 5- to 6-membered monocyclic heteroaryl having 1 to 4 R a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 9 is a 5-6 membered monocyclic heteroaryl.

[0319] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 9 is an 8- to 10-membered fused bicyclic heterocyclyl, and the 8- to 10-membered fused bicyclic heterocyclyl is a fused bicyclic heterocyclyl having 1 to 4 R aIn some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 9 is an 8- to 10-membered fused bicyclic heterocyclyl, and the 8- to 10-membered fused bicyclic heterocyclyl is a fused bicyclic heterocyclyl having 1 to 4 R a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 9 is an 8- to 10-membered fused bicyclic heterocyclyl.

[0320] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 9 is an 8- to 10-membered fused bicyclic heteroaryl, and the 8- to 10-membered fused bicyclic heteroaryl is a fused bicyclic heteroaryl having 1 to 4 R a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 9 is an 8- to 10-membered fused bicyclic heteroaryl, and the 8- to 10-membered fused bicyclic heteroaryl is a fused bicyclic heteroaryl having 1 to 4 R a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 9 is an 8-10 membered fused bicyclic heteroaryl.

[0321] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 9 is a 7- to 10-membered spirocyclic heterocyclyl, which is a 7- to 10-membered spirocyclic heterocyclyl having 1 to 4 R a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 9 is a 7- to 10-membered spirocyclic heterocyclyl, which is a 7- to 10-membered spirocyclic heterocyclyl having 1 to 4 R a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 9 is a 7- to 10-membered spirocyclic heterocyclyl.

[0322] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 9is a 4- to 7-membered monocyclic heterocyclyl, which is a 4- to 7-membered monocyclic heterocyclyl having 1 to 4 R a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 9 is a 4- to 7-membered monocyclic heterocyclyl, and the 4- to 7-membered monocyclic heterocyclyl is selected from -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 9 is a 4- to 7-membered monocyclic heterocyclyl, which is a 4- to 7-membered monocyclic heterocyclyl having 1 to 4 R a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 9 is a 4- to 7-membered monocyclic heterocyclyl, and the 4- to 7-membered monocyclic heterocyclyl is selected from -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R is substituted with 1 to 3 groups independently selected from alkyl. 9 is a 4- to 7-membered monocyclic heterocyclyl.

[0323] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 9 is a 5- to 7-membered monocyclic heterocyclyl, which is a 5- to 7-membered monocyclic heterocyclyl having 1 to 4 R a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 9 is a 5- to 7-membered monocyclic heterocyclyl, and the 5- to 7-membered monocyclic heterocyclyl is selected from -OH, halogen, -CN, -NR 11 R 11 , C 1~3 Alkoxy, and C 1~3In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 9 is 5~ 7-membered monocyclic heterocyclyl, and 5- to 7-membered monocyclic heterocyclyl is 1 to 4 R a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 9 is a 5- to 7-membered monocyclic heterocyclyl, and the 5- to 7-membered monocyclic heterocyclyl is selected from -OH, halogen, -CN, -NR 11 R 11 , C 1~3 Alkoxy, and C 1~3 In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R is substituted with 1 to 3 groups independently selected from alkyl. 9 is a 5- to 7-membered monocyclic heterocyclyl.

[0324] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 9 is a 4- to 7-membered monocyclic heterocyclyl, which has one ring heteroatom which is N.

[0325] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 9 -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 and a 4- to 7-membered monocyclic heterocyclyl substituted with 1 to 3 groups independently selected from alkyl.

[0326] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 9 is azetidinyl, pyrrolidinyl, or piperidinyl, each of which is C 1~3 It is substituted with alkyl.

[0327] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 9 is morpholinyl or piperazinyl, each of which has one C 1~3 optionally substituted with alkyl, C 1~3 The alkyl is optionally substituted with one group independently selected from -OH, halogen, and -CN.

[0328] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 9 is a 6- to 10-membered bridged bicyclic heterocyclyl, which is a 6- to 10-membered bridged bicyclic heterocyclyl having 1 to 4 R a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 9 is a 6- to 10-membered bridged bicyclic heterocyclyl, and the 6- to 10-membered bridged bicyclic heterocyclyl is selected from -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 9 is a 6- to 10-membered bridged bicyclic heterocyclyl, and the 6- to 10-membered bridged bicyclic heterocyclyl is selected from -OH, halogen, -CN, -NR 11 R 11 , C 1~3 Alkoxy, and C 1~3 In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 9 is a 6- to 10-membered bridged bicyclic heterocyclyl, which is a 6- to 10-membered bridged bicyclic heterocyclyl having 1 to 4 R a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 9 is a 6- to 10-membered bridged bicyclic heterocyclyl, and the 6- to 10-membered bridged bicyclic heterocyclyl is selected from -OH, halogen, -CN, oxo, -NR 11 R11 , C 1~4 Alkoxy, and C 1~5 In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R is substituted with 1 to 3 groups independently selected from alkyl. 9 is a 6- to 10-membered bridged bicyclic heterocyclyl, and the 6- to 10-membered bridged bicyclic heterocyclyl is selected from -OH, halogen, -CN, -NR 11 R 11 , C 1~3 Alkoxy, and C 1~3 In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R is substituted with 1 to 3 groups independently selected from alkyl. 9 is a 6- to 10-membered bridged bicyclic heterocyclyl.

[0329] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 9 -O H, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 and 6-10 membered bridged bicyclic heterocyclyl optionally substituted with 1-3 groups independently selected from alkyl.

[0330] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 9 teeth,

[0331] [ka] and This includes -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 Optionally substituted with 1 to 2 groups independently selected from alkyl.

[0332] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 8is -NR 10 R 10 is.

[0333] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, one R 8 is -NR 10 R 10 is.

[0334] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 8 is -S(O)2R 5a is.

[0335] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is —NR 6 R 7 In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is -NHR 6 or -N(CH3)R 6 In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is -NHR 6 In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is -N(CH3)R 6 is.

[0336] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is —S(O)R 6 is.

[0337] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is —C(O)NR 6 R 7 In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is —C(O)N(H)R 6 In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is -C(O)N(CH3)R 6 is.

[0338] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R6 is C 1~6 Alkyl, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 a bridged bicyclic cycloalkyl, a 4- to 7-membered monocyclic heterocyclyl, a phenyl, a naphthalenyl, a 5- to 6-membered monocyclic heteroaryl, an 8- to 10-membered fused bicyclic heterocyclyl, a 6- to 10-membered bridged bicyclic heterocyclyl, an 8- to 10-membered fused bicyclic heteroaryl, or a 7- to 10-membered spirocyclic heterocyclyl; C 1~6 Alkyl is one to four R b and optionally substituted with a group, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 Bridged bicyclic cycloalkyl, 4- to 7-membered monocyclic heterocyclyl, phenyl, naphthalenyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl each independently represent 1 to 4 R a is optionally substituted with a group.

[0339] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 6 is C 1~6 Alkyl, C 3~7 monocyclic cycloalkyl, 4- to 7-membered monocyclic heterocyclyl, or 6- to 10-membered bridged bicyclic heterocyclyl; C 1~6 Alkyl is one to three R b and optionally substituted with a group, C 3~7 The monocyclic cycloalkyl, 4- to 7-membered monocyclic heterocyclyl, and 6- to 10-membered bridged bicyclic heterocyclyl each independently have 1 to 3 R a optionally substituted with a group In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 6 is C 1~6 Alkyl, C 3~7monocyclic cycloalkyl, 4- to 7-membered monocyclic heterocyclyl, or 6- to 10-membered bridged bicyclic heterocyclyl; C 1~6 Alkyl is -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and R e and optionally substituted with 1 to 3 groups independently selected from C 3~7 The monocyclic cycloalkyl, the 4- to 7-membered monocyclic heterocyclyl, and the 6- to 10-membered bridged bicyclic heterocyclyl are each independently —OH, halogen, —CN, oxo, —C(O)R 11 , -NR 11 R 11 , C 1~4 Alkoxy, C 1~5 Alkyl, and R f and optionally substituted with 1 to 3 groups independently selected from C 1~5 Alkyl is -OH, halogen, -CN, oxo, -NR 12 R 12 , and -C(O)N(R 12 )(R 12 Optionally substituted with 1 to 3 groups independently selected from Each R e is independently a 4- to 7-membered monocyclic heterocyclyl or a 5- to 6-membered monocyclic heteroaryl; Each R f independently, C 3~7 monocyclic cycloalkyl, 4- to 7-membered monocyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, or 7- to 10-membered spirocyclic heterocyclyl, 3~7 The monocyclic cycloalkyl, 4- to 7-membered monocyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, and 7- to 10-membered spirocyclic heterocyclyl are each independently optionally substituted with 1 to 3 groups independently selected from oxo and halogen.

[0340] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 6 is C1~6 alkyl or 4- to 7-membered monocyclic heterocyclyl; C 1~6 Alkyl is one to three R b and optionally substituted with a group, A 4- to 7-membered monocyclic heterocyclyl is one to three R a and optionally substituted with a group, In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 6 is C 1~6 alkyl or 4- to 7-membered monocyclic heterocyclyl; C 1~6 Alkyl is -OH, halogen, -CN, oxo, -NR 11 R 11 , and C 1~4 optionally substituted with 1 to 3 groups independently selected from alkoxy; 4- to 7-membered monocyclic heterocyclyl is -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 Optionally substituted with 1 to 3 groups independently selected from alkyl.

[0341] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 6 is C 1~6 alkyl or 4- to 7-membered monocyclic heterocyclyl; C 1~6 Alkyl is -OH, halogen, -NR 11 R 11 , and C 1~3 optionally substituted with 1 to 2 groups independently selected from alkoxy; 4-7 membered monocyclic heterocyclyl is -OH, halogen, -CN, -NR 11 R 11 , C 1~3 Alkoxy, and C 1~3 Optionally substituted with 1 to 3 groups independently selected from alkyl.

[0342] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 6 is C 1~6 alkyl, C 1~6 Alkyl is one to four R b In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 6 is C 1~6 alkyl, C 1~6 Alkyl is one to three R b In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 6 is C 1~6 alkyl, C 1~6 Alkyl is -OH, halogen, -CN, oxo, -NR 11 R 11 , and C 1~4 In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R is optionally substituted with 1 to 3 groups independently selected from alkoxy. 6 is C 1~6 alkyl, C 1~6 Alkyl is -OH, halogen, -CN, oxo, -NR 11 R 11 , and C 1~3 Optionally substituted with 1 to 2 groups independently selected from alkoxy.

[0343] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 6 is C 1~6 alkyl, C 1~6 Alkyl is one to four R b In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 6 is C 1~6 alkyl, C 1~6 Alkyl is one to three R b In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 6 is C 1~6 alkyl, C 1~6Alkyl is -OH, halogen, -CN, oxo, -NR 11 R 11 , and C 1~4 In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R is substituted with 1 to 3 groups independently selected from alkoxy. 6 is C 1~6 alkyl, C 1~6 Alkyl is -OH, halogen, -CN, oxo, -NR 11 R 11 , and C 1~3 and substituted with 1 to 2 groups independently selected from alkoxy.

[0344] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 6 is a C substituted with 1 to 2 groups independently selected from 4 to 7-membered monocyclic heterocyclyl and 5 to 6-membered monocyclic heteroaryl. 1~6 It is alkyl.

[0345] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 6 is C substituted with one group selected from pyrrolidinyl, piperidinyl, morpholinyl, and pyridinyl; 1~4 It is alkyl.

[0346] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 6 is C 1~6 It is alkyl.

[0347] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 6 is C 1~4 alkyl, C 1~4 Alkyl is one to four R b In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 6 is C 1~4 alkyl, C 1~4 Alkyl is one to three R bIn some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 6 is C 1~4 alkyl, C 1~4 Alkyl is -OH, halogen, -CN, oxo, -NR 11 R 11 , and C 1~4 In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R is optionally substituted with 1 to 3 groups independently selected from alkoxy. 6 is C 1~4 alkyl, C 1~4 Alkyl is -OH, halogen, -CN, oxo, -NR 11 R 11 , and C 1~3 Optionally substituted with 1 to 2 groups independently selected from alkoxy.

[0348] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 6 is C 1~4 alkyl, C 1~4 Alkyl is one to four R b In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 6 is C 1~4 alkyl, C 1~4 Alkyl is one to three R b The compound of formula I is substituted with a group. In some embodiments of the pharmaceutically acceptable salt thereof, R 6 is C 1~4 alkyl, C 1~4 Alkyl is -OH, halogen, -CN, oxo, -NR 11 R 11 , and C 1~4 In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R is substituted with 1 to 3 groups independently selected from alkoxy. 6 is C 1~4 alkyl, C 1~4 Alkyl is -OH, halogen, -CN, oxo, -NR11 R 11 , and C 1~3 and substituted with 1 to 2 groups independently selected from alkoxy.

[0349] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 6 is one -NR 11 R 11 C optionally substituted with 1~4 In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 6 is a C substituted with one group independently selected from -NH, NH(CH), and N(CH) 1~4 It is alkyl.

[0350] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 6 is C 1~4 It is alkyl.

[0351] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 6 is C 3~7 is a monocyclic cycloalkyl, C 3~7 Monocyclic cycloalkyl is a group consisting of 1 to 4 R a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 6 is C 3~7 is a monocyclic cycloalkyl, C 3~7 Monocyclic cycloalkyl is a group consisting of 1 to 4 R a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 6 is C 3~7 It is a monocyclic cycloalkyl.

[0352] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 6 is a C optionally substituted with one 4- to 7-membered monocyclic heterocyclyl or one 7- to 10-membered spirocyclic heterocyclyl; 3~7Monocyclic cycloalkyl, 4- to 7-membered monocyclic heterocyclyl and 7- to 10-membered spirocyclic heterocyclyl are each independently optionally substituted with 1 to 3 groups independently selected from oxo and halogen.

[0353] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 6 is a C optionally substituted with one 6- to 10-membered bridged bicyclic heterocyclyl 3~7 The monocyclic cycloalkyl and 6-10 membered bridged bicyclic heterocyclyl are optionally substituted with 1 to 3 groups independently selected from oxo and halogen.

[0354] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 6 is cyclobutyl.

[0355] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 6 represents cyclohexyl, pyrrolidinyl, substituted with azetidinyl,

[0356] [ka] and Each of these is optionally substituted with 1 to 3 groups independently selected from oxo and fluoro.

[0357] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 6 is cyclohexyl substituted with one 6- to 10-membered bridged bicyclic heterocyclyl, wherein the 6- to 10-membered bridged bicyclic heterocyclyl is optionally substituted with 1 to 3 groups independently selected from oxo and halogen.

[0358] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 6 teeth,

[0359] [ka] and cyclohexyl substituted with .

[0360] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 6 is C 7~10 is a fused bicyclic cycloalkyl, C 7~10 A fused bicyclic cycloalkyl is one to four R a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 6 is C 7~10 is a fused bicyclic cycloalkyl, C 7~10 A fused bicyclic cycloalkyl is one to four R a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 6 is C 7~10 It is a fused bicyclic cycloalkyl.

[0361] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 6 is C 5~10 Bridged bicyclic cycloalkyl, C 5~10 A bridged bicyclic cycloalkyl is one to four R a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 6 is C 5~10 Bridged bicyclic cycloalkyl, C 5~10 A bridged bicyclic cycloalkyl is one to four R a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 6 is C 5~10 It is a bridged bicyclic cycloalkyl.

[0362] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 6 is a 4- to 7-membered monocyclic heterocyclyl, which is a 4- to 7-membered monocyclic heterocyclyl having 1 to 4 R aIn some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 6 is a 4- to 7-membered monocyclic heterocyclyl, and the 4- to 7-membered monocyclic heterocyclyl is a 4- to 7-membered monocyclic heterocyclyl having 1 to 3 R a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 6 is a 4- to 7-membered monocyclic heterocyclyl, and the 4- to 7-membered monocyclic heterocyclyl is selected from -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 6 is a 4- to 7-membered monocyclic heterocyclyl, and the 4- to 7-membered monocyclic heterocyclyl is selected from -OH, halogen, -CN, -NR 11 R 11 , C 1~3 Alkoxy, and C 1~3 In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R is 1 to 3 optionally substituted groups independently selected from alkyl, aryl, aryl, arylsulfonyl ... 6 is a 5- to 6-membered monocyclic heterocyclyl, and the 5- to 6-membered monocyclic heterocyclyl is selected from -OH, halogen, -CN, -NR 11 R 11 , C 1~3 Alkoxy, and C 1~3 and optionally substituted 1 to 3 groups independently selected from alkyl.

[0363] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 6 is a 4- to 7-membered monocyclic heterocyclyl, which is a 4- to 7-membered monocyclic heterocyclyl having 1 to 4 R a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 6 is a 4- to 7-membered monocyclic heterocyclyl, and the 4- to 7-membered monocyclic heterocyclyl is 1 to 3 Ra In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 6 is a 4- to 7-membered monocyclic heterocyclyl, and the 4- to 7-membered monocyclic heterocyclyl is selected from -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R is substituted with 1 to 3 groups independently selected from alkyl. 6 is a 4- to 7-membered monocyclic heterocyclyl, and the 4- to 7-membered monocyclic heterocyclyl is selected from -OH, halogen, -CN, -NR 11 R 11 , C 1~3 Alkoxy, and C 1~3 In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R is substituted with 1 to 3 groups independently selected from alkyl. 6 is a 5- to 6-membered monocyclic heterocyclyl, and the 5- to 6-membered monocyclic heterocyclyl is selected from -OH, halogen, -CN, -NR 11 R 11 , C 1~3 Alkoxy, and C 1~3 and substituted with 1 to 3 groups independently selected from alkyl.

[0364] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 6 is a 4- to 7-membered monocyclic heterocyclyl. In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 6 is a 5- to 6-membered monocyclic heterocyclyl.

[0365] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 6 is azetidinyl.

[0366] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 6 -OH, halogen, -CN, oxo, -C(O)R 11, -NR 11 R 11 , C 1~4 Alkoxy, C 1~5 Alkyl, and R f is a 5- to 6-membered monocyclic heterocyclyl optionally substituted with 1 to 3 groups independently selected from C 1~5 Alkyl is -OH, halogen, -CN, oxo, -NR 12 R 12 , and -C(O)N(R 12 )(R 12 Optionally substituted with 1 to 3 groups independently selected from R f is C 3~7 monocyclic cycloalkyl or 4- to 7-membered monocyclic heterocyclyl In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 6 is pyrrolidinyl or piperidinyl, each of which is substituted with 1 to 3 groups independently selected from fluoro, methyl, —CHOH, —CHCN, —CF, ethyl, —CHCHOH, —CHCHCN, —CHCF, —CHCHF, —CHCHCF, cyclobutyl, oxetanyl, —CHC(O)NH, —CHC(O)N(CH), —C(O)CHNH, and —C(O)CHN(CH).

[0367] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 6 is pyrrolidinyl or piperidinyl, each of which is selected from the group consisting of —OH, halogen, —CN, —NR 11 R 11 , C 1~3 Alkoxy, and C 1~3 Optionally substituted with 1 to 3 groups independently selected from alkyl.

[0368] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 6 is halogen and C 1~3 Optionally substituted with 1 to 3 groups independently selected from alkyl.

[0369] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 6 is optionally substituted with 1 to 3 groups independently selected from fluoro and methyl.

[0370] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 6 teeth,

[0371] [ka] is.

[0372] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 6 is phenyl, and the phenyl is a group having one to four R a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 6 is phenyl, and the phenyl is a group having one to four R a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 6 is phenyl.

[0373] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 6 is naphthalenyl, and naphthalenyl is a group having 1 to 4 R a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 6 is naphthalenyl, and naphthalenyl is a group having 1 to 4 R a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 6 is naphthalenyl.

[0374] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 6is a 5- to 6-membered monocyclic heteroaryl, and the 5- to 6-membered monocyclic heteroaryl is a 5- to 6-membered monocyclic heteroaryl having 1 to 4 R a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 6 is a 5- to 6-membered monocyclic heteroaryl, and the 5- to 6-membered monocyclic heteroaryl is a 5- to 6-membered monocyclic heteroaryl having 1 to 4 R a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 6 is a 5-6 membered monocyclic heteroaryl.

[0375] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 6 is an 8- to 10-membered fused bicyclic heterocyclyl, and the 8- to 10-membered fused bicyclic heterocyclyl is a fused bicyclic heterocyclyl having 1 to 4 R a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 6 is an 8- to 10-membered fused bicyclic heterocyclyl, and the 8- to 10-membered fused bicyclic heterocyclyl is a fused bicyclic heterocyclyl having 1 to 3 R a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 6 is an 8- to 10-membered fused bicyclic heterocyclyl, and the 8- to 10-membered fused bicyclic heterocyclyl is selected from the group consisting of -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 Optionally substituted with 1 to 3 groups independently selected from alkyl.

[0376] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 6 is an 8- to 10-membered fused bicyclic heterocyclyl, and the 8- to 10-membered fused bicyclic heterocyclyl is a fused bicyclic heterocyclyl having 1 to 4 R a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 6 is an 8- to 10-membered fused bicyclic heterocyclyl, and the 8- to 10-membered fused bicyclic heterocyclyl is a fused bicyclic heterocyclyl having 1 to 3 Ra In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 6 is an 8- to 10-membered fused bicyclic heterocyclyl, and the 8- to 10-membered fused bicyclic heterocyclyl is selected from -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 and substituted with 1 to 3 groups independently selected from alkyl.

[0377] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 6 is 8~ It is a 10-membered fused bicyclic heterocyclyl.

[0378] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 6 is a 6- to 10-membered bridged bicyclic heterocyclyl, which is a 6- to 10-membered bridged bicyclic heterocyclyl having 1 to 4 R a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 6 is a 6- to 10-membered bridged bicyclic heterocyclyl, which is a 6- to 10-membered bridged bicyclic heterocyclyl having 1 to 3 R a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 6 is a 6- to 10-membered bridged bicyclic heterocyclyl, and the 6- to 10-membered bridged bicyclic heterocyclyl is selected from -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 Optionally substituted with 1 to 3 groups independently selected from alkyl.

[0379] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 6 is a 6- to 10-membered bridged bicyclic heterocyclyl, which is a 6- to 10-membered bridged bicyclic heterocyclyl having 1 to 4 R aIn some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 6 is a 6- to 10-membered bridged bicyclic heterocyclyl, which is a 6- to 10-membered bridged bicyclic heterocyclyl having 1 to 3 R a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 6 is a 6- to 10-membered bridged bicyclic heterocyclyl, and the 6- to 10-membered bridged bicyclic heterocyclyl is selected from -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 and substituted with 1 to 3 groups independently selected from alkyl.

[0380] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 6 is a 6- to 10-membered bridged bicyclic heterocyclyl, and the 6- to 10-membered bridged bicyclic heterocyclyl is selected from -OH, halogen, -CN, oxo, -C(O)R 11 , -NR 11 R 11 , C 1~4 Alkoxy, C 1~5 Alkyl, and R f and optionally substituted with 1 to 3 groups independently selected from C 1~5 Alkyl is -OH, halogen, -CN, oxo, -NR 12 R 12 , and -C(O)N(R 12 )(R 12 Optionally substituted with 1 to 3 groups independently selected from Each R f independently, C 3~7 monocyclic cycloalkyl, 4- to 7-membered monocyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, or 7- to 10-membered spirocyclic heterocyclyl; C 3~7The monocyclic cycloalkyl, 4- to 7-membered monocyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, and 7- to 10-membered spirocyclic heterocyclyl are each independently optionally substituted with 1 to 3 groups independently selected from oxo and halogen.

[0381] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 6 is a 6- to 10-membered bridged bicyclic heterocyclyl.

[0382] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 6 teeth,

[0383] [ka] is.

[0384] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 6 is 7~ 10-membered spirocyclic heterocyclyl, and 7- to 10-membered spirocyclic heterocyclyl is 1 to 4 R a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 6 is a 7- to 10-membered spirocyclic heterocyclyl, which is a 7- to 10-membered spirocyclic heterocyclyl having 1 to 4 R a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 6 is a 7- to 10-membered spirocyclic heterocyclyl.

[0385] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 7 is H, C 1~6 Alkyl, C 3~7 monocyclic cycloalkyl or 4- to 6-membered monocyclic heterocyclyl, 1~6 Alkyl, C 3~7Monocyclic cycloalkyl and 4- to 6-membered monocyclic heterocyclyl are each independently selected from -OH, halogen, -CN, and C 1~6 Optionally substituted with 1 to 4 groups independently selected from alkoxy.

[0386] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 7 is H, C 1~3 Alkyl, or C 3~7 is a monocyclic cycloalkyl, C 1~3 Alkyl is a group consisting of -OH, halogen, -CN, and C 1~3 Optionally substituted with 1 to 3 groups independently selected from alkoxy.

[0387] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 7 is H, C 1~3 Alkyl, or C 3~7 is a monocyclic cycloalkyl, C 1~3 Alkyl is a group that can be substituted with -OH, halogen, and C 1~3 Optionally substituted with 1 to 2 groups independently selected from alkoxy.

[0388] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 7 is H or C 1~3 In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 7 is H or methyl.

[0389] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 7 is C 2~3 Alkyl or C 3~7 is a monocyclic cycloalkyl, C 2~3 Alkyl is a group that can be substituted with -OH, halogen, and C 1~3 Optionally substituted with 1 to 2 groups independently selected from alkoxy.

[0390] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 7 is ethyl, —CH2CH2OCH3, cyclopropyl, cyclobutyl, or cyclopentyl.

[0391] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 7 is H.

[0392] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 7 is C 1~6 alkyl, C 1~6 Alkyl is a group consisting of -OH, halogen, -CN, and C 1~6 In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R is optionally substituted with 1 to 4 groups independently selected from alkoxy. 7 is C 1~6 alkyl, C 1~6 Alkyl is a group consisting of -OH, halogen, -CN, and C 1~6 In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R is substituted with 1 to 4 groups independently selected from alkoxy. 7 is C 1~6 In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 7 is C 1~3 In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 7 is methyl.

[0393] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 7 is C 3~7 is a monocyclic cycloalkyl, C 3~7 Monocyclic cycloalkyls include -OH, halogen, -CN, and C 1~6 In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R is optionally substituted with 1 to 4 groups independently selected from alkoxy. 7 is C3~7 is a monocyclic cycloalkyl, C 3~7 Monocyclic cycloalkyls include -OH, halogen, -CN, and C 1~6 In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R is substituted with 1 to 4 groups independently selected from alkoxy. 7 is C 3~7 It is a monocyclic cycloalkyl.

[0394] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 7 is a 4- to 6-membered monocyclic heterocyclyl, and the 4- to 6-membered monocyclic heterocyclyl is selected from the group consisting of —OH, halogen, —CN, and C 1~6 In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R is optionally substituted with 1 to 4 groups independently selected from alkoxy. 7 is a 4-6 monocyclic heterocyclyl, and the 4-6 monocyclic heterocyclyl is selected from -OH, halogen, -CN, and C 1~6 In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R is substituted with 1 to 4 groups independently selected from alkoxy. 7 is a 4-6 membered monocyclic heterocyclyl. In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 7 is oxetanyl.

[0395] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is —C(O)R 13 is.

[0396] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 13 is C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10a bridged bicyclic cycloalkyl, a 4- to 7-membered monocyclic heterocyclyl, a phenyl, a naphthalenyl, a 5- to 6-membered monocyclic heteroaryl, an 8- to 10-membered fused bicyclic heterocyclyl, a 6- to 10-membered bridged bicyclic heterocyclyl, an 8- to 10-membered fused bicyclic heteroaryl, or a 7- to 10-membered spirocyclic heterocyclyl; C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 Bridged bicyclic cycloalkyl, 4- to 7-membered monocyclic heterocyclyl, phenyl, naphthalenyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl each independently represent 1 to 4 R a is optionally substituted with a group.

[0397] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 13 is a 4- to 7-membered monocyclic heterocyclyl, an 8- to 10-membered fused bicyclic heterocyclyl, a 6- to 10-membered bridged bicyclic heterocyclyl, or a 7- to 10-membered spirocyclic heterocyclyl; The 4- to 7-membered monocyclic heterocyclyl, the 8- to 10-membered fused bicyclic heterocyclyl, the 6- to 10-membered bridged bicyclic heterocyclyl, and the 7- to 10-membered spirocyclic heterocyclyl each independently represent 1 to 3 R a is optionally substituted with a group.

[0398] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 13 is a 4- to 7-membered monocyclic heterocyclyl, an 8- to 10-membered fused bicyclic heterocyclyl, a 6- to 10-membered bridged bicyclic heterocyclyl, or a 7- to 10-membered spirocyclic heterocyclyl; The 4- to 7-membered monocyclic heterocyclyl, the 8- to 10-membered fused bicyclic heterocyclyl, the 6- to 10-membered bridged bicyclic heterocyclyl, and the 7- to 10-membered spirocyclic heterocyclyl are each independently —OH, halogen, —CN, oxo, —NR 11 R 11 , phenyl, C 1~4Alkoxy, and C 1~5 optionally substituted with 1 to 3 groups independently selected from alkyl; C 1~5 Alkyl is -OH, halogen, -CN, oxo, -NR 12 R 12 , -C( O)N(R 12 )(R 12 ), and R g and optionally substituted with 1 to 3 groups independently selected from Each R g is independently a 4- to 7-membered monocyclic heterocyclyl.

[0399] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 13 is a 4- to 7-membered monocyclic heterocyclyl, an 8- to 10-membered fused bicyclic heterocyclyl, a 6- to 10-membered bridged bicyclic heterocyclyl, or a 7- to 10-membered spirocyclic heterocyclyl; The 4- to 7-membered monocyclic heterocyclyl, the 8- to 10-membered fused bicyclic heterocyclyl, the 6- to 10-membered bridged bicyclic heterocyclyl, and the 7- to 10-membered spirocyclic heterocyclyl are each independently —OH, halogen, —CN, oxo, —NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 optionally substituted with 1 to 3 groups independently selected from alkyl; C 1~5 Alkyl is -OH, halogen, -CN, oxo, and -NR 12 R 12 and optionally substituted with 1 to 3 groups independently selected from:

[0400] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 13 is a 4- to 7-membered monocyclic heterocyclyl, an 8- to 10-membered fused bicyclic heterocyclyl, a 6- to 10-membered bridged bicyclic heterocyclyl, or a 7- to 10-membered spirocyclic heterocyclyl; The 4- to 7-membered monocyclic heterocyclyl, the 8- to 10-membered fused bicyclic heterocyclyl, the 6- to 10-membered bridged bicyclic heterocyclyl, and the 7- to 10-membered spirocyclic heterocyclyl are each independently —OH, halogen, —CN, oxo, —NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 optionally substituted with 1 to 3 groups independently selected from alkyl; C 1~5 Alkyl is -OH, halogen, -CN, and -NR 12 R 12 and optionally substituted with 1 to 2 groups independently selected from Each R 12 are independently H or C 1~3 It is alkyl.

[0401] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 13 is an 8- to 10-membered fused bicyclic heterocyclyl or a 6- to 10-membered bridged bicyclic heterocyclyl, The 8- to 10-membered fused bicyclic heterocyclyl and the 6- to 10-membered bridged bicyclic heterocyclyl are each independently —OH, halogen, —CN, oxo, —NR 11 R 11 , phenyl, C 1~4 Alkoxy, and C 1~5 optionally substituted with 1 to 3 groups independently selected from alkyl; C 1~5 Alkyl is -OH, halogen, -CN, oxo, --NR 12 R 12 , -C(O)N(R 12 )(R 12 ), and R g and optionally substituted with 1 to 3 groups independently selected from Each R g is independently a 4- to 7-membered monocyclic heterocyclyl.

[0402] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 13is an 8- to 10-membered fused bicyclic heterocyclyl or a 6- to 10-membered bridged bicyclic heterocyclyl, each of which is selected from -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 optionally substituted with 1 to 3 groups independently selected from alkyl; C 1~5 Alkyl is substituted with halogen and -C(O)N(R 12 )(R 12 Optionally substituted with 1 to 3 groups independently selected from:

[0403] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 13 is an 8- to 10-membered fused bicyclic heterocyclyl or a 6- to 10-membered bridged bicyclic heterocyclyl, each of which is optionally substituted with one group selected from —NH, —CF, or —CHC(O)NH.

[0404] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 13 is C 3~7 is a monocyclic cycloalkyl, C 3~7 Monocyclic cycloalkyl is a group consisting of 1 to 4 R a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 13 is C 3~7 is a monocyclic cycloalkyl, C 3~7 Monocyclic cycloalkyl is a group consisting of 1 to 4 R a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 13 is C 3~7 It is a monocyclic cycloalkyl.

[0405] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 13 is C 7~10 is a fused bicyclic cycloalkyl, C 7~10A fused bicyclic cycloalkyl is one to four R a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 13 is C 7~10 is a fused bicyclic cycloalkyl, C 7~10 A fused bicyclic cycloalkyl is one to four R a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 13 is C 7~10 It is a fused bicyclic cycloalkyl.

[0406] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 13 is C 5~10 Bridged bicyclic cycloalkyl, C 5~10 A bridged bicyclic cycloalkyl is one to four R a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 13 is C 5~10 Bridged bicyclic cycloalkyl, C 5~10 A bridged bicyclic cycloalkyl is one to four R a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 13 is C 5~10 It is a bridged bicyclic cycloalkyl.

[0407] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 13 is a 4- to 7-membered monocyclic heterocyclyl, which is a 4- to 7-membered monocyclic heterocyclyl having 1 to 4 R a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 13 is a 4- to 7-membered monocyclic heterocyclyl, and the 4- to 7-membered monocyclic heterocyclyl is a 4- to 7-membered monocyclic heterocyclyl having 1 to 3 R a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 13is a 4- to 7-membered monocyclic heterocyclyl, and the 4- to 7-membered monocyclic heterocyclyl is selected from -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 optionally substituted with 1 to 3 groups independently selected from alkyl, C 1~5 Alkyl is -OH, halogen, -CN, oxo, and -NR 12 R 12 In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 13 is a 4- to 7-membered monocyclic heterocyclyl, and the 4- to 7-membered monocyclic heterocyclyl is selected from -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 optionally substituted with 1 to 3 groups independently selected from alkyl, C 1~5 Alkyl is -OH, halogen, -CN, oxo, and -NR 12 R 12 and each R 12 are independently H or C 1~3 It is alkyl.

[0408] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 13 is a 4- to 7-membered monocyclic heterocyclyl, which is a 4- to 7-membered monocyclic heterocyclyl having 1 to 4 R a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereo...

Claims

1. A compound of formula I, 【Chemistry 1】 or a pharmaceutically acceptable salt thereof During the ceremony, R1 is a 4-7 member monocyclic heterocyclyl, a 5-6 member monocyclic heteroaryl, or an 8-10 member condensed bicyclic heteroaryl. (1) Here, the 4-7 member monocyclic heterocyclyl, 5-6 member monocyclic heteroaryl, and 8-10 member condensed bicyclic heteroaryl of R1 are each independently and optionally substituted with 1 to 4 groups independently selected from -OH, halogen, -CN, oxo, -NR11R11, and C1-5 alkyl. (1a) Here, the C1-5 alkyl group is optionally substituted with 1-3 groups independently selected from -OH, halogen, and -CN; R2 is a C1-6 alkyl group, and the C1-6 alkyl group is optionally substituted with 1 to 4 groups independently selected from halogens and C1-6 alkoxy groups; X is CR 3; R3 is H or C1-6 alkyl, and the C1-4 alkyl is optionally substituted with 1-3 groups independently selected from -OH, halogen, -CN, -NR4R4, and C1-4 alkoxy; Z is a C1-10 alkyl, -C(O)R13, ​​-C(O)NR6R7, C3-7 monocyclic cycloalkyl, C7-10 condensed bicyclic cycloalkyl, C5-10 crosslinked bicyclic cycloalkyl, 4-7 member monocyclic heterocyclil, phenyl, naphthalenyl, 5-6 member monocyclic heteroaryl, 8-10 member condensed bicyclic heterocyclil, 6-10 member crosslinked bicyclic heterocyclil, 8-10 member condensed bicyclic heteroaryl, or 7-10 member spirocyclic heterocyclil. (1) Here, the C1-10 alkyl group of Z is optionally substituted with 1-4 groups independently selected from 4-7 member monocyclic heterocyclines, 8-10 member condensed bicyclic heterocyclines, 6-10 member bridged bicyclic heterocyclines, and 7-10 member spirocyclic heterocyclines. (1a) Here, the 4-7 member monocyclic heterocyclil, the 8-10 member condensed bicyclic heterocyclil, the 6-10 member bridged bicyclic heterocyclil, and the 7-10 member spirocyclic heterocyclil are each independently and optionally substituted with 1-3 Rd groups; (2) Here, the C3-7 monocyclic cycloalkyl, C7-10 condensed bicyclic cycloalkyl, C5-10 crosslinked bicyclic cycloalkyl, 4-7 member monocyclic heterocyclil, phenyl, naphthalenyl, 5-6 member monocyclic heteroaryl, 8-10 member condensed bicyclic heterocyclil, 6-10 member crosslinked bicyclic heterocyclil, 8-10 member condensed bicyclic heteroaryl, and 7-10 member spirocyclic heterocyclil of Z are each independently and optionally substituted with 1-2 R8 groups, and each independently and optionally substituted with 1-3 Ra groups; R6 is a C1-6 alkyl, C3-7 monocyclic cycloalkyl, C7-10 condensed bicyclic cycloalkyl, C5-10 cross-linked bicyclic cycloalkyl, 4-7 member monocyclic heterocyclil, phenyl, naphthalenyl, 5-6 member monocyclic heteroaryl, 8-10 member condensed bicyclic heterocyclil, 6-10 member cross-linked bicyclic heterocyclil, 8-10 member condensed bicyclic heteroaryl, or 7-10 member spirocyclic heterocyclil. (1) Here, the C1-6 alkyl group of R6 is optionally substituted with 1-4 Rb groups, (2) Here, the C3-7 monocyclic cycloalkyl, C7-10 condensed bicyclic cycloalkyl, C5-10 crosslinked bicyclic cycloalkyl, 4-7 member monocyclic heterocyclil, phenyl, naphthalenyl, 5-6 member monocyclic heteroaryl, 8-10 member condensed bicyclic heterocyclil, 6-10 member crosslinked bicyclic heterocyclil, 8-10 member condensed bicyclic heteroaryl, and 7-10 member spirocyclic heterocyclil of R6 are each independently and optionally substituted with 1-4 Ra groups; R 13 is a C3-7 monocyclic cycloalkyl, a C7-10 condensed bicyclic cycloalkyl, a C5-10 cross-linked bicyclic cycloalkyl, a 4-7 member monocyclic heterocyclil, phenyl, naphthalenyl, a 5-6 member monocyclic heteroaryl, an 8-10 member condensed bicyclic heterocyclil, a 6-10 member cross-linked bicyclic heterocyclil, an 8-10 member condensed bicyclic heteroaryl, or a 7-10 member spirocyclic heterocyclil. (1) Here, the C3-7 monocyclic cycloalkyl, C7-10 condensed bicyclic cycloalkyl, C5-10 crosslinked bicyclic cycloalkyl, 4-7 member monocyclic heterocyclil, phenyl, naphthalenyl, 5-6 member monocyclic heteroaryl, 8-10 member condensed bicyclic heterocyclil, 6-10 member crosslinked bicyclic heterocyclil, 8-10 member condensed bicyclic heteroaryl, and 7-10 member spirocyclic heterocyclil of R13 are each independently and optionally substituted with 1-4 Ra groups; Each R4 is independently H or C1-3 alkyl; R7 is H, C1-6 alkyl, C3-7 monocyclic cycloalkyl, or 4-6 membered monocyclic heterocyclil, and the C1-6 alkyl, C3-7 monocyclic cycloalkyl, and 4-6 membered monocyclic heterocyclil are each independently and optionally substituted with 1-4 groups independently selected from -OH, halogen, -CN, and C1-6 alkoxy; Each R8 independently comprises halogen, -C(O)R9, -NR10R10, C1-6 alkyl, C3-7 monocyclic cycloalkyl, C7-10 condensed bicyclic cycloalkyl, C5-10 cross-linked bicyclic cycloalkyl, 4-7 member monocyclic heterocyclil, phenyl, naphthalenyl, 5-6 member monocyclic heteroaryl, 8-10 member condensed bicyclic heterocyclil, 6-10 member cross-linked bicyclic heterocyclil, 8-10 member condensed bicyclic heteroaryl, 7-10 member spirocyclic heterocyclil, -OR5, -C(O)OR5, -C(O)N(R5)(R5), -N(R5)2(R5)+, and -N(R5)C(O)R5 , -N(R 5 )C(O)OR 5 , -N(R 5 )C(O)N(R 5 )(R 5 ), -N(R 5 )S(O) 2 (R 5a ), -NR 5 S(O) 2 N(R 5 )(R 5 ), -NR 5 S(O) 2 O(R 5a ), -OC(O)R 5 , -OC(O)OR 5 , -OC(O)N(R 5 )(R 5 ), -SR 5 , -S(O)R 5a , -S(O)(NH)R 5 , -S(O) 2 R 5a , -S(O) 2 N(R 5 )(R 5 ), or -N=S(R 5a )(R 5a )=O, (1) Here, the C1-6 alkyl group of R8 is optionally substituted with 1-4 Rb groups, (2) Here, the C3-7 monocyclic cycloalkyl, C7-10 condensed bicyclic cycloalkyl, C5-10 crosslinked bicyclic cycloalkyl, 4-7 member monocyclic heterocyclil, phenyl, naphthalenyl, 5-6 member monocyclic heteroaryl, 8-10 member condensed bicyclic heterocyclil, 6-10 member crosslinked bicyclic heterocyclil, 8-10 member condensed bicyclic heteroaryl, and 7-10 member spirocyclic heterocyclil of R8 are each independently and optionally substituted with 1-4 Ra groups; R9 is a C2-6 alkenyl, C2-6 alkynyl, C3-7 monocyclic cycloalkyl, C7-10 condensed bicyclic cycloalkyl, C5-10 cross-linked bicyclic cycloalkyl, phenyl, naphthalenyl, 4-7 member monocyclic heterocyclil, 5-6 member monocyclic heteroaryl, 8-10 member condensed bicyclic heterocyclil, 6-10 member cross-linked bicyclic heterocyclil, 8-10 member condensed bicyclic heteroaryl, or 7-10 member spirocyclic heterocyclil. (1) Here, the C2-6 alkenyl and C2-6 alkynyl groups of R9 are each independently and optionally substituted with 1 to 4 Rb groups. (2) Here, the C3-7 monocyclic cycloalkyl, C7-10 condensed bicyclic cycloalkyl, C5-10 crosslinked bicyclic cycloalkyl, phenyl, naphthalenyl, 4-7 member monocyclic heterocyclil, 5-6 member monocyclic heteroaryl, 8-10 member condensed bicyclic heterocyclil, 6-10 member crosslinked bicyclic heterocyclil, 8-10 member condensed bicyclic heteroaryl, and 7-10 member spirocyclic heterocyclil of R9 are each independently and optionally substituted with 1-4 Ra groups; Each R5 and R10 is independently H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-7 monocyclic cycloalkyl, C7-10 condensed bicyclic cycloalkyl, C5-10 cross-linked bicyclic cycloalkyl, phenyl, naphthalenyl, 4-7 member monocyclic heterocyclil, 5-6 member monocyclic heteroaryl, 8-10 member condensed bicyclic heterocyclil, 6-10 member cross-linked bicyclic heterocyclil, 8-10 member condensed bicyclic heteroaryl, or 7-10 member spirocyclic heterocyclil. (1) Here, the C1-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl of R5 or R10 are each independently and optionally substituted with 1 to 4 Rb groups. (2) Here, the C3-7 monocyclic cycloalkyl, C7-10 condensed bicyclic cycloalkyl, C5-10 crosslinked bicyclic cycloalkyl, phenyl, naphthalenyl, 4-7 member monocyclic heterocyclil, 5-6 member monocyclic heteroaryl, 8-10 member condensed bicyclic heterocyclil, 6-10 member crosslinked bicyclic heterocyclil, 8-10 member condensed bicyclic heteroaryl, and 7-10 member spirocyclic heterocyclil are each independently and optionally substituted with 1-4 Ra groups; Each R 5a is independently a C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-7 monocyclic cycloalkyl, C7-10 condensed bicyclic cycloalkyl, C5-10 cross-linked bicyclic cycloalkyl, phenyl, naphthalenyl, 4-7 member monocyclic heterocyclil, 5-6 member monocyclic heteroaryl, 8-10 member condensed bicyclic heterocyclil, 6-10 member cross-linked bicyclic heterocyclil, 8-10 member condensed bicyclic heteroaryl, or 7-10 member spirocyclic heterocyclil. (1) Here, the C1-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl groups of R 5a are each independently and optionally substituted with 1 to 4 Rb groups. (2) Here, the C3-7 monocyclic cycloalkyl, C7-10 condensed bicyclic cycloalkyl, C5-10 crosslinked bicyclic cycloalkyl, phenyl, naphthalenyl, 4-7 member monocyclic heterocyclil, 5-6 member monocyclic heteroaryl, 8-10 member condensed bicyclic heterocyclil, 6-10 member crosslinked bicyclic heterocyclil, 8-10 member condensed bicyclic heteroaryl, and 7-10 member spirocyclic heterocyclil of R5a are each independently and optionally substituted with 1-4 Ra groups; Each R a independently comprises oxo, imino, halogen, -NO2, -N3, -CN, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-7 monocyclic cycloalkyl, C7-10 condensed bicyclic cycloalkyl, C5-10 cross-linked bicyclic cycloalkyl, phenyl, naphthalenyl, 4-7 member monocyclic heterocyclil, 5-6 member monocyclic heteroaryl, 8-10 member condensed bicyclic heterocyclil, 6-10 member cross-linked bicyclic heterocyclil, 8-10 member condensed bicyclic heteroaryl, 7-10 member spirocyclic heterocyclil, -OR11, -C(O)R11, -C(O)OR11, -C(O)N(R11)(R11), and -NR11. R 11 , -N(R 11 ) 2 (R 11 ) + , -N(R 11 )C(O)R 11 , -N(R 11 )C(O)OR 11 , -N(R 11 )C(O)N(R 11 )(R 11 ), -N(R 11 )S(O) 2 (R 11a ), -NR 11 S(O) 2 N(R 11 )(R 11 ), -NR 11 S(O) 2 O(R 11a ), -OC(O)R 11 , -OC(O)OR 11 , -OC(O)N(R 11 )(R 11 ), -SR 11 , -S(O)R 11a -S(O)(NH)R 11, -S(O) 2R 11a, -S(O) 2N(R 11)(R 11), or -N=S(R 11a)(R 11a)=O, (1) Here, the C1-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl groups of Ra are each independently and optionally substituted with 1 to 3 Rc groups. (2) Here, the C3-7 monocyclic cycloalkyl, C7-10 condensed bicyclic cycloalkyl, C5-10 crosslinked bicyclic cycloalkyl, phenyl, naphthalenyl, 4-7 member monocyclic heterocyclil, 5-6 member monocyclic heteroaryl, 8-10 member condensed bicyclic heterocyclil, 6-10 member crosslinked bicyclic heterocyclil, 8-10 member condensed bicyclic heteroaryl, and 7-10 member spirocyclic heterocyclil are each independently and optionally substituted with 1-3 Rd groups. Each R b independently corresponds to an oxo, imino, halogen, -NO2, -N3, -CN, C3-7 monocyclic cycloalkyl, C7-10 condensed bicyclic cycloalkyl, C5-10 cross-linked bicyclic cycloalkyl, phenyl, naphthalenyl, 4-7 member monocyclic heterocyclil, 5-6 member monocyclic heteroaryl, 8-10 member condensed bicyclic heterocyclil, 8-10 member cross-linked bicyclic heterocyclil, 6-10 member cross-linked bicyclic heterocyclil, 8-10 member condensed bicyclic heteroaryl, 7-10 member spirocyclic heterocyclil, -OR11, -C(O)R11, -C(O)OR11, -C(O)N(R11)(R11), -NR11R11, -N(R 11 ) 2 (R 11 ) + , -N(R 11 )C(O)R 11 , -N(R 11 )C(O)OR 11 , -N(R 11 )C(O)N(R 11 )(R 11 ), -N(R 11 )S(O) 2 (R 11a ), -NR 11 S(O) 2 N(R 11 )(R 11 ), -NR 11 S(O) 2 O(R 11a ), -OC(O)R 11 , -OC(O)OR 11 , -OC(O)N(R 11 )(R 11 ), -SR 11 , -S(O)R 11a , -S(O)(NH)R 11 -S(O) 2 R 11a, -S(O) 2 N(R 11)(R 11), or -N=S(R 11a)(R 11a)=O, (1) Here, the C3-7 monocyclic cycloalkyl, C7-10 condensed bicyclic cycloalkyl, C5-10 crosslinked bicyclic cycloalkyl, phenyl, naphthalenyl, 4-7 member monocyclic heterocyclil, 5-6 member monocyclic heteroaryl, 8-10 member condensed bicyclic heterocyclil, 6-10 member crosslinked bicyclic heterocyclil, 8-10 member condensed bicyclic heteroaryl, and 7-10 member spirocyclic heterocyclil are each independently and optionally substituted with 1-3 Rd groups; Each R c independently corresponds to halogen, -CN, C7-10 condensed bicyclic cycloalkyl, C5-10 cross-linked bicyclic cycloalkyl, phenyl, naphthalenyl, 4-7 member monocyclic heterocyclil, 5-6 member monocyclic heteroaryl, 8-10 member condensed bicyclic heterocyclil, 6-10 member cross-linked bicyclic heterocyclil, 8-10 member condensed bicyclic heteroaryl, 7-10 member spirocyclic heterocyclil, -OR 12, -C(O)R 12, -C(O)OR 12, -C(O)N(R 12)(R 12), -NR 12 R 12, -N(R 12) 2(R 12)+, -N(R 12)C(O)R 12, -N(R 12) )C(O)OR 12 , -N(R 12 )C(O)N(R 12 )(R 12 ), -N(R 12 )S(O) 2 (R 12a ), -NR 12 S(O) 2 N(R 12 )(R 12 ), -NR 12 S(O) 2 O(R 12a ), -OC(O)R 12 , -OC(O)OR 12 , -OC(O)N(R 12 )(R 12 ), -SR 12 , -S(O)R 12a -S(O)(NH)R 12 , -S(O) 2 R 12a , -S(O) 2 N(R 12 )(R 12 ), or -N=S(R 12a )(R 12a) = O; Each R d independently corresponds to oxo, halogen, -CN, C7-10 condensed bicyclic cycloalkyl, C5-10 cross-linked bicyclic cycloalkyl, phenyl, naphthalenyl, 4-7 member monocyclic heterocyclil, 5-6 member monocyclic heteroaryl, 8-10 member condensed bicyclic heterocyclil, 6-10 member cross-linked bicyclic heterocyclil, 8-10 member condensed bicyclic heteroaryl, 7-10 member spirocyclic heterocyclil, -OR 12, -C(O)R 12, -C(O)OR 12, -C(O)N(R 12)(R 12), -NR 12 R 12, -N(R 12) 2(R 12)+, -N(R 12)C(O)R 12, -N(R 12 ) C(O)OR 12 , -N(R 12 )C(O)N(R 12 )(R 12 ), -N(R 12 )S(O) 2 (R 12a ), -NR 12 S(O) 2 N(R 12 )(R 12 ), -NR 12 S(O) 2 O(R 12a ), -OC(O)R 12 , -OC(O)OR 12 , -OC(O)N(R 12 )(R 12 ), -SR 12 , -S(O)R 12a , -S(O)(NH)R 12 , -S(O) 2 R 12a , -S(O) 2 N(R 12 )(R 12 ), or −N=S(R 12a)(R 12a) = O; Each R11 is independently H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-7 monocyclic cycloalkyl, C7-10 condensed bicyclic cycloalkyl, C5-10 cross-linked bicyclic cycloalkyl, phenyl, naphthalenyl, 4-7 member monocyclic heterocyclil, 5-6 member monocyclic heteroaryl, 8-10 member condensed bicyclic heterocyclil, 6-10 member cross-linked bicyclic heterocyclil, 8-10 member condensed bicyclic heteroaryl, or 7-10 member spirocyclic heterocyclil. (1) Here, the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-7 monocyclic cycloalkyl, C7-10 condensed bicyclic cycloalkyl, C5-10 crosslinked bicyclic cycloalkyl, phenyl, naphthalenyl, 4-7 member monocyclic heterocyclil, 5-6 member monocyclic heteroaryl, 8-10 member condensed bicyclic heterocyclil, 6-10 member crosslinked bicyclic heterocyclil, 8-10 member condensed bicyclic heteroaryl, and 7-10 member spirocyclic heterocyclil are each independently and optionally substituted with 1-3 Rc groups; Each R 11a is independently a C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-7 monocyclic cycloalkyl, C7-10 condensed bicyclic cycloalkyl, C5-10 cross-linked bicyclic cycloalkyl, phenyl, naphthalenyl, 4-7 member monocyclic heterocyclil, 5-6 member monocyclic heteroaryl, 8-10 member condensed bicyclic heterocyclil, 6-10 member cross-linked bicyclic heterocyclil, 8-10 member condensed bicyclic heteroaryl, or 7-10 member spirocyclic heterocyclil. (1) Here, the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-7 monocyclic cycloalkyl, C7-10 condensed bicyclic cycloalkyl, C5-10 crosslinked bicyclic cycloalkyl, phenyl, naphthalenyl, 4-7 member monocyclic heterocyclil, 5-6 member monocyclic heteroaryl, 8-10 member condensed bicyclic heterocyclil, 6-10 member crosslinked bicyclic heterocyclil, 8-10 member condensed bicyclic heteroaryl, and 7-10 member spirocyclic heterocyclil are each independently and optionally substituted with 1-3 Rc groups; Each R12 is independently H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-7 monocyclic cycloalkyl, C7-10 condensed bicyclic cycloalkyl, C5-10 cross-linked bicyclic cycloalkyl, phenyl, naphthalenyl, 4-7 member monocyclic heterocyclil, 5-6 member monocyclic heteroaryl, 8-10 member condensed bicyclic heterocyclil, 6-10 member cross-linked bicyclic heterocyclil, 8-10 member condensed bicyclic heteroaryl, or 7-10 member spirocyclic heterocyclil; Each R 12a is independently a C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-7 monocyclic cycloalkyl, C7-10 condensed bicyclic cycloalkyl, C5-10 cross-linked bicyclic cycloalkyl, phenyl, naphthalenyl, 4-7 member monocyclic heterocyclil, 5-6 member monocyclic heteroaryl, 8-10 member condensed bicyclic heterocyclil, 6-10 member cross-linked bicyclic heterocyclil, 8-10 member condensed bicyclic heteroaryl, or 7-10 member spirocyclic heterocyclil; Each four-membered monocyclic heterocyclyl independently has one ring heteroatom selected from N, O, and S; Each 5- to 7-membered monocyclic heterocyclil independently has 1 to 2 ring heteroatoms independently selected from N, O, and S; Each six-membered bridged bicyclic heterocycline independently has one ring heteroatom selected from N, O, and S; Each seven-membered bridged bicyclic heterocycline independently has one or two ring heteroatoms independently selected from N, O, and S; and Each of the 5-6 member monocyclic heteroaryls, 8-10 member condensed bicyclic heterocyclines, 8-10 member bridging bicyclic heterocyclines, 8-10 member condensed bicyclic heteroaryls, and 7-10 member spirocyclic heterocyclines independently has 1-4 ring heteroatoms independently selected from N, O, and S. A compound, or a pharmaceutically acceptable salt thereof.

2. R2 is a C1-6 alkyl group, wherein the C1-6 alkyl group is optionally substituted with 1 to 3 groups independently selected from halogens and C1-6 alkoxy groups; R3 is H or C1-4 alkyl; Z is a C1-10 alkyl, -C(O)R13, ​​-C(O)NR6R7, C3-7 monocyclic cycloalkyl, 4-7 member monocyclic heterocyclil, phenyl, 5-6 member monocyclic heteroaryl, 8-10 member condensed bicyclic heterocyclil, 6-10 member bridged bicyclic heterocyclil, 8-10 member condensed bicyclic heteroaryl, or 7-10 member spirocyclic heterocyclil. (1) Here, the C1-10 alkyl group of Z is optionally substituted with 1-3 groups independently selected from 4-7 member monocyclic heterocyclines, 8-10 member condensed bicyclic heterocyclines, 6-10 member bridged bicyclic heterocyclines, and 7-10 member spirocyclic heterocyclines. (1a) Here, the 4-7 member monocyclic heterocyclil, 8-10 member condensed bicyclic heterocyclil, 6-10 member bridged bicyclic heterocyclil, and 7-10 member spirocyclic heterocyclil are each independently and optionally substituted with 1 to 3 groups independently selected from -OH, halogen, -CN, oxo, and NR12 R12. (2) Here, the C3-7 monocyclic cycloalkyl, phenyl, 5-6 member monocyclic heteroaryl, 8-10 member condensed bicyclic heterocyclil, 6-10 member bridged bicyclic heterocyclil, 8-10 member condensed bicyclic heteroaryl, and 7-10 member spirocyclic heterocyclil of Z are each independently and optionally substituted with 1-2 R8 groups, and each independently and optionally substituted with 1-3 Ra groups, (3) Here, the 4- to 7-membered monocyclic heterocyclyl of Z is substituted with 1 to 2 R8 groups and optionally substituted with 1 to 3 Ra groups; R6 is a C1-6 alkyl, C3-7 monocyclic cycloalkyl, 4-7 member monocyclic heterocyclil, or 6-10 member cross-linked bicyclic heterocyclil. (1) Here, the C1-6 alkyl group of R6 is optionally substituted with 1-3 Rb groups, (2) Here, the C3-7 monocyclic cycloalkyl, 4-7 member monocyclic heterocyclil, and 6-10 member bridged bicyclic heterocyclil of R6 are each independently and optionally substituted with 1-3 Ra groups; R 13 is a 4-7 member monocyclic heterocycline, an 8-10 member condensed bicyclic heterocycline, a 6-10 member bridged bicyclic heterocycline, or a 7-10 member spirocyclic heterocycline. (1) Here, the 4-7 member monocyclic heterocyclil, 8-10 member condensed bicyclic heterocyclil, 6-10 member bridging bicyclic heterocyclil, and 7-10 member spirocyclic heterocyclil of R13 are each independently and optionally substituted with 1-3 Ra groups; R7 is H, C1-3 alkyl, or C3-7 monocyclic cycloalkyl, (1) Here, the C1-3 alkyl group of R7 is optionally substituted with 1 to 3 groups independently selected from -OH, halogen, -CN, and C1-3 alkoxy; Each R8 is independently -C(O)R9, C1-6 alkyl, -NR10R10, C3-7 monocyclic cycloalkyl, 4-7 member monocyclic heterocyclil, 6-10 member bridged bicyclic heterocyclil, 7-10 member spirocyclic heterocyclil, or -S(O)2R5a. (1) Here, the C1-6 alkyl group of R8 is optionally substituted with 1-3 Rb groups, (2) Here, the C3-7 monocyclic cycloalkyl, 4-7 member monocyclic heterocyclil, 6-10 member bridged bicyclic heterocyclil, and 7-10 member spirocyclic heterocyclil of R8 are each independently and optionally substituted with 1-3 Ra groups; R9 is a 4-7 member monocyclic heterocycline or a 6-10 member bridged bicyclic heterocycline. (1) Here, the 4-7 member monocyclic heterocyclil and the 6-10 member bridged bicyclic heterocyclil of R9 are each independently and optionally substituted with 1-3 Ra groups; Each R 10 is independently H, a 4-7 member monocyclic heterocycline, or a 6-10 member bridged bicyclic heterocycline. (1) Here, the 4-7 member monocyclic heterocyclil and the 6-10 member bridged bicyclic heterocyclil of R 10 are each independently and optionally substituted with 1-3 Ra groups; R5a is a 4- to 7-membered monocyclic heterocycline, and the 4- to 7-membered monocyclic heterocycline is optionally substituted with 1 to 3 Ra groups; Each four-membered monocyclic heterocyclyl independently has one ring heteroatom selected from N, O, and S; Each 5- to 7-membered monocyclic heterocyclil independently has 1 to 2 ring heteroatoms independently selected from N, O, and S; Each six-membered bridged bicyclic heterocycline independently has one ring heteroatom selected from N, O, and S; Each seven-membered bridged bicyclic heterocycline independently has one or two ring heteroatoms independently selected from N, O, and S; and Each of the 5-6 member monocyclic heteroaryls, 8-10 member condensed bicyclic heterocyclines, 8-10 member bridging bicyclic heterocyclines, 8-10 member condensed bicyclic heteroaryls, and 7-10 member spirocyclic heterocyclines independently has 1-4 ring heteroatoms independently selected from N, O, and S. The compound according to claim 1, or a pharmaceutically acceptable salt thereof.

3. R1 is a 4-7 member monocyclic heterocyclyl, a 5-6 member monocyclic heteroaryl, or an 8-10 member condensed bicyclic heteroaryl, (1) Here, the 4-7 member monocyclic heterocyclyl, 5-6 member monocyclic heteroaryl, and 8-10 member condensed bicyclic heteroaryl of R1 are each independently and optionally substituted with 1 to 3 groups independently selected from -OH, halogen, -CN, oxo, -NR11R11, and C1-5 alkyl. (1a) Here, the C1-5 alkyl group is optionally substituted with 1-3 groups independently selected from -OH, halogen, and CN; R2 is a C1-6 alkyl group, and the C1-6 alkyl group is optionally substituted with 1 to 3 groups independently selected from halogens and C1-3 alkoxy groups; X is CR 3; R3 is H or C1-4 alkyl; Z is a C1-10 alkyl, -C(O)R13, ​​-C(O)NR6R7, C3-7 monocyclic cycloalkyl, 4-7 member monocyclic heterocyclil, phenyl, 5-6 member monocyclic heteroaryl, 8-10 member condensed bicyclic heterocyclil, 6-10 member bridged bicyclic heterocyclil, 8-10 member condensed bicyclic heteroaryl, or 7-10 member spirocyclic heterocyclil. (1) Here, the C1-10 alkyl group of Z is optionally substituted with 1-3 groups independently selected from 4-7 membered monocyclic heterocyclines and 7-10 membered spirocyclic heterocyclines. (1a) Here, the 4- to 7-membered monocyclic heterocyclil and the 7- to 10-membered spirocyclic heterocyclil are each independently and optionally substituted with 1 to 3 groups independently selected from -OH, halogen, -CN, oxo, and NR12 R12, (2) Here, the C3-7 monocyclic cycloalkyl, phenyl, 5-6 member monocyclic heteroaryl, 8-10 member condensed bicyclic heterocyclil, 6-10 member bridged bicyclic heterocyclil, 8-10 member condensed bicyclic heteroaryl, and 7-10 member spirocyclic heterocyclil of Z are each independently and optionally substituted with 1-2 R8 groups, and each is independently and optionally substituted with 1-3 groups independently selected from -OH, halogen, -CN, oxo, -NR11R11, C1-4 alkoxy, 4-7 member monocyclic heterocyclil, and C1-5 alkyl, (3) Here, the 4- to 7-membered monocyclic heterocyclyl of Z is substituted with 1 to 2 R8 groups and is optionally substituted with 1 to 3 groups independently selected from -OH, halogen, -CN, oxo, -NR11R11, C1-4 alkoxy, and C1-5 alkyl; R6 is a C1-6 alkyl, C3-7 monocyclic cycloalkyl, 4-7 member monocyclic heterocyclil, or 6-10 member cross-linked bicyclic heterocyclil. (1) Here, the C1-6 alkyl group of R6 is optionally substituted with 1 to 3 groups independently selected from -OH, halogen, -CN, oxo, -NR11R11, C1-4 alkoxy, and Re. (2) Here, the C3-7 monocyclic cycloalkyl, 4-7 member monocyclic heterocyclil, and 6-10 member bridged bicyclic heterocyclil of R6 are each independently and optionally substituted with 1 to 3 groups independently selected from -OH, halogen, -CN, oxo, -C(O)R11, -NR11R11, C1-4 alkoxy, C1-5 alkyl, and Rf. (2a) Here, the C1-5 alkyl group is optionally substituted with 1 to 3 groups independently selected from -OH, halogen, -CN, oxo, -NR12R12, and -C(O)N(R12)(R12), Each Re is independently a 4- to 7-membered monocyclic heterocycline or a 5- to 6-membered monocyclic heteroaryl. Each R f is independently a C3-7 monocyclic cycloalkyl, a 4-7 member monocyclic heterocycline, a 6-10 member bridged bicyclic heterocycline, or a 7-10 member spirocyclic heterocycline, and each of the C3-7 monocyclic cycloalkyl, 4-7 member monocyclic heterocycline, 6-10 member bridged bicyclic heterocycline, and 7-10 member spirocyclic heterocycline is independently and optionally substituted with 1-3 groups independently selected from oxo and halogen groups; R 13 is a 4-7 member monocyclic heterocycline, an 8-10 member condensed bicyclic heterocycline, a 6-10 member bridged bicyclic heterocycline, or a 7-10 member spirocyclic heterocycline. (1) Here, the 4-7 member monocyclic heterocyclil, 8-10 member condensed bicyclic heterocyclil, 6-10 member bridged bicyclic heterocyclil, and 7-10 member spirocyclic heterocyclil of R 13 are each independently and optionally substituted with 1 to 3 groups independently selected from -OH, halogen, -CN, oxo, -NR 11 R 11, phenyl, C1-4 alkoxy, and C1-5 alkyl. The C1-5 alkyl group is optionally substituted with 1 to 3 groups independently selected from -OH, halogen, -CN, oxo, -NR12R12, -C(O)N(R12)(R12), and Rg. Each R g is independently a 4- to 7-membered monocyclic heterocycline; R7 is H, C1-3 alkyl, or C3-7 monocyclic cycloalkyl, (1) Here, the C1-3 alkyl group of R7 is optionally substituted with one or two groups independently selected from -OH, halogens, and C1-3 alkoxy groups; Each R8 is independently -C(O)R9, C1-6 alkyl, -NR10R10, C3-7 monocyclic cycloalkyl, 4-7 member monocyclic heterocyclil, 6-10 member bridged bicyclic heterocyclil, 7-10 member spirocyclic heterocyclil, or -S(O)2R5a. (1) Here, the C1-6 alkyl group of R8 is optionally substituted with 1 to 3 groups independently selected from -OH, halogen, -CN, oxo, -NR11R11, -C(O)N(R11)(R11), -S(O)2R11a, C1-4 alkoxy, and Rh. (2) Here, the C3-7 monocyclic cycloalkyl, 4-7 member monocyclic heterocyclil, 6-10 member bridged bicyclic heterocyclil, and 7-10 member spirocyclic heterocyclil of R8 are each independently and optionally substituted with 1 to 3 groups independently selected from -OH, halogen, -CN, oxo, -NR11R11, C1-4 alkoxy, and C1-5 alkyl. (2a) Here, the C1-5 alkyl group is optionally substituted with 1-3 groups independently selected from -OH, halogen, oxo, 4-7 membered monocyclic heterocyclyl, and -C(O)N(R12)(R12), (2b) Here, the C1-4 alkoxy is optionally substituted with 1-3 halogen groups, Each R h is independently a C3-7 monocyclic cycloalkyl or a 4-7 membered monocyclic heterocycline; R9 is a C3-7 monocyclic cycloalkyl, a 4-7 member monocyclic heterocyclil, or a 6-10 member bridged bicyclic heterocyclil, which is optionally substituted with -NR11R11. (1) Here, the 4-7 member monocyclic heterocyclil and the 6-10 member bridged bicyclic heterocyclil of R9 are each independently and optionally substituted with 1 to 3 groups independently selected from -OH, halogen, -CN, oxo, -NR11R11, C1-4 alkoxy, and C1-5 alkyl. (1a) Here, the C1-5 alkyl group is optionally substituted with 1-3 groups independently selected from -OH, halogen, and -CN; Each R 10 is independently H, a 4-7 member monocyclic heterocycline, or a 6-10 member bridged bicyclic heterocycline, and the 4-7 member monocyclic heterocycline and the 6-10 member bridged bicyclic heterocycline are each independently optionally substituted with -OH, halogen, -CN, oxo, -NR 11 R 11, C 1-4 alkoxy, and C 1-5 alkyl; R 5a is a 4- to 7-membered monocyclic heterocycline; Each R11 is independently H, C1-4 alkyl, or C3-7 monocyclic cycloalkyl; Each R 11a is independently a C 1-4 alkyl group; Each R12 is independently H or C1-4 alkyl; Each four-membered monocyclic heterocyclyl independently has one ring heteroatom selected from N, O, and S; Each 5- to 7-membered monocyclic heterocyclil independently has 1 to 2 ring heteroatoms independently selected from N, O, and S; Each six-membered bridged bicyclic heterocycline independently has one ring heteroatom selected from N, O, and S; Each seven-membered bridged bicyclic heterocycline independently has one or two ring heteroatoms independently selected from N, O, and S; and Each of the 5-6 member monocyclic heteroaryls, 8-10 member condensed bicyclic heterocyclines, 8-10 member bridging bicyclic heterocyclines, 8-10 member condensed bicyclic heteroaryls, and 7-10 member spirocyclic heterocyclines independently has 1-4 ring heteroatoms independently selected from N, O, and S. A compound according to claim 1 or 2, or a pharmaceutically acceptable salt thereof.

4. (i) R1 is pyridinyl, 【Chemistry 2】 And, Each of these is independently optionally substituted with one to three groups independently selected from -OH, halogen, -CN, oxo, -NR11R11, and C1-5 alkyl groups; (ii) R1 is substituted with 1 to 3 groups independently selected from oxo and C1-3 alkyl groups; (iii) R1 is substituted with 1 to 3 groups independently selected from oxo and methyl groups; (iv) R1 is pyridinyl or 【Transformation 3】 And, Each of these is independently and optionally substituted with one to three methyl groups; (v) R 1 is, [Chemistry 4A] It is; (vi) R 1 is, 【Transformation 5】 is; and / or (vii) R2 is a C1-4 alkyl group, and the C1-4 alkyl group is optionally substituted with 1-3 groups independently selected from halogens and C1-3 alkoxy groups; (viiii) R2 is a C1-3 alkyl group; (ix)R2 is ethyl or isopropyl; (x) R2 is isopropyl, and R1 is 【Transformation 6】 is; and / or X is CH. A compound according to any one of claims 1 to 3, or a pharmaceutically acceptable salt thereof.

5. (i) Z substituted with 1 to 2 R8 groups, 【Chemistry 12】 It is; (ii) Z substituted with 1-2 R 8 groups, 【Chemistry 13】 It is; (iii) Z substituted with 1-2 R 8 groups, 【Chemistry 14】 It is; (iv)Z is cyclopropyl, wherein the cyclopropyl is optionally substituted with 1 to 2 R8 groups and optionally substituted with 1 to 3 groups independently selected from -OH, halogen, -CN, oxo, -NR11R11, C1-4 alkoxy, and C1-5 alkyl; or (v) Z is cyclopropyl, and the cyclopropyl is substituted with one R8 group. A compound according to any one of claims 1 to 4, or a pharmaceutically acceptable salt thereof.

6. The compound according to any one of claims 1 to 4, or a pharmaceutically acceptable salt thereof, wherein Z is -C(O)NR 6 R 7.

7. (i) R6 is a C1-6 alkyl or a 4-7 member monocyclic heterocycline, The C1-6 alkyl group is optionally substituted with one or two groups independently selected from -OH, halogen, -NR11R11, and C1-3 alkoxy groups. The 4- to 7-membered monocyclic heterocyclil is optionally substituted with 1 to 3 groups independently selected from -OH, halogen, -CN, -NR11R11, C1-3 alkoxy, and C1-3 alkyl; (ii) R6 is a C1-4 alkyl group optionally substituted with one -NR11R11; (iii) R 6 is a C1-4 alkyl group substituted with one group independently selected from -NH2, NH(CH3), and N(CH3)2; (iv) R6 is a C1-6 alkyl group substituted with one or two groups, independently selected from 4- to 7-membered monocyclic heterocyclyls and 5- to 6-membered monocyclic heteroaryls; (v) R6 is a C1-4 alkyl group substituted with one group, selected from pyrrolidinyl, piperidinyl, morpholinyl, and pyridinyl; (vi) R6 is a C3-7 monocyclic cycloalkyl group optionally substituted with one 4-7 membered monocyclic heterocycline or one 7-10 membered spirocyclic heterocycline, wherein the 4-7 membered monocyclic heterocycline and the 7-10 membered spirocyclic heterocycline are each optionally substituted with 1-3 groups independently selected from oxo and halogen groups; (vii) R6 is a C3-7 monocyclic cycloalkyl group optionally substituted with one 6-10 membered bridging bicyclic heterocycline, wherein the 6-10 membered bridging bicyclic heterocycline is optionally substituted with 1-3 groups independently selected from oxo and halogen groups; (viiii) R 6 is cyclobutyl; (ix) R 6 contains azetidinil, pyrrolidinil, 【Chemistry 24】 It is a cyclohexyl substituted with, Each of these is optionally substituted with one to three groups, independently selected from oxo and fluoro groups; (x) R 6 is a cyclohexyl substituted with one 6-10 membered bridged bicyclic heterocycline, wherein the 6-10 membered bridged bicyclic heterocycline is optionally substituted with 1-3 groups independently selected from oxo and halogen; (xi)R 6 is, 【Chemistry 25】 It is a cyclohexyl substituted with; (xi)R 6 is a 5-6 membered monocyclic heterocycline that is optionally substituted with 1-3 groups independently selected from -OH, halogen, -CN, oxo, -C(O)R 11, -NR 11R 11, C1-4 alkoxy, C1-5 alkyl, and R f. The C1-5 alkyl group is optionally substituted with 1 to 3 groups independently selected from -OH, halogen, -CN, oxo, -NR12R12, and -C(O)N(R12)(R12). R f is a C3-7 monocyclic cycloalkyl or a 4-7 member monocyclic heterocycline; or (xiiii)R 6 is pyrrolidinyl or piperidinyl, each of which is substituted with one to three groups independently selected from fluoro, methyl, -CH2OH, -CH2CN, -CF3, ethyl, -CH2CH2OH, -CH2CH2CN, -CH2CF3, -CH2CHF2, -CH2CH2CF3, cyclobutyl, oxetanyl, -CH2C(O)NH2, -CH2C(O)N(CH3)2, -C(O)CH2NH2, and -C(O)CH2N(CH3)2. A compound according to any one of claims 1 to 4 and 6, or a pharmaceutically acceptable salt thereof.

8. R 6 is, 【Chemistry 27】 A compound according to any one of claims 1 to 4, 6, and 7, or a pharmaceutically acceptable salt thereof.

9. A compound according to any one of claims 1 to 4 and 6 to 8, or a pharmaceutically acceptable salt thereof, wherein R7 is H or methyl.

10. The compound according to any one of claims 1 to 4, or a pharmaceutically acceptable salt thereof, wherein Z is -COR 13.

11. (i) R 13 is a 4-7 member monocyclic heterocycline, an 8-10 member condensed bicyclic heterocycline, a 6-10 member bridged bicyclic heterocycline, or a 7-10 member spirocyclic heterocycline, The aforementioned 4-7 member monocyclic heterocyclils, 8-10 member condensed bicyclic heterocyclils, 6-10 member bridged bicyclic heterocyclils, and 7-10 member spirocyclic heterocyclils are each independently and optionally substituted with 1 to 3 groups independently selected from -OH, halogen, -CN, oxo, -NR11R11, C1-4 alkoxy, and C1-5 alkyl groups. The C1-5 alkyl group is optionally substituted with one or two groups independently selected from -OH, halogen, -CN, and -NR12R12. Each R12 is independently H or C1-3 alkyl; (ii) R 13 contains pyrrolidinil, piperidinil, piperazinil, diazepanil, 【Chemistry 28】 And, Each of these is independently optionally substituted with 1 to 3 groups independently selected from -OH, halogen, -CN, oxo, -NR11R11, C1-4 alkoxy, and C1-5 alkyl groups. The C1-5 alkyl group is optionally substituted with one or two groups independently selected from -OH, halogen, -CN, and -NR12R12. Each R12 is independently H or C1-3 alkyl; or (iii) R 13 is piperidinyl or piperazinyl, and each of these is independently optionally substituted with 1 to 3 groups independently selected from -OH, halogen, -CN, oxo, -NR 11 R 11, C1-4 alkoxy, and C1-5 alkyl. The C1-5 alkyl group is optionally substituted with one or two groups independently selected from -OH, halogen, -CN, and -NR12R12. Each R12 is independently H or C1-3 alkyl. A compound according to any one of claims 1 to 4 and 10, or a pharmaceutically acceptable salt thereof.

12. The compound is a compound of formula II, 【Chemistry 31】 or a pharmaceutically acceptable salt thereof, in the formula, R 13 is a 4-7 member monocyclic heterocycline, an 8-10 member condensed bicyclic heterocycline, a 6-10 member bridged bicyclic heterocycline, or a 7-10 member spirocyclic heterocycline. The aforementioned 4-7 member monocyclic heterocyclils, 8-10 member condensed bicyclic heterocyclils, 6-10 member cross-linked bicyclic heterocyclils, and 7-10 member spirocyclic heterocyclils are each independently and optionally substituted with 1-3 groups independently selected from -OH, halogen, -CN, oxo, -NR11R11, phenyl, C1-4 alkoxy, and C1-5 alkyl groups. The C1-5 alkyl group is optionally substituted with 1 to 3 groups independently selected from -OH, halogen, -CN, oxo, -NR12R12, -C(O)N(R12)(R12), and Rg. Each R g is independently a 4- to 7-membered monocyclic heterocycline; or R 13 is a 4-7 member monocyclic heterocycline, an 8-10 member condensed bicyclic heterocycline, a 6-10 member bridged bicyclic heterocycline, or a 7-10 member spirocyclic heterocycline. The aforementioned 4-7 member monocyclic heterocyclils, 8-10 member condensed bicyclic heterocyclils, 6-10 member bridged bicyclic heterocyclils, and 7-10 member spirocyclic heterocyclils are each independently and optionally substituted with 1 to 3 groups independently selected from -OH, halogen, -CN, oxo, -NR11R11, C1-4 alkoxy, and C1-5 alkyl groups. The C1-5 alkyl group is optionally substituted with one or two groups independently selected from -OH, halogen, -CN, and -NR12R12. Each R12 is independently H or C1-3 alkyl; or Here, 【Transformation 33】 but, 【Transformation 34】 And, Each of these is independently optionally substituted with 1 to 3 groups independently selected from -OH, halogen, -CN, oxo, -NR11R11, C1-4 alkoxy, and C1-5 alkyl groups. The C1-5 alkyl group is optionally substituted with one or two groups independently selected from -OH, halogen, -CN, and -NR12R12. Each R12 is independently H or C1-3 alkyl. A compound according to any one of claims 1 to 4 and 10, or a pharmaceutically acceptable salt thereof.

13. (i) 【Chemistry 13-1】 【Chemistry 13-2】 or a pharmaceutically acceptable salt thereof; or (ii) 【Chemistry 13-3】 【Chemistry 13-4】 or its pharmaceutically acceptable salt; or (iii) 【Chemistry 13-5】 【Chemistry 13-6】 or a pharmaceutically acceptable salt thereof; or (iv) 【Chemistry 13-7】 or its pharmaceutically acceptable salt; or (v) 【Chemistry 13-8】 and 【Chemistry 13-9】 or its pharmaceutically acceptable salt; or (vi) 【Chemistry 13-10】 【Chemistry 13-11】 [Chemistry 13-12] 【Chemistry 13-13】 [Chemistry 13-14] [Chemistry 13-15] [Chemistry 13-16] [Chemistry 13-17] [Chemistry 13-18] [Chemistry 13-19] [Chemistry 13-20] [Chemistry 13-21] [Chemistry 13-22] or a pharmaceutically acceptable salt thereof; or (vii) [Chemistry 13-23] [Chemistry 13-24] [Chemistry 13-25] or a pharmaceutically acceptable salt thereof; or (viiii) [Chemistry 13-26] or its pharmaceutically acceptable salt A compound selected from the group consisting of the following.

14. A pharmaceutical composition comprising a compound according to any one of claims 1 to 13, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient or carrier.

15. A pharmaceutical composition according to claim 14, further comprising one or more additional therapeutic agents or pharmaceutically acceptable salts thereof, wherein, optionally, the one or more additional therapeutic agents comprise an antimalarial agent, or an antimalarial agent selected from chloroquine and hydroxychloroquine, or pharmaceutically acceptable salts thereof.

16. A composition for use in therapy, comprising a compound according to any one of claims 1 to 13 or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition according to any one of claims 14 or 15.

17. (i) In a subject requiring inhibition of the activity of Toll-like receptors 7 and / or 8, inhibiting the activity of Toll-like receptors 7 and / or 8; (ii) In subjects requiring treatment for diseases or disorders associated with elevated Toll-like receptor 7 and / or 8 activity, to treat diseases or disorders associated with elevated Toll-like receptor 7 and / or 8 activity; (iii) To treat an inflammatory condition; (iv) To treat systemic lupus erythematosus; (v) To treat cutaneous lupus erythematosus; or (vi) Treating lupus nephritis A composition for use in [location], comprising a compound according to any one of claims 1 to 13 or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition according to claim 14 or 15.

18. The composition according to claim 17, wherein, (i) The inflammatory condition is selected from inflammatory bowel disease, psoriasis, psoriatic arthritis, rheumatoid arthritis, glomerulonephritis, mixed connective tissue disease (MCTD), dermatomyositis, polymyositis, systemic sclerosis, antineutrophil cytoplasmic antibody-associated vasculitis, antiphospholipid syndrome, autoimmune hemolytic anemia, macrophage activation syndrome-driven inflammatory anemia, IgA nephropathy, type 1 diabetes mellitus, non-alcoholic steatohepatitis, and Sjögren's syndrome; (ii) The composition is characterized by being administered in combination with one or more additional therapeutic agents, wherein, if necessary, the one or more additional therapeutic agents are bertzumab, PF-06835375, eculizumab, milatuzumab, SM-06, SM-03, BT-063, QX-006-N, BOS-161721, AK-101, TNX-1500, ceralizumab, daxzirimab, TAK-079, ferzalta-mab, itorizumab, aniflorumab, iscarimab, dapirolizumab pegol pegol), lanalumab, LY-3361237, JNJ-55920839, UBP-1213, DS-7011, PFI-102, BIIB-059, obexerimab, talakotzumab, bovalilizumab, TE-2324, PRV-3279, chloroquine, hydroxychloroquine, hydroxychloroquine sulfate, COV-08-0064, GNKS-356, AVO-101, rozibafusp α alfa), VRN-02, annexuzlimab, ALPN-101, bendamustine hydrochloride, BMS-986256, NKTR-35, atacicept, teritacicept, BMS-986256, M-5049, KZR-616, KPG-818, verdinexor, ALPN-303, buldifurocept, LA-1, senerimod, prednisone, corticotropin, duclavacitinib, CPL-409116, CS-12192, Tofacitinib citrate, ISB-830, DV-1079, Jureminic acid, Iverdomide, TAM-01, BML-258, Prepocitinib, SDC-1801, SDC-1802, ICP-330, NTR-441, Darazatide, GSK-2646264, SKI-O-703, Ranraprenib (GS-9876), GNS-1653, HMPL-523, RSLV-132, Interleukin-2Anteluke, Interking Recombinant Human Interleukin-2, ILT-101, CUG-252, DZ-2002, PEG-modified HLA-x (SLE), AC-0058, Fenebrutinib, XNW-1011, Tirabrutinib Hydrochloride, Branebrutinib, Elsbrutinib, Olerabrutinib, DWP-213388, INV-103, R-Salbutamol Sulfate, Anchorins, NIK-SMI1, X-6, INV-17, Oshadi D, selected from the group consisting of baricitinib, upadacitinib, filgotinib, itacitinib, INCB-54707, delgocitinib, DWP-212525, CKD-971, asmomethasone, betamethasone, folligerimod, anandamide, DCB-SLE1, arsenic trioxide, tairuimide, TV-4710 (edratide), LC-200, BI-705564, SM-934, GX-101, TXR-712, TXR-711, CIT-013, MHV-370, Panzyga®, TPX-6001, TPX-7001, artenimol, and AMG-592, or pharmaceutically acceptable salts thereof; and / or (iii) The subject is a human being. composition.

Images